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The rapid development of biopharmaceuticals suggests that many future 
vaccines will involve the delivery of peptide or protein sub units. The overall goal of 
this work is to design novel vaccine adjuvants based on biodegradable polymers that 
protect, stabilize, and enhance the immunogenicity of these protein antigens. 
Polyanhydrides, which are surface erodible polymers, have shown excellent 
performance as drug carriers. Their hydrophobic nature prevents water penetration 
into the bulk, thus eliminating water-induced covalent aggregation of proteins.  
Unfortunately, protein inactivation by non-covalent aggregation may still persist. It 
has been suggested that the use of carriers containing both hydrophobic and 
hydrophilic entities may provide a gentler environment for proteins. Hence, the 
synthesis and characterization of a novel amphiphilic polyanhydride system based 
on the anhydride monomers 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) was carried out. Subsequently, as most 
vaccines involve the delivery of peptides or protein subunits, protein stabilization in 
the CPTEG:CPH environment was analyzed. It was demonstrated that CPTEG:CPH 
system provides a gentle environment for proteins and sustained release from 
copolymer microspheres is attained. In order to evaluate the adjuvant characteristics 
of the CPTEG:CPH system, the activation of immune cells incubated with 
CPTEG:CPH microspheres and the implications for vaccine design were addressed. 
The promising adjuvant capabilities of CPTEG-content microspheres were 





presenting cells of the immune system. Altogether, the studies presented in this 
thesis provide an excellent foundation for testing the viability of this system as an 
effective adjuvant for the development of vaccines.  Development and application of 
this technology will facilitate the rational design of vaccines and the ability to 



















 Approximately 20 years ago, the first protein drug (recombinant insulin) was 
approved by the US Food and Drug Administration (FDA). Since then, research in 
the area of therapeutic protein delivery has increased to the point where around 500 
candidate biopharmaceuticals are currently undergoing clinical evaluation and 
annual research expenditures surpass $30 billion. A study done in 2003 revealed 
that the largest category under development were vaccines, with 50% aimed at 
treating or preventing cancer and the rest aimed at treating infectious diseases (i.e., 
hepatitis and HIV)1. 
 Despite the rapid growth of these biopharmaceuticals, there is still a lack of 
proper administration. Many future vaccines will involve the delivery of peptide or 
protein subunits, which means that besides enhancing the immune response, the 
delivery carrier must ensure protein stability2. Proteins are amphiphilic structures 
arranged in three-dimensional patterns that need to be conserved for their natural 
bioactivity. Typically, therapeutic proteins are unstable in physiological environments 
and their delicate structures can be easily disrupted. Hence they have short half 
lives when administered alone and their incorporation in therapeutic regimens is a 
challenge. There is an urgent need to design appropriate protein carriers that will 





involves a fundamental understanding of the interactions between the protein and 
the carrier, and the carrier chemistry.  
 For about two decades, the need for suitable materials for the delivery of 
drugs in a safe and controlled manner has led to the development of numerous 
biodegradable polymers. Controlled release of a variety of therapeutic drugs has 
been achieved with the use of biodegradable polymeric devices for the treatment of 
a wide range of complex diseases such as cancer, Alzheimer, and diabetes3. Some 
of the outstanding characteristics of these carriers that make them attractive for drug 
delivery applications include: enhanced efficacy, reduced toxicity, and improved 
patient compliance and convenience when compared to conventional drug 
administrations (Fig. 1.1)4. In a controlled drug release regimen, the level of drug is 
maintained within the desired therapeutic range for longer periods with a single 
dose. On the other hand, in a conventional drug administration, more doses are 
needed to obtain the desired therapeutic efficacy and there is a high risk of 



































































Among biodegradable polymers, polyesters and polyanhydrides have shown 
excellent performance as drug carriers. Biocompatibility studies have shown that 
these hydrophobic biomaterials degrade into non-mutagenic and non-cytotoxic 
products5-7. However, the erosion mechanism of each polymer confers special 
characteristics that in turn affect drug release. Polyesters degrade by bulk erosion, 
where a significant amount of water enters into the device. Therefore, interactions 
between drug and water are likely to take place. In contrast, polyanhydrides are 
surface erodible polymers, where the rate of erosion far exceeds the rate of water 
penetration. In consequence, the drug is released at the same rate as the polymer 
degradation and water-drug interactions are minimized. This is particularly relevant 
when delivering proteins, as these can be easily destabilized by chemical and 
physical pathways, as discussed below.  
 Two common physical pathways responsible for protein denaturation are 
covalent and non-covalent aggregation. As discussed above, the highly hydrophobic 
nature of polyanhydrides prevents water penetration into the bulk, thus eliminating 
water-induced covalent aggregation of some proteins. Unfortunately, protein 
inactivation by non-covalent aggregation may still persist. It has been suggested that 
the use of carriers containing both hydrophobic and hydrophilic entities may provide 
a gentler environment for proteins, since they are naturally amphiphilic structures8, 9. 
 In addition to stabilizing protein antigens in a vaccine delivery device, it is 
critical to enhance the immune response. A physiological immune response begins 
with the activation of the antigen presenting cell (APC). This is the crucial step of the 





generated against a particular antigen. The best APCs responsible to activate helper 
T cells, killer T cells and B cells are dendritic cells (DCs)10. As most recombinant 
proteins are poorly immunogenic, a vaccine adjuvant, which does not have a specific 
antigenic effect, must stabilize the protein antigen while enhancing the activation of 
DCs.  
 The overall objective of this research is to design a novel amphiphilic 
polyanhydride system for the sustained delivery of vaccines, which will provide the 
dual characteristics of protein stabilization and immune modulation. A rational 
approach to achieve this goal begins with the synthesis and characterization of the 
novel polyanhydride system, composed of the anhydride monomers 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) (Fig. 1.2). Briefly, synthesis, purity, material properties, and erosion 
mechanisms are analyzed in the context of drug delivery applications in Chapter 4. 
As most vaccines involve protein sub-units, protein stabilization and release will be 
demonstrated from CPTEG:CPH amphiphilic carriers in Chapters 5 and 6. The 
adjuvant characteristics of CPTEG:CPH microspheres are investigated in Chapter 7 
by their ability to activate DCs. The understanding gained from these experiments 
will provide insights for the evaluation of CPTEG:CPH formulations for cancer 
vaccine delivery using animal models as described in Chapter 8. The last chapter 
discusses current and future experiments that embrace a variety of potential 
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 Polyanhydrides are a class of bioerodible polymers that have shown excellent 
characteristics as drug and protein delivery carriers. The properties of these 
biomaterials can be tailored to obtain desirable controlled release characteristics. In 
Section 2.2, the extensive research on these promising biomaterials is discussed. 
Briefly, the chemical structures and synthesis methods of various polyanhydrides are 
presented, followed by a discussion of their physical, chemical and thermal 
properties with potential biomedical applications discussed at the end. Section 2.3 
discusses the mechanisms that can alter protein stability. Chemical and physical 
degradation pathways that can lead to protein denaturation are presented in order to 
motivate the development of a rational approach when designing new delivery 
carriers for these fragile macromolecules. Highlights of the immune system are 
presented in Section 2.4, where antigen presentation and the subsequent immune 
response are discussed. In section 2.5, the functions of adjuvants and their 
importance in vaccines are reviewed. The role of the biodegradable polymers that 
had been investigated as vaccine carriers is discussed in a comprehensive review in 
Section 2.6. Finally, Section 2.7 introduces the potential of peptide antigen-based 
cancer vaccines and the promising glycoproteins Mucin-1 and Mucin-4, which are 
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2.2 Polyanhydrides 
Reprinted from Encyclopedia of Chemical Processing: 2247-2257, Copyright 2006, 
with permission from Taylor & Francis. 




 The need for suitable materials for the delivery of drugs in a safe and 
controlled manner has led to the development of numerous biodegradable polymers.  
Controlled release of a variety of therapeutic agents has been achieved with the use 
of biodegradable polymeric devices. Research has focused on poly( -hydroxy 
acids), poly(orthoesters), and poly(anhydrides). Poly( -hydroxy acids) (e.g., 
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers) undergo bulk 
erosion and the drug release kinetics from these carriers is not well defined. On the 
other hand, poly(orthoesters) and polyanhydrides undergo surface erosion with 
predictable kinetics.  In the case of polyanhydrides, the degradation rates can be 
tailored to suit specific applications by changing the chemistry. 
 Polyanhydrides are comprised of monomer units connected by water-labile 
anhydride bonds. In the presence of water the polymer is cleaved across the 
anhydride bond into two carboxylic acid groups (Fig 2.1). It is precisely this hydrolytic 
instability that precluded their use in the textile industry in the 1950’s and led 
researchers to suggest their potential as drug delivery carriers in the 1980’s. Since 





variety of biomedical applications. The promising characteristics of polyanhydrides 
for biomedical applications rely on the surface erosion mechanism that translates 
into well-controlled release kinetics, where the drug release rate coincides with the 
degradation rate of the polymer. In an aqueous environment, the macromolecules at 
the surface break into smaller chains before water penetrates into the device. Thus, 
the drug is released as the polymer degrades. In contrast, bulk eroding polymers 
degrade slowly and water penetrates into the system much faster, having, in 
consequence, less predictable kinetics as drug is released from the entire matrix. A 
comparison of surface and bulk erosion mechanisms is shown in Fig. 2.2.  
 Polyanhydride-based drug delivery devices (Gliadel®) have been approved by 
the Food and Drug Administration (FDA) for the treatment of brain tumors. This 
device is a polyanhydride wafer composed of sebacic acid (SA) and 1,3-bis(p-
carboxyphenoxy)propane (CPP) (CPP:SA copolymer in 20:80 molar ratio) loaded 
with the chemotherapeutic agent, carmustine, 1,3-bis[2-chloroethyl]-1-nitro-sourea 
(BCNU). Other potential applications of CPP:SA copolymers include the release of 
bethanechol for the treatment of Alzheimer’s disease and the controlled release of 
insulin1. The treatment of osteomyelitis, which is a bone infection difficult to treat by  
conventional methods, has been carried out with 20:80 CPP:SA copolymer loaded 
with gentamicin sulfate1. Several chemotherapeutic drugs, local anesthetics, 

























Figure 2.1. Hydrolysis of Polyanhydrides 
This section provides an overview of polyanhydrides and their potential as 
drug carriers. First, chemical structures and synthesis methods are discussed. This 
is followed by a discussion of the physical, chemical and thermal properties and the 
effect of these on the degradation mechanism of polyanhydrides.   This is followed 











Figure 2.2. Mechanisms of polymer erosion: surface (left) and bulk (right). t0 and tf are the times previous and 
subsequent erosion.  











 There are three major classes of polyanhydrides: aliphatic, unsaturated, and 
aromatic. The chemical structures are shown in Table 2.1. 
 
2.2.2.1 Aliphatic Polyanhydrides 
 The first aliphatic polyanhydride synthesized was from the monomer adipic 
acid (AA), which is thermally unstable and forms cyclic dimers and polymeric rings 
when heated at high temperatures. In the 1930’s, the aliphatic polyanhydride most 
widely used currently in drug delivery applications, poly(sebacic acid) (SA), was 
synthesized for the first time2. Typical properties of aliphatic polyanhydrides include 
crystallinity, melting temperature range of 50-90 C (increasing with monomer chain 
length), and solubility in chlorinated hydrocarbons. These degrade and are 
eliminated from the body within weeks. When copolymerized with aromatic 
polyanhydrides, the degradation time can be extended to several months as the 
aromatic composition increases. The most widely studied aliphatic-aromatic 
copolymer system is based on SA and 1,3-bis(p-carboxyphenoxy)propane (CPP)3. 
 
2.2.2.2 Unsaturated Polyanhydrides 
 The development of unsaturated polyanhydrides responded to the necessity 
of improving the mechanical properties of the polymers for applications such as 
temporary replacement of bone4.  Unsaturated polyanhydrides, prepared by melt or 
solution polymerization, include homopolymers of fumaric acid (FA), 





The chemical structures of poly(FA) and poly(ACDA) are shown in  Table 2.1. These 
polymers are highly crystalline and insoluble in common organic solvents. The 
double bonds of these monomers make them suitable for further crosslinking to 
improve mechanical properties of polyanhydrides. When copolymerized with 
aliphatic diacids, less crystalline polymers with enhanced solubility in chlorinated 
solvents result.   
 
2.2.2.3 Aromatic Polyanhydrides 
 The first aromatic polyanhydrides synthesized were poly(isophthalic acid) 
(IPA) and poly(terephthalic acid) (TA)5. A few common aromatic polyanhydrides are 
shown in Table 2.1. Homopolymers of aromatic diacids are crystalline, insoluble in 
common organic solvents, and have melting points greater than 100 C. Their 
hydrophobicity results in a slow degradation rate that can last over a year in some 
cases. Thus aromatic polyanhydrides are not suitable for drug delivery when used 
as homopolymers. To overcome their slow degradation rates, they have been 
copolymerized with aliphatic diacids, i.e., CPP:SA copolymers, and with other 
aromatic monomers.  The copolymers of the aromatic monomers TA and IPA are 
amorphous, soluble, have a faster degradation, and a melting point below 120 C 6.  
 
2.2.2.4 Other Polyanhydride Chemistries 
 Although it is impossible to discuss in detail all the polyanhydrides that have 
been synthesized, some distinguishable classes are discussed here. Typical 





and fatty acids, and those modified by copolymerization with esters and ethers. The 
polyanhydrides derived from amino acids, including trimellitylimido glycine (shown in 
Table 2.1), pyromellitylimido alanine, and trimellitylimido L-tyrosine have been 
copolymerized with aliphatic (SA) and aromatic (CPP and CPH) monomers to obtain 
enhanced degradation and improved mechanical strength due the presence of the 
imide bond7. These polymers have been studied as vaccine carriers8. Some 
polyanhydrides have been synthesized from dimer and trimer unsaturated fatty 
acids, and from nonlinear hydrophobicfatty acid esters such as ricinoleic and maleic 
acid. Other classes of polyanhydrides include ones copolymerized with esters and 
ethers, which have been suggested as potential drug carriers in the last decade9, 10. 
Uhrich and co-workers recently synthesized novel poly(anhydride-co-ester)s 
containing salicylic acid in the backbone11-13. The in vitro/in vivo release of salicylic 
acid (the active form of aspirin) was studied for the treatment of Crohn’s disease and 
tuberculosis.  Copolymers of aliphatic polyanhydrides with -caprolactone, 
trimethylene carbonate, ethylene glycol14, and lactic acid have been synthesized.  
Several modifications of anhydride monomers have been carried out in order to 
obtain desired characteristics for particular applications15-17. An example is the 
incorporation of triethylene glycol (TEG) into an aromatic monomer (CPH) in order to 
enhance the hydrophilicity of the monomer, resulting in faster degradation rate18. 
The resulting polymer (Table 2.1) is poly(1,8-bis(p-carboxyphenoxy)-3,6-








































                         
            
   Classification                                            R group                            Examples
x=4 Adipic anhydride (AA)




meta: isophtalic anhydride (IPA)

























 The most widely used method to synthesize polyanhydrides is melt 
condensation polymerization, which results in high molecular weight polymers19. 
Other methods include Schotten-Baumann condensation, dehydrative coupling, and 
ring opening polymerization. 
 
2.2.3.1 Melt Polycondensation 
 The general process for melt polycondensation of polyanhydrides is shown in 
Figure 2.3. It consists of reacting dicarboxylic acid monomers with an excess of 
acetic anhydride to form oligomers that are polymerized at high temperature under 
vacuum. The degree of polymerization is influenced by the monomer purity, the 
strength of the vacuum, the reaction temperature, and the reaction time.  It has been 
found that for most polyanhydrides, the optimal polymerization temperature is in the 
range of 170-190 C 20. In general, the condensation reaction is conducted for 2-3 
hours, as significant depolymerization can occur after heating for longer periods21. 
With optimal conditions, molecular weights greater than 100,000 can be produced. 
 The polyanhydrides synthesized by melt condensation have fiber-forming 
properties in the molten state. They hydrolyze when exposed to air and this 
degradation is mainly controlled by the composition of the polymer. Homopolymers 
of aromatic monomers, such as CPH, degrade at a rate that is several orders of 


















180O C />1mm Hg
m=1-20
n=100-1000  
Figure 2.3. Melt condensation polymerization of polyanhydrides. 
 
Several variations have been made to the melt condensation process. In the 
case of polymerization with propionic anhydride and butyric anhydride, harsh 
conditions can be used for the removal of unreacted anhydride due the high boiling 
point of both chemicals6. A variety of catalysts have been used to polymerize 
polyanhydrides within 20-60 minutes, but the main disadvantage for biomedical 
applications is the potential toxicity from catalysts such as cadmium acetate, earth 
metal oxides, and ZnEt2-H2O 6.  
 
2.2.3.2 Schotten-Bauman Condensation  
 The Schotten-Bauman condensation produces polyanhydrides with moderate 
molecular weights by a dehydrochlorination reaction between a diacid chloride and a 
dicarboxylic acid20. The polymerization takes place by reacting the monomers for 1 





methods. Solvents that are used in solution polymerization include dichloromethane, 
chloroform, benzene, and ethyl ether. The degree of polymerization obtained with 
this method is ~20-30. Lower molecular weight products are obtained for less 
reactive monomers such as isophthaloyl chloride. 
 Polymerization conducted in aqueous interfacial systems suffers from 
hydrolytic decomposition. The decomposition reaction can be minimized when 
contact with water is avoided. In the case of polymerization in non-aqueous 
interfacial environments, products with number average molecular weights up to 
5,000 can be obtained21. Various aromatic polymers were prepared from the 
reaction of equimolar amounts of the acid dissolved in aqueous base and the 
corresponding diacid chloride dissolved in organic solvent. Reaction occurred 
between dibasic acid in one phase and an acid chloride in the other. Polar solvents 
for this reaction include dimethylformamide and 1,4-dicyanobutane. 
 
2.2.3.3 Dehydrative Coupling 
 Another method to synthesize polyanhydrides is by dehydrative coupling of 
two carboxyl groups. Even though this method produces lower molecular weights 
(mostly oligomers) compared with the methods described above, it is a single step 
polymerization where a dicarboxylic acid monomer can be directly converted into the 
polymer. Moreover, it can be conducted at low temperatures suitable for monomers 
that cannot resist harsh reaction conditions. 
 A number of dehydrative agents have been effective in coupling the carboxyl 





N-phenylphosphoroamidochloridate, diphenyl chlorophosphate, diethyl 
phosphorobromidate, dicyclohexylcarbodiimide, chlorosulfonylisocyanate, and 1,4-
phenylene diisocyanate21. In general, higher molecular weights were obtained with 
polar solvents such as dichloromethane and chloroform. The major disadvantage of 
this method is the problematic isolation and purification of the final products while 
preventing hydrolytic decomposition. 
 
2.2.3.4 Ring Opening Polymerization 
 Low molecular weight linear polymers undergo transformations between 
linear and cyclic forms. When a mixture of low and high molecular weight polymers 
is subjected to molecular distillation, cyclic monomers and dimers are distilled off 
and a high molecular weight polymer remains behind. The cyclic molecules are 
transformed to a polymer that contains large ring structures6.  
 Another variation of this process is the preparation of adipic acid from cyclic 
adipic anhydride (oxepane-2,7-dione). The monomer is prepared by the reaction of 
adipic acid and acetic anhydride followed by catalytic depolymerization under 
vacuum. Factors that affect this reaction include temperature, reaction time, and, if 
used, concentration of catalyst. When catalyzed, reaction at 180 C for 30 minutes 
produced polymers with molecular weights up to 300,000. Uncatalyzed reactions 









 In order to understand the properties that make polyanhydrides suitable drug 
carriers, their chemical, physical, and thermal behavior need to be characterized. 
This section discusses methods to determine the chemical structure and 
composition, the molecular weight, the thermal properties, the phase behavior, the 
stability, and the erosion mechanism of polyanhydrides. 
 
2.2.4.1 Chemical Structure and Composition 
 The technique most widely used for determining the chemical structure and 
composition of polyanhydrides is 1H NMR spectroscopy. The chemical structure is 
assigned in accord with the chemical shifts characteristic of aliphatic and aromatic 
protons. The protons close to electronegative groups, i.e. aromatic groups, absorb at 
lower frequencies (6.5-8.5 ppm), while aliphatic protons absorb at higher frequencies 
(1-2ppm) 22. 1H NMR has also been used to determine the degree of randomness in 
polyanhydride copolymers23. By integration of NMR peaks it is possible to determine 
if a copolymer has a random or block-like structure. Other useful information 
obtainable from 1H NMR spectra includes the conversion of polymerization 
reactions, the actual composition of the polymer, the polymer molecular weight, and 
degradation rate. 
 Fourier transform infrared (FTIR) and Raman spectroscopy have also been 
used to authenticate polyanhydrides structures. Aliphatic polymers absorb at 1740 
and 1810 cm-1, while aromatic polymers absorb at 1720 and 1780 cm-1 23. All the 





twisting. Aside from being used to ascertain polyanhydrides structures, these 
techniques can be used to determine degradation progress, by monitoring the area 
of carboxylic acid peak (1770-1675 cm-1) with respect to the characteristic anhydride 
peaks over time. 
  
2.2.4.2 Molecular Weight 
 The molecular weight of polyanhydrides can be determined by gel permeation 
chromatography (GPC), viscosity measurements, and 1H NMR spectroscopy. Vapor 
pressure osmometry (VPO) cannot be used for molecular weight determination, as 
depolymerization occurs during the experiment. The weight average molecular 
weight (Mw) of polyanhydrides ranges from 5,000 to 300,000. Typical polydispersity 
indexes are in the range of 2 to 15, which increases with molecular weight. GPC 
determines the molecular weight relative to polystyrene standards. The intrinsic 
viscosity ( ) is proportional to Mw, as shown by the Mark Houwink relationship for 
CPP:SA copolymer (Eq 1). This relationship was calculated from viscosity 






CHCl M.                                     (1) 
 An alternative way to estimate the molecular weight of polyanhydrides is by 
end group analysis from 1H NMR spectra. The degree of polymerization can be 
calculated from the ratio of the area of the inner chain protons to the area of 
terminating groups. The number average degree of polymerization (DP) of CPP:SA 





inner chain protons, (Ac) represent the acetylated end group, and (SA*) and (CPP*) 




SACPPDP                                            (2) 
 
2.2.4.3 Thermal Properties 
 The thermal transitions of polyanhydrides have been determined from 
differential scanning calorimetry (DSC). DSC thermal scans provide properties such 
as glass transition temperature (Tg), melting temperature (Tm), and heat of fusion 
(∆H). It is important to know the values of Tg and Tm in the fabrication of drug 
delivery devices such as tablets and microspheres. While Tg determines the 
minimum temperature required for compression molding, Tm determines the 
minimum temperature necessary for injection molding or melt compression. A 
general decreasing trend in Tg’s has been observed as methylene groups are added 
into the main chain of an anhydride monomer. As mentioned earlier, aliphatic 
polyanhydrides melt at temperatures below 100 C and aromatic polyanhydrides 
have melting points greater than 100 C.  
 It has been shown that the crystallinity of polymers affects erosion and drug 
release rates, as crystalline regions erode slower than amorphous ones25. Moreover, 
highly crystalline polyanhydrides affect device morphology as it creates irregular 
external surfaces. The crystallinity of polyanhydrides has been determined using X-
ray diffraction, DSC, 1H NMR spectroscopy, and small-angle X-ray scattering 





diacids are crystalline. When copolymerized, polyanhydrides exhibited a decrease in 
crystallinity in copolymers of equimolar compositions, i.e. CPP:SA, CPH:SA, and 
FA:SA copolymers25. The ∆H from DSC thermographs exhibited a decrease as the 
copolymers approached equimolar compositions. This decrease in crystallinity is 
representative of the random behavior of the polymer chain, as determined by 1H 
NMR spectra. In general, the copolymers rich in one monomer had higher 
crystallinity.   
 
2.2.4.4 Phase Behavior 
 Polymers blends, which display distinct physical and chemical properties, are 
used for the design of materials for diverse applications. This variation in properties 
may lead to microphase separation, which in turns affect drug release, as drugs 
thermodynamically partition between the phases, depending on their compatibility 
with the phase26. Research has shown that aliphatic, aromatic, and copolymers of 
anhydrides monomers are miscible and the blends had a single melting temperature 
that was lower than that of the starting polymers6. On the other hand, 
polyanhydrides that are partially miscible with poly(orthoesters), poly(hydroxybutyric 
acids), and low molecular weight poly(esters), with two melting temperatures, was 
clearly indicative of the phase separation. Blends of polyanhydrides with 
poly(caprolactone) (poly(CL)) are completely immiscible. Degradation studies in 
blends of poly(CL) with poly(dodecanedioic anhydride) (poly(DD)) indicated that the 
anhydride component degraded rapidly and released from the blend, without 





microphase-separated copolymers of poly(SA) with poly(CPH) or poly(ethylene 
glycol)27, 28. The phase diagram for the poly(CPH)/poly(SA) blend system has been 
determined using small angle X-ray scattering (SAXS), optical microscopy, and 
molecular simulations, while the blends of poly(SA) and PEG were characterized by 
DSC and IR spectra. The poly(CPH)/poly(SA) system exhibits an upper critical 
solution temperature behavior.   
 
2.2.4.5 Stability 
 The stability of polyanhydrides has been studied in solid state and in dry 
chloroform. Aromatic polyanhydrides such as poly(CPP), poly(CPH), and poly(CPM) 
maintained their original molecular weight for at least 1 year in solid state upon 
storage under dry argon or vacuum at 21 C. In contrast, aliphatic polyanhydrides 
such as poly(SA) have a rapidly degradation rate at the same storage conditions1. 
Studies performed with GPC revealed that weight average molecular weight tend to 
decrease rapidly initially, and later a constant stabilized decrease in molecular 
weight is observed. The decrease in molecular weight was explained by an internal 
anhydride interchange mechanism resulting in ring formation, as revealed by 1H 
NMR. This mechanism was supported by the fact that the decrease in molecular 
weight was reversible and heating of the depolymerized polymer at 180 C for 20 min 
yielded the original high molecular weight polymer23. It is important to mention that 
polyanhydrides experienced significant weight loss when stored at ambient 





 The stability of polyanhydrides in solution was studied using chloroform under 
dry nitrogen atmosphere at 37 C 1. The aromatic polyanhydrides remained stable 
under these conditions during a 3 day period, while copolymers with aliphatic SA 
had a significant molecular weight loss during the same time period. Therefore, 
polyanhydrides can be processed in solution environment as long as the time is not 
extended over this period. 
 -irradiation methods have been utilized for sterilization of polyanhydrides. In 
this technique, aliphatic and aromatic homo- and copolymers were irradiated at 2.5 
MRad and the chemical structure as well as the physical properties were found to be 
the same before and after irradiation23.  The studies showed that saturated 
polyanhydrides are stable during -irradiation, as a slight increase in molecular 
weight was observed. Electron paramagnetic resonance (EPR) spectroscopy was 
used to characterize free radicals in -sterilized polyanhydrides29. Polymers with high 
melting temperatures produced the highest yields of room temperature radicals, 
which in turn transform into less conjugated polyanhydrides that leads to lower 
molecular weight polymers.  
 
2.2.4.6 Degradation and Erosion 
 Polymer erosion (i.e., mass loss) is a complex process that is determined by 
numerous factors that include the molecular weight loss (degradation), the swelling, 
the dissolution and diffusion of oligomers and monomers, and morphological 





of the chemical instability of the anhydride bond. Thus, degradation and erosion are 
limited to the surface, as water does not penetrate into the device31. 
 Erosion kinetics is complicated when the anhydride monomers of a copolymer 
system exhibit micro-phase separation that leads to erosion of the different phases 
at different rates. The erosion of a fast eroding phase may leave intact the slow 
eroding phase32. At this point, the monomer solubility plays a major role in 
polyanhydride erosion kinetics, as monomers are accumulated in eroding zones of 
the matrix and its dissolution will depend on the pH of the microenvironment33. It is 
known that the saturation concentration of the monomers CPH, SA, and CPTEG is a 
function of pH and that at a particular pH, the order of solubility of the monomers is 
CPTEG > SA > CPH, which provides valuable information when describing drug 
release from polymers containing any of these monomers18, 32. 
 
2.2.5 Polyanhydride-based Drug Delivery Systems 
 
2.2.5.1 Biocompatibility 
The biocompatibility of implantable polyanhydride disks was studied in the 
brains of rats, rabbits, monkeys, and eventually in human clinical trials34. Wafers of 
poly(CPP:SA) and poly(FAD:SA) were implanted in the frontal lobes of rats, rabbits, 
and monkeys. In all studies the animals receiving the implants showed no behavioral 
changes or neurological deficits indicating that the polymers were not invoking a 
systemic or local toxicity. To determine how the body metabolized the poly(CPP:SA) 
radio-labeled copolymers were implanted in the brains of rats20. Seven days after 





urine, and 2% feces, and 10% still in the implanted device. In the same period only 
4% of the 14C CPP-labeled polymer was excreted by urine and feces. 
The biocompatibility of poly(CPP), poly(TA), and copolymers of CPP:SA and 
CPP:TA implanted in the corneas of rabbits was studied35, 36. Six weeks after 
implantation, the cornea remained clear and showed no evidence of corneal edema 
or neovascularization, indicating biocompatibility of the polymer matrix implant.   
Subcutaneous implants of 20:80 CPP:SA copolymer were administered in 
rats at doses of 40 and 120 times the size to be used in humans. The purpose of 
these experiments was to test the systemic toxicity of the polymers. Eight weeks 
after implanting the disks the rats were sacrificed and their organs underwent 
histopathological evaluations. In general there was little to no difference between the 
organs of the experimental group (receiving the implant) and those of the control 
group. Again, in all cases the polymers underwent degradation and were found to 
cause minimal inflammation at the site of implantation. Thus, polyanhydrides are 
inert and suitable for in vivo drug delivery37. 
 
2.2.5.2 Drug/Polymer Interactions 
When selecting polymers as drug delivery carriers, it is necessary to establish 
whether the polymer will react with the incorporated or the released drug. Three 
factors need to be considered: the reactivity of the drug, the hydrophobicity of the 
drug, and the fabrication method. The reactivity of CPP:SA copolymer with the para 
substituted anilines: p-nitroaniline (PNA), p-bromoaniline, and p-anisidine, and p-





polymer matrix using injection and compression molding. When injection molding 
was used to encapsulate the drugs at 120ºC the more reactive drugs (p-
bromoaniline, and p-anisidine, and p-phenylenediamine) reacted with the polymer 
forming amides. However, when the drugs were incorporated into the polymer matrix 
using compression molding at room temperature the drugs did not react with the 
polymer during the fabrication process.  
The hydrophobicity of the drug can also influence interactions between the 
drug and the polymer. When hydrophilic dyes (acid orange and brilliant blue) were 
encapsulated in polyanhydrides the Tm’s of the polymers were unchanged.  When 
hydrophobic dyes (p-nitroaniline and methyl red) were encapsulated the Tm’s of the 
polymers changed, indicating an interaction between the polymer and the drug38. 
 
2.2.5.3 Device Fabrication 
Polyanhydride drug delivery devices have been fabricated as implantable39 
and injectable devices. Implantable devices are fabricated by either compression, 
melt molding, or by solvent casting. The first step of compression molding is to 
obtain a fine powder of the drug and the polymer. The powders are physically mixed 
and placed in a piston mold. The wafer is formed by applying a pressure (typically 30 
kpsi) and by heating the sample to a temperature 5-10ºC above the Tg of the 
polymer1, 40. One drawback of this method is the uneven distribution of the drug in 
the polymer, leading to poor reproducibility. The Gliadel® system is a compression 





polymer are spray dried together to form microspheres. The microspheres are then 
compression molded to form the wafer.   
The alternative to compression molding is melt compression. This procedure 
requires the polymer and drug to be heated 10ºC above the Tm of the polymer, 
forming a viscous solution1, 40. The solution can then be placed in either a 
conventional mold under low pressure or it can be injection molded. This fabrication 
method results in an even drug distribution. However, the elevated temperatures 
needed to melt the polymer could cause adverse reactions in temperature sensitive 
drugs, such as proteins. 
Solvent casting is done by co-dissolving or suspending the drug in the 
polymer solution. The solution is then poured into a flat open mold and cooled on dry 
ice. The resulting film is often fragile. If the drug is not soluble in the polymer it will 
settle on the bottom of the film leading to an uneven drug distribution26, 29.   
To form an injectable drug delivery device the drug is loaded into polymer 
microspheres. Drug-loaded polyanhydride microspheres have been fabricated using 
different methods. The most common method is the solvent extraction method; 
which includes water/oil/water, water/oil/oil or solid/oil/oil (dependent on whether the 
drug is soluble in the polymer solvent). In the w/o/w method the drug (typically 
proteins) is dissolved in an aqueous phase and then emulsified with a larger volume 
of polymer dissolved in an organic, typically methylene chloride. The inner emulsion 
is then added to a larger volume of water that contains a surfactant, usually PVA, 





w/o/o or s/o/o the outer aqueous PVA phase is replaced with an immiscible organic, 
i.e. silicon oil. The spheres are typically collected by either centrifugation or filtration.   
Microspheres can also be fabricated by the hot-melt procedure, however this 
method is not ideal for encapsulating temperature sensitive drugs, such as proteins1. 
Spray drying or atomizing the polymer and drug together can also be used to 
fabricate microspheres. This method requires the use of either a spray dryer or 
atomization1, 41. In the case of the spray dryer the polymer/drug suspension is 
pumped into the spray drier and as the suspension is sprayed a stream of air causes 
the polymer spheres to harden. Microspheres are fabricated by atomization by 
passing the drug/polymer suspension through an atomizing nozzle. As the 
polymer/drug spheres leave the nozzle they are collected in a bath of liquid nitrogen 
sitting on top of a frozen layer of ethanol41. The liquid nitrogen/ethanol bath is then 
stored at -80ºC for three days. During this time the ethanol slowly thaws and the 
frozen microspheres fall into it. As the microspheres sit in the ethanol the organic 
solvent (methylene chloride) slowly diffuses out, leaving solid spheres to be 
collected by filtration. 
 
2.2.5.4 In Vitro Release 
The rate at which an encapsulated drug will be released from a polyanhydride 
device, either a wafer or a microsphere, is strongly dependent on polymer 
composition and drug distribution. Other factors that contribute to the release rate of 
drugs include: fabrication technique, size/shape of the device, and pH of the 





The hydrophobicity of a drug influences its distribution within the polymeric 
device26. PNA and disperse yellow have higher affinities for poly(CPH) and poly(SA) 
respectively. The two drugs were encapsulated in tablets of poly(CPH), poly(SA), 
and copolymers of the two to determine if the drugs would partition into the more 
favorable polymer micro-domain. When the dominant polymer had a low affinity for 
the drug, a burst effect was seen. In the case of 50:50 CPH:SA copolymer, each 
drug followed the release of the monomers, indicating that the drug was partitioning 
into the more favorable domain.   
The size of the device may also influence drug distribution and release rate42.  
Monodisperse microspheres of differing average diameters were studied to 
determine the influence of the size of the device on the delivery. Smaller diameter 
microspheres showed a more prolonged release rate of drug than did microspheres 
that had a large diameter. As the diameter increased the time it took for the 
microsphere to form by precipitation increased, thus increasing the time for the drug 
to segregate towards the surface of the microspheres. 
As the anhydride bonds in the polymer backbone are hydrolyzed carboxylic 
acids are formed. The formation of the acidic degradation products reduces the local 
pH of the eroding device. The diffusion of the acidic degradation products away from 
the device is expedited when the device is in a basic solution. However, when the 








2.2.5.5 In Vivo Delivery 
 As mentioned previously, the 20:80 CPP:SA copolymer was the first 
polyanhydride to be clinically tested in humans. The copolymer was used to 
encapsulate BCNU, a chemotherapeutic drug used to treat glioblastoma multiforme, 
a fatal form of brain cancer. BCNU was co-dissolved with the polymer and disks 
were fabricated by compression molding. The preclinical trials in rat, rabbit, dog, and 
monkey brains demonstrated the effectiveness of the polymer in delivering an active 
drug that remained localized, minimizing systemic reaction to the drug44. The wafer, 
once implanted into the brain of the glioblastoma patients, releases the BCNU for ~3 
weeks45. SEM was used to monitor the erosion of the wafer both in vitro and in 
vivo46. It was found that the erosion of the wafer was controlled by diffusion of BCNU 
and erosion of the polymer. The delivery device was approved in 1996 by the US-
FDA for use in conjunction with surgery for patients suffering from recurrent 
glioblastoma. In 2003 the US-FDA approved the use of the device in newly 
diagnosed advanced cases of malignant gliomas to be used in conjunction with 
surgery and radiation. 
The use of 20:80 CPP:SA and 18:82 FAD:SA copolymers disks as drug 
delivery devices for carboplatin, a treatment for glioma, was also investigated in 
rodents47. The majority of the drug was released in seven days from the CPP:SA 
copolymer disk and 65% of the drug was released from the FAD:SA copolymer disk 
in seven days. This method of delivery was more effective than systemic therapy 





A separate polyanhydride system has also been investigated for treatment of 
osteomyelitis, a bone infection typically caused by bacteria48-50. 50:50 FAD:SA 
copolymer implants containing gentamicin were tested in the backs of rats, in 
infected tarsocrural joints of horses, and in humans with infected prosthetic hips or 
knees49. In all cases the local delivery of gentamicin was successful and the 
systemic exposure to the drug was avoided. 
 
2.3 Protein Stability 
2.3.1 Introduction 
 
 There are several hundred protein-based drugs that are being currently 
investigated by the U.S. FDA. In 2003, the estimated annual research expenditures 
in this area was $30 billion51. However, major challenges still exist as a 
consequence of protein susceptibility to chemical and physical instability, which in 
consequence may hinder their therapeutic efficacy.  
 Proteins have complex structures essential for their biological activity. They 
possess different structural levels that start with the primary structure (amino acid 
sequence) and can extend to more complex secondary, tertiary and quaternary 
structures. In general, the hydrophobic groups of the protein are packed within the 
core and the polar residues that can interact with polar solvents are located in the 
surface. Instability of peptides involves primarily chemical pathways of degradation, 
while proteins can degrade by chemical and physical pathways to the same extent. 
The stabilities of the interactions are so interdependent that disruption of a very 





most prominent routes of protein inactivation by chemical and physical pathways 
and how these can be related with polymeric systems. 
 
2.3.2 Chemical Instability 
 Chemical instability is produced when a new chemical structure is formed as 
a result of bond formation or disruption53. Typically this degradation pathway 
involves the disruption of the primary sequence and the reactivity of the side 
chains54. The chemical reactions that will be discussed are the most commonly 
encountered, including deamidation, hydrolysis, oxidation, β-elimination of disulfide, 
and disulfide scrambling. 
 
2.3.2.1 Deamidation 
 The deamidation of asparagines and glutamines residues of a protein are the 
most common chemical pathway that lead to protein degradation, and it can be 
influenced by endogenous and exogenous factors55-58. Deamidation causes an 
intramolecular rearrangement to form a five-membered succinimide ring that in turn 
is susceptible to hydrolysis and racemization59. Among the endogenous factors, the 
nature of the amino acid residue near the asparagines is the principal cause for 
deamidation. Important is the fact that certain proteins will not be affected by this 
factor as their native conformational arrangement does not provide the flexibility to 
produce the cyclic imide53. On the other hand, the major external factor that 
influences deamidation of these residues is the pH environment. Under neutral or 





formed by intramolecular attack. The rate constants of deamidation in these 
environments were much faster than in acidic solutions, and maximum stability was 
observed in the pH range of 3.0-5.0 60. Other external factors that may influence the 
deamidation of protein residues are elevated temperature, nature of buffer, buffer 
concentration, moisture and ionic strength. As expected, this chemical pathway can 
lead to changes in protein conformation and aggregation, detrimental to the protein.  
 
2.3.2.2 Hydrolysis 
 An acidic environment may cause the spontaneous hydrolysis of the peptide 
backbone. This reaction is of particular importance when peptides and proteins are 
loaded into a polymeric system that erodes by bulk erosion mechanism, allowing 
significant amount of water to enter into the device. Biodegradable polymers that are 
particularly unstable are the polyesters that degrade into monomeric acidic entities. 
The amino acid that is most labile to this degradation pathway is the aspartic acid, 
which hydrolyzes about 100 times faster than other peptide bonds59. Cleavage can 
occur at either the carbon or nitrogen terminal peptide bonds of aspartate to form a 
cyclic imide prone to racemization. 
 
2.3.2.3 Oxidation 
 The amino acid residues most prone to oxidation in the presence of oxidizing 
agents are serine, cysteine, methionine, histidine, tryptophan, and tyrosine. At mildly 
acidic conditions in the presence of hydrogen peroxide, methionine is the primary 





non-selectively with all amino acids. The loss of biological activity will be determined 
by the location where the oxidation occurs that may disrupt the protein native 
structure. Besides oxidation by reactive oxygen species, there are other oxidative 
degradation pathways. Some of these routes includes metal-catalyzed oxidation and 
auto-oxidation by molecular oxygen in the absence of any catalytic process 53. 
 
2.3.2.4 β-Elimination of Disulfide 
 Disulfide bonds of cysteines are susceptible to β-elimination. Unstable 
products results from the nucleophilic attack of a hydroxide ion on a carbon atom in 
a carbon-sulfur bond. The presence of the hydroxide ion catalyzes the β-elimination, 
so alkaline conditions facilitates this chemical degradation reaction59. The 
bioavailability of the proteins undergoing β-elimination is likely to be affected as 
disulfides play a role in maintaining the three-dimensional structure of a protein. 
 
2.3.2.5 Disulfide Scrambling 
 As mentioned above, disulfide bonds are partially responsible for maintaining 
the conformational structure of a protein. In the same way, an incorrect formation 
and position of these bonds may lead to drastic changes in protein function. 
Adsorption and non-covalent aggregation (precipitation) can also result from 
disulfide scrambling that can occur at acidic and alkaline environments. The low 







2.3.3 Physical Instability 
 Physical instability refers to changes in the structural level of proteins that can 
lead to denaturation, adsorption, and precipitation53. The protein loses its ability to 
retain at least its tertiary structure, that is crucial for biological activity54. The factors 
that promote this instability comprise changes in temperature, pH, and ionic 
strength, among others. Some proteins unfold by means of the so-called two-state 
equilibrium process, which involves a thermodynamic equilibrium between a native 
and denatured state. This unfolded state is characterized by minimal or no 
bioactivity. Advances in research led to the discovery that unfolding of globular 
proteins involves equilibrium intermediates called “molten globules”, which are 
characterized by having a native like secondary structure but lacking the tertiary 
structure important for their biological function61, 62. These intermediates can lead to 
irreversible denaturation by promoting aggregation.  
 The forces involved in stabilizing the native state include electrostatic, van der 
Waals, and hydrophobic interactions. The native structure is stabilized slightly over 
the denatured one; typically, the Gibbs free energy for the folding equation is only 
about 5-50 kJ/mol 63, 64. Therefore, a moderate change in the protein environment 
can lead to the disruption of the delicate balance of forces involved in stabilizing 
protein conformation59. 
 Protein unfolding usually leads to the exposure of hydrophobic moieties 
previously buried in the protein interior. This unfavorable situation can be 
ameliorated by the association of unfolded molecules via non-covalent interactions 





between them, unfolded proteins may bind to hydrophobic polymeric surfaces and in 
consequence promote non-covalent aggregation. Unfolding is a reversible process, 
but aggregation is practically irreversible59. Exogenous factors that cause protein’s 
physical instability that will be discussed are thermal instability, pH, interfacial 
tension, and dehydration.  
 
2.3.3.1 Thermal Instability 
 When proteins are exposed to increasing temperature, losses of solubility or 
bioactivity occurs over a fairly narrow range. These changes may or may not be 
reversible, depending on the protein nature and the severe conditions of the 
temperature. As the temperature is increased, a number of bonds in the protein 
molecule are weakened and in consequence the conformational tertiary structure is 
disrupted to become more flexible. As these bonds are first weakened, the protein 
exposes groups that were previously buried to solvent. If heating ceases at this 
stage the protein should be able to readily refold to the native structure. When 
heating continues, the hydrogen bonds responsible to maintain the secondary 
structure of the protein will begin to be disrupted. As these bonds are broken, water 
can interact with and form new hydrogen bonds with the amide nitrogen and 
carbonyl oxygen of the peptide bonds. As a result, more hydrophobic groups are 
exposed to the solvent and an irreversible unfolded state is produced. At 








 The effect of pH in physical instability is unpredictable and highly protein 
dependent. At the isoelectric point (pI) of the protein, the protein charge is neutral. 
Proteins tend to be least soluble at pH values near their isoelectric point, where 
charge repulsions will be at minimum and many proteins will precipitate (aggregated) 
as a result of the reduced solubility52. If the pH is lowered below the pI, usually at 
acidic pH, some of the protein’s side chain carboxyl groups become protonated and 
lose their ionic charge. The like charges will repel each other and prevent the protein 
from aggregating. Nevertheless, the intramolecular repulsion may be so strong that 
unfolding of the protein can occur as the requirement for flexibility is fulfilled by the 
compensation of attractive and repulsive interactions63. This will have an effect 
similar to that of mild heat treatment on the protein structure and some hydrophobic 
groups that were previously buried in the protein interior are exposed. In some cases 
the unfolding may be extensive enough to expose significant hydrophobic groups 
and cause irreversible aggregation. It is important to take into consideration that 
some proteins contain acid labile groups and even relatively mild acid treatment may 
cause irreversible loss of their function. The effects of high pH are analogous to 
those of low pH. At basic pH, amino groups become deprotonated, and in 
consequence large negative charge is conferred to the protein that can lead to 
unfolding and aggregation. As can be seen both pH extremes lead to conformational 







2.3.3.3 Interfacial Tension 
 The inherent surface activity of the protein promotes their tendency to 
concentrate at interfaces. The more important role of the interface lies in its ability to 
generate or kinetically trap partially unfolded proteins, which in consequence 
produce aggregates that lead to denaturation53. The common interfaces that lead to 
protein inactivation are either liquid-air or aqueous-organic interfaces54. In the 
aqueous-organic interface, the protein comes into contact with a hydrophobic 
environment, where protein hydrophobic groups gain more flexibility that can lead to 
unfolding. The flexibility of the tertiary structure of the protein confers the protein the 
ability to accommodate into the lowest energy configuration possible. The principle 
of like dissolves like can be applied to this process, as hydrophobic groups that 
usually lie in the interior will tend to expose to the organic solvent and the hydrophilic 
groups at the surface will try to hide in order to look for more stable conformational 
arrangement. This process will continue until random fluctuations in protein structure 
can no longer yield a configuration of lower free energy. This unfolding is essentially 
non-reversible because of the large energy barriers.  
 The same forces are in operation when a protein migrates to a liquid-air 
interface. Hydrophobic groups tend to associate in the air and the protein unfolds. 
The presence of shear causes to help unfold the protein and to introduce more air 
into the solution. Both of these effects can be minimized by keeping the temperature 
low (to weaken hydrophobic bonds) and by minimizing the interfacial area. If the 





presence of this denatured protein will serve as a barrier to further denaturation.  
 
2.3.3.4 Dehydration 
 The dehydration or lyophilization process can result in protein instability if 
appropriate precautions are not taken53. The kinetic approach assumes that some 
degree of mobility is required for unfolding to occur. Consequently by vitrification of a 
protein in a glassy amorphous matrix below its glass transition temperature (Tg), the 
kinetic barrier to unfolding will be limiting. The possible changes in conformational 
structure during lyophilization may or may not be reversible. The irreversibility of the 
conformational altered proteins in the dehydrated solid may be largely due the 

















2.4 Immune System 
2.4.1 Introduction 
 A physiological immune response begins with the antigen presenting cell 
(APC). This is the crucial step of the immune system activation. Without proper 
activation of these cells, no response is generated against a particular antigen. The 
best APC responsible to activate helper T cells, killer T cells and B cells are the 
dendritic cells (DC). Immature DCs are found under the skin and mucous 
membranes where they sample surrounding for possible pathogens through 
pathogen-associated molecular patterns (PAMPs) receptors, which play a role in the 
activation of DCs and influence their subsequent activation. After detecting a 
pathogen, these cells engulf it through phagocytosis and migrate to lymph nodes 
where they become mature. Once inside the DC, pathogens are degraded into small 
fragments that are further expressed at their surface where they can be presented to 
T cells and B cells (Fig. 2.4). After the specific T cell and B cell becomes activated, 
these will generate a cascade of events that will lead to attack the disease. 
Figure 2.4. Dendritic cell (DC) activation. 
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2.4.2 Antigen Presentation 
 
 There are two antigen presenting pathways of DCs to the Major 
Histocompatibility Complex (MHC) molecules, whose function is to bind peptide 
fragments derived from pathogens and display them on the cell surface for T cell 
recognition66. One of these pathways is the endogenous, which involves 
presentation of peptide-MHC I molecules to CD8+ T cells. Tumor specific CD8+ T 
cells activated by DCs presenting tumor antigens can kill tumor cells directly by 
activating cytotoxic mechanisms (granzymes and perforins) associated with these 
tumor-specific CD8+ T cells. On the other hand, the exogenous pathway involves 
presentation of MHC II molecules to CD4+ T cells. Subset of activated CD4+ T cells, 
known as helper T cells Th1 and Th2, are responsible for cell-mediated and humoral 
immunity respectively67. Both CD4+ and CD8+ T cells are important in achieving 
immunological control of tumors and the survival and persistence of CD8+ T cells as 
memory cells is regulated by tumor specific CD4+ T cells68. Tumor cells do not 
usually express MHC class II molecules69, therefore most tumor antigens are not 
presented to CD4+ helper T cells, a fact that has to be considered when developing 
a cancer vaccine. There is a need to find proper immunomodulatory agents that 
enhance response from CD4+ helper T cells to ensure their proper activation.  
 
2.4.3 Immune Response 
 The effector functions of T cells are determined by the array of effector 
molecules they produce after their activation. This activation can be measured by 





messengers that regulate the innate and adaptive immune responses as a result of 
immune recognition. Activated DCs produce the cytokines tumor necrosis factor 
alpha (TNF-α), which mediates acute inflammation, and a variety of interleukins, 
such as IL-1, IL-6, IL-8, IL-12, and IL-10. IL-1 induces secretion of IL-2, which 
induces maturation of the precursors for antigen specific cytotoxic T lymphocytes 
(CTL) and natural killer (NK) cells, and B cells. NK cell cytotoxicity do not require 
specific antigen recognition as opposed to CTLs70. Th1 responses associate with the 
release of interferon gamma (IFN-γ), which is an immunoregulatory protein, and 
tumor necrosis factor (TNF) for immediate anti-tumor effects. A Th2 response 
associate with release of IL-4, IL-5, and IL-13 67. Thus the immune response 
generated after antigen presentation can be elucidated by the proper measurement 
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An adjuvant is an agent that stimulates the immune system, increasing the 
response to a vaccine, while not having any specific antigenic effect. Adjuvants are 
immunoenhancing materials that perform three major functions, i) provide a “depot” 
for the antigen, creating an antigenic reservoir for slow release, ii) facilitate targeting 
of the antigen to immune cells (APCs) and enhancing phagocytosis, and iii) 
modulate and enhance the type of immune response induced by the antigen alone 
(e.g., isotype switching induce Th1 vs. Th2 bias)71-73. Adjuvants may also provide 
the danger signal the immune system needs in order to respond to the antigen as it 










2.5.2 Functions of Adjuvants 
The first function, providing a depot for the immunogen, is accomplished by 
entrapping the antigen in a poorly metabolized, non-dissolving or slowly dissolving 
substance, or otherwise sequestering the antigen to allow for the slow clearance of 
the antigen from the body. Some of these adjuvants are discussed in more depth in 
other sections of the review. Aluminum phosphate and aluminum hydroxide, 
commonly referred to as alum, are the adjuvants most often used in human vaccines 
and the gel-like matrix of alum creates a slow-release environment for the 
immunogen. Oil-water emulsions also work by sequestering the antigen and slowly 
releasing it. The classic oil-in-water emulsion, Incomplete Freund’s adjuvant, is 
widely used in livestock vaccines, even though it has a tendency to induce 
granulomas75. It is not used in vaccine formulations for human use because of this 
tendency. Other mineral oil emulsions, such as Drakeol, Marcol, ISA 206, and ISA 
25 from Seppic Montanide are carriers also used in various livestock vaccines75. 
Recently, MF59, a variation of the biodegradable oil squalene, has proven to be a 
potent adjuvant with a satisfactory safety record and, thus, is suitable for human 
use75,76. Virosomes, virus-like particles, ISCOMs, and liposomes all allow for the 
slow clearance of antigen by incorporating the antigen into small particles composed 
of stabilized lipids, phospholipids, or proteins. Furthermore, antigen sequestering 
can be achieved by incorporating the antigen into microspheres composed of 
polymeric units of a biodegradable material. As the microsphere degrades, the 






The second function of adjuvants is to enhance the immune response by 
targeting the antigen to immune cells, enhancing phagocytosis, and/or activating the 
APC. This can be accomplished by properties of the antigen, by a property of the 
carrier, or by inclusion of immunostimulatory molecules. Pertussis toxin binds with 
high affinity to epithelial cells, enhancing uptake of the vaccine74. Other toxins, 
cholera toxin and Escherichia coli heat-labile toxin (LT), bind selectively to M cells of 
the intestinal tract77. These cells translocate the vaccine particle across the epithelial 
barrier to a region rich in lymphocytes74,75,78. While bacterial toxins such as cholera 
toxin and E. coli LT augment a strong humoral (Th2) immune responses, the 
response to the anti-toxin may overshadow the response to the conjugate antigen74. 
Another bacterial-derived immunostimulant is LPS which is derived from the outer 
membrane of gram-negative bacteria such as B. pertussis. These bacterial products 
directly interact with the innate immune system via LPS receptors CD14 and TLR-4 
78. Human TLRs, when triggered by LPS, stimulate the activation of NF- B, a 
transcriptional activator for the production of pro-inflammatory cytokines75. Because 
humans are very sensitive to endotoxins, LPS is generally too toxic for inclusion in 
many human vaccine preparations and the majority of injectable solutions for 
medical use are pyrogen free.  
These first two mechanisms of immunity are illustrated in Figure 2.5. Some 
adjuvants may interact directly with TLRs on APC (See Fig 2.5a), and can be 
derived from pathogens that display highly conserved structures (e.g. PAMPs)79.  As 





antigen as in the more traditional depot effect. Many adjuvants exhibit a combination 
of these characteristics.  
 
Immune modulation can be influenced by other characteristics of the 
adjuvant/delivery system80. As mentioned above, an immune response can be 
categorized as either Th1- or Th2-like. Many different factors can contribute to Th1-
Th2 bias of the immune response including route of antigen delivery (intramuscular, 
subcutaneous, intranasal, oral), antigen dose, duration of antigen presentation, 
number or frequency of immunizations and inclusion of co-stimulatory molecules 
(e.g. LPS, exogenous cytokines) with the antigen81. Adjuvants can affect all of these 
factors in different ways, the role of the vaccinologist is the use the correct adjuvant 
to induce a protective immune response81.  
In addition, the form (e.g. particulate or soluble) of the antigen, delivery 
system, and route of delivery can all affect the Th1-Th2 bias of a subsequent 
Figure 2.5. Recognition of antigen and adjuvant by immature DC. An adjuvant may interact directly with 
DC thru PAMPs (a), or have a ‘depot’ effect to where the antigen is presented over time as the adjuvant 

















immune response to a vaccine, and the type of immune response (Th1 or Th2) that 
will be protective varies with the disease in question. Antigen, adjuvants and delivery 
systems need to be chosen with care to obtain the most protective response. 
Current licensed vaccines for the most part are lacking in their ability to induce Th1 
type immune responses without also generating undesirable toxic side-effects such 
as the severe inflammation associated with whole-cell pertussis vaccines82. While 
traditional alum-based vaccines initiate T helper type 2 (Th2) response75, a T helper 
type 1 (Th1) response may be more effective for preventing some diseases8. Alum is 
still widely used in veterinary vaccines, but is frequently associated with granulomas 
in tissues and subsequent carcass losses83. Oil-based liposomes are capable of 
inducing a strong Th1 response, but are also associated with adverse tissue 
reactivity, granuloma formation, and subsequent carcass loss84, 85.  
In the United States, two adjuvants are currently approved for use in humans; 
alum and MF59, a biodegradable plant oil emulsion containing muramyl tripeptide. 
Highly purified muramyl tripeptide (MTP) is a synthetic component similar to that 
found in mycobacterial cell walls and MTP retains immunostimulatory properties 
while eliminating much the toxic effects associated with the whole bacterium86. MF59 
is used in the H5N1 bird flu vaccine developed by Novartis. MF59 was chosen for 
dose-sparing effects and is recommended in elderly (>65) including those with 








2.6 Polymer Vaccines 
2.6.1 Introduction 
Biodegradable polymers have been studied for many years because they 
show promise for the development of single dose vaccines88, 89.  Polymeric 
compounds have the ability to sustain the release of the vaccine antigen by a 
controlled mechanism over an extended period of time, thus eliminating the need of 
subsequent doses of vaccines.  Other potential advantages of these materials are 
that immunomodulatory properties (i.e. adjuvanticity) can also be achieved with the 
proper tailoring of the polymer chemistry90. Studies evaluating the use of controlled-
release, single dose polymeric vaccines in both laboratory animals and livestock 
species (i.e., sheep, mini-pigs, cattle, and horses) have shown promise when 
encapsulating protein antigens91-95. 
Biodegradable polymers also offer the advantage that MPLA, CpG DNA 
motifs or other immunoenhancing molecules can be incorporated to create a 
pathogen-mimicking solid particle96.  Polymeric vaccine particles have been shown 
to induce demonstrable immune responses when administered by several routes 
including, parenteral (e.g. intramuscularly or subcutaneously), intranasal, or orally77.  
These materials also have the added advantage over stable (non-degradable) 
devices (e.g. pumps) in that after administration, there is no need to remove them, 
therefore eliminating another surgical procedure.  Furthermore, most are 
manufactured from synthetic base compounds, eliminating many potential reactive 






The controlled release of antigens by parenteral administration of polymeric 
microspheres has been assessed. The release kinetics from the polymeric adjuvant 
plays a major role. There are two main approaches: “pulsatile” and “continuous” 
release59. The “pulsatile” release can be obtained from depot or storage formation at 
the site of injection and the “continuous” release is achieved when the antigen is 
efficiently presented to antigen presenting cells in a continuous manner. 
Microspheres greater than 10 μm can act as depots at the site of injection, while the 
smaller microspheres can be efficiently taken up (phagocytosed) by antigen-
presenting cells95. After the antigen presenting cells take up the microspheres, they 
can present the antigen to immune cells responsible for eliciting an immune 
response. Thus, the controlled release over prolonged periods may produce an 
sustained immune response. On the other hand, a pulsatile release is expected to 
exhibit high levels of antibodies after the second pulse, when memory cells are 
already available. Despite the advantages of enhancing and modulating 
immunogenicity using polymeric microspheres as vaccine carriers, to date no 
vaccines based on polymeric carriers have been approved for human use. 
The two most widely studied polymer classes for controlled release vaccines 
are polyesters97-106 and polyanhydrides1, 6, 8, 11, 25, 36, 38, 107-113.  Other classes of 
polymeric compounds have been evaluated and shown to successfully deliver 
antigen to laboratory animals73, 114-126. Key findings of research done with these 
polymeric systems as vaccines carriers are discussed below and some of the 






 Table 2.2. Structure of common polymers used as vaccine adjuvants.  
Polymer Structure Reference 











































































   








Microspheres composed of polyesters have been the most widely studied. 
Polymers of lactic acid and glycolic acid (e.g. poly(lactide-co-glycolide), PLGA) have 
been utilized in biomedical applications such as bone pins and dissolvable sutures 
for many years and recently have proven effective as vaccine delivery vehicles for 
the induction of protective immunity in laboratory animals97-101.  The greatest benefits 
of PLGA in biodegradable materials is that the degradation products, lactic acid and 
glycolic acid, are naturally occurring metabolites and are readily absorbed by 
neighboring cells102, 140.  However, as the polyester degrades and the acidic 
monomers are released, an acidic microenvironment is created.  Prolonged 
exposure to aqueous or acidic environments has been shown to be detrimental to 
the stability and immunogenicity of proteins, especially the proteins used in 
recombinant and subunit vaccines, e.g., tetanus toxoid (TT) and diphtheria toxoid104, 
105.  Some attempts to minimize this acidity have been recently evaluated by 
incorporating a basic compound like magnesium carbonate (MgCO3) into the PLGA 





significantly improved peptide stability but did enhance the antibody production, 
acting as a potential adjuvant.   
Antigen-loaded PLGA microspheres function as an adjuvant by at least two 
mechanisms: 1) creating a depot for the antigen in vivo, and 2) enhancing 
phagocytic uptake of the antigen-loaded particle by APCs101.  The uptake of PLGA 
microspheres by macrophages or DCs has been demonstrated following 
administration by intraperitoneal or intradermal routes, respectively141.  Other 
immunostimulatory properties of PLGA were observed in studies showing an 
enhanced cytokine production and proliferation when cells were incubated in vitro 
with blank PLGA microspheres140.  Similarly, oral administration of PLGA 
nanoparticles containing type II collagen promoted the induction of tolerogenic 
immune responses that ameliorated arthritis142. The prolonged presence of the 
nanoparticles in the Peyer’s patches and the induction of elevated TGFβ suggested 
the differential activation of DCs that modulated the subsequent immune response. 
Vaccine formulations based on PLGA, PLA, or PGA variants have been 
successful in inducing immune responses to a large number of antigens including: 
Yersinia pestis antigens, HIV gp140, Bordetella  pertussis antigens, measles virus 
antigen, OVA antigen, TT, diphtheria toxin, type II collagen, malarial antigens, 
cancer cell antigens, Escherichia coli adhesion proteins, Vibrio cholerae antigens, 
influenza virus antigens, hepatitis B viral antigens, and ricin toxoid77, 140, 142, 143.  
These vaccines have been delivered by a variety of routes including intradermally, 
intravaginally, intranasally, orally, or parenterally into laboratory animals to induce 





induction of secondary immune responses (e.g., isotype switching) as determined 
when individuals were analyzed up to a year after single immunization140, 144.  Many 
groups have reported the successful induction of immunity following use of a single 
dose vaccine formulation composed of PLGA microspheres of various compositions 
145 99, 146-148 149, 150.  Furthermore, encapsulation of antigens in PLGA microspheres 
was shown to enhance antigen presentation via MHC I leading to increased 
activation of antigen specific cytotoxic T cells89, 143, 145.  However, most of these 
studies were conducted in vitro, some investigations included MPLA, a known Th1 
immune response activator in the microsphere while others used multiple injection 
regimens in vivo.  There is no consensus opinion, however, as to whether PLGA-
based vaccines are more efficacious than current adjuvant systems such as alum. 
Antibody responses induced in mice and guinea pigs following vaccination with TT-
loaded PLGA were greater than those induced by single injection of soluble TT 
alone or two doses of alum absorbed TT. Additionally, a stronger anamnestic 
response (higher titer) was observed when individuals that had received the TT-
loaded PLGA microparticles were boosted one year later144.  On the other hand, 
Walker et al, observed that encapsulation of TT in PLGA microspheres did not 
induce serum antibody titers higher than alum-based TT vaccines149.  Only small 
amounts of antigenically active TT were released in the first two days from PLGA 
microspheres, even though protein continued to be released for up to 11 weeks144. 
Collectively, evaluation of PLGA studies does not provide strong correlation between 
release of antigenic peptides, length of in vitro release of peptides, and immune 





Some studies have suggested that immunization with PLGA microspheres 
effects immune deviation.  Moore et al showed the ability of HIV gp120 protein 
loaded PLGA microspheres to shift the T cell response from a dominant Th2 or 
mixed Th1/Th2 to a more dominant Th1 immune response as indicated by the 
presence of IFNγ producing CD4+ T cells151.  In other studies, the Th2-biased 
hepatitis B core antigen has been formulated with the Th1 immune stimulator MPLA 
in PLGA nanoparticles to develop a stronger Th1 response72.  More recently, a 
vaccine formulation prepared against malaria and composed of PLGA microspheres 
and Montanide ISA 720 was shown to induce an antibody response (IgG isotype 
class switching) characteristic of Th1 response152. 
Variations in reported efficacy of PLGA microspheres may be due to dose of 
antigen, method of encapsulation (e.g. spray drying vs solvent evaporation), route of 
immunization, and/or the size of the microspheres103, 143.  Following primary 
immunization with small microspheres (10-20 μm), a greater anamnestic response 
was generated one year later following a low dose booster than that observed in 
animals initially receiving larger microspheres (>60 μm) 144, however, nanoparticles 
(200-600 nm) were less effective at inducing cell-mediated immune response than 
microspheres143.  This may be because microspheres <10μm in diameter are readily 
phagocytosed by macrophages and DCs that would enhance antigen processing 
and presentation100, 147, 153-156.  On the other hand, the route of immunization with 
PLGA  microparticles influenced the type of immune response generated.  The 
intraperitoneal route induced Th1 cell-mediated response while the intramuscular 





done with PLGA as antigen carriers, some with success in animal models, no 
formulation has been reported to induce a protective immunity in humans157.  
 
2.6.3 Polyanhydrides 
Polyanhydrides are a class of surface erodible, biocompatible polymers that 
have been extensively used as carriers for controlled drug delivery1, 6, 11, 25, 38, 107-112, 
158-160. These biodegradable polymers are currently approved by the FDA for use in 
a variety of biomedical applications and can also be fabricated into protein-loaded 
microspheres107.  Biocompatibility studies have shown that these biomaterials 
degrade into carboxylic acids, which are non-mutagenic and non-cytotoxic 
products23, 34.  The surface erosion mechanism leads to a controlled release profile 
with predictable degradation profiles, which can range from days to months, 
depending on the co-polymer composition26, 129.  In addition, studies involving 
polyanhydride delivery systems for vaccines have shown attractive features such as 
improved adjuvanticity, antigen stabilization, and enhanced immune responses1, 22, 
59, 107. 
The main advantage of polyanhydrides over polyesters as antigen carriers is 
associated with the enhanced protein stability following encapsulation. Studies have 
shown that polyanhydrides are capable of stabilizing polypeptides and sustaining 
their release without the inclusion of potentially reactive excipients or stabilizers130, 
133, 161, 162.  The hydrophobicity and surface erosion characteristics of polyanhydrides 
prevent water from penetrating to the interior of the microsphere thus preserving the 





degradation products of polyanhydrides are less acidic than those of polyesters, 
which may further enhance the stability of encapsulated antigens and reduce tissue 
reactions to the polymer130, 133.  Despite these beneficial characteristics, the use of 
polyanhydrides for vaccine delivery has not been extensively evaluated. 
Recently, in vivo studies to evaluate the induction of immune responses 
following immunization with antigen-loaded microspheres based on the anhydride 
monomers sebacic acid (SA) and 1,6-bis(p-carboxyphenoxy)hexane (CPH) 90 were 
performed.  Microspheres encapsulating TT antigen were injected in C3H/HeOuJ 
mice.  These studies demonstrated that TT maintained its immunogenicity and 
antigenicity following encapsulation.  The type of immune response generated, Th1 
vs. Th2, was evaluated by antibody isotypes measured by ELISA.  It was observed 
that TT loaded 20:80 CPH:SA microspheres enhanced the immune response after a 
single dose and indicated a Th2 dominant response.  However the 50:50 CPH:SA 
produced a balanced Th1/Th2 response.  Total TT-specific IgG titer remained high 
regardless of dominant isotype.  The preferential enhancement of the Th1 immune 
response resulting in more balanced immune response (i.e., immune deviation) is a 
unique and valuable feature of this delivery vehicle that makes it a promising 
adjuvant candidate for vaccines.  Current work is corroborating the 
immunomodulatory properties of the CPH:SA system with other antigens as well as 
investigating the adjuvant properties of novel amphiphilic polyanhydride chemistries.  
Copolymers of CPH and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 





candidates for the development of vaccines as it has been shown to provide a 
conducive environment for protein stabilization131-133, 163. 
Anhydride monomers have been copolymerized with other chemistries and 
their potential as adjuvants have been evaluated.  An immunogenic subcellular 
extract obtained from Salmonella enteriditis cells (HE) has been encapsulated in 
nanoparticles  of the copolymer comprised of methyl vinyl ether and maleic 
anhydride (PVM/MA), best known as Gantrez® polymer139.  In this study, 80% of the 
Gantrez®-HE immunized mice survived even when the nanoparticle formulation was 
administered 49 days previous the lethal challenge. As early as 10 days after 
immunization, a Th1 immune response was demonstrable in these mice as 
determined by the IgG2a antibody titer in the serum.  On the other hand, a dominant 
Th2 immune response was present at 49 days after immunization (IgG1>IgG2a).  
Since it is known that a Th1/Th2 balance is required to protect against Salmonella 
entereditis infection, this copolymer is an ideal candidate for the development of 
future vaccines.  In this regard, blank nanoparticles of Gantrez® administered 
subcutaneously four weeks prior to challenge induced a level of protection similar to 
that induced by antigen-loaded nanoparticles or the Rv6 commercial available 
vaccine against Salmonella entereditis serovar abortusuis136.  While the authors did 
not demonstrate the presence of antigen-specific immunity, this data suggests that 
the blank nanoparticles were able to induce and sustain sufficient innate immunity to 
provide non-specific protection against subsequent Salmonella infection. In this 
same study, abortusovis antigen-loaded poly(ε-caprolactone) microparticles did not 





In another attempt to design suitable carriers specifically intended for vaccine 
delivery, Hanes et al synthesized poly(anhydrides-co-imides) with the adjuvant L-
tyrosine incorporated in the polymer backbone8.  In these studies, a predictable and 
controlled protein release was observed from microspheres of poly[trimellitylimido-L-
tyrosine-co-sebacic acid-co-1,3-bis(carboxyphenoxy)propane] and polymeric 
implants were well tolerated after subcutaneous implantation in rats.  More recent 
studies demonstrating the suitability of polyanhydrides for use in single dose 
vaccines involved the design of a core-shelled cylindrical device composed of a 
biodegradable hydrophobic coating and laminated core of polyanhydrides and 
polyphosphazenes164.  Polyanhydrides based on SA were used as isolating layers of 
the cylinder in order to produce a pulsatile drug release, a mechanism which would 
minimize doses of vaccines.  Even though these polyanhydride systems showed 
promising characteristics for vaccines design, no further in vivo studies evaluating 
the characteristics of the proposed adjuvant were validated. 
A comparative study between polyanhydrides and polyesters has 
demonstrated the potential capabilities of polyanhydrides for oral vaccination 165. 
Microspheres (0.1-10μm) composed of fumaric acid (FA) and SA proved to have 
strong adhesive interactions with the mucosal gastrointestinal lining of rats, as 
opposed to poly(lactic acid) (LA), which showed minimal uptake. The adhesive 
interactions are ideal to prolong the biological activity of the delivered antigen or 
bioavailability of encapsulated drugs. Not surprisingly, plasmid DNA- and 
anticoagulant drug dicumarol-encapsulated FA:SA microspheres enhanced gene 





same studies, blends of FA and LA were used for insulin delivery and groups that 
received the formulation were able to regulate glucose levels as opposed to the 
groups that received insulin only.  Even though the biological activity of insulin was 
preserved, it was the adhesive characteristic of FA the responsible for the efficient 
delivery. 
 
2.6.4 Other Polymers 
2.6.4.1 Natural-derived 
Several naturally derived polymeric materials, such as dextran, chitosan, 
starch, and alginate have been evaluated in laboratory models for use as vaccine 
adjuvants. In the case of dextran, it has been chemically modified or use in 
conjunction with other adjuvants in order to improve its immunogenicity. 
Immunization of cattle with dextran in combination with mineral oil against 
Streptococcus bovis and Lactobacillus spp induced the highest serum IgG 
responses when compared with other adjuvants (i.e. FCA, QuilA, alum), presumably 
due to the combined effect of both substances114. In studies involving vaccination of 
cattle against Mycobacterium tuberculosis, diethylaminoethyl (DEAE)-dextran 
induced high levels of IL-2 and low levels of IFN-γ, indicating a strong humoral 
response not desirable for this particular disease115. Interesting results were 
obtained when a dietary supplementation of Lactobacillus casei with dextran 
enhances humoral immune responses, and chickens were able to maintain the 
growth of the bacteria in their intestines and prevent possible infections116. Vaccines 





conjugated TT induced serum antibody to TT for long periods, eliminating the need 
of additional booster doses127.  
Chitosan, a synthetic cationic polysaccharide from the exoskeleton of insects, 
can also be formulated into microparticles capable of encapsulating antigen128.  
Studies with chitosan showed that the immune bias induced by vaccination with 
antigen containing chitosan microparticles was more dependent on the route of 
delivery (e. g., intranasal vs. parenteral) than the nature of this adjuvant77, 117.  An 
intranasal delivery of N-trimethyl chitosan chloride (TMC) containing diphteria toxoid 
enhanced the immune response when compared with the conventional alum 
adsorbed vaccine128. This enhancement in nasal vaccination is probably a result of 
the mucoadhesive properties of chitosan, which enhance penetration across nasal 
mucosa118, 119. More recent studies with chitosan and TMC establish that chemical 
variables, such as molecular weight in chitosan and degree of quaternization in TMC 
influence the magnitude of the immune response after nasal administration120. 
Another natural polymer with potential in vaccines is starch, which also has 
been assessed in mucosal vaccines. Some advantages of starch include its inert 
properties, proven safety, and commercial availability121. Heritage et al found that 
human serum albumin delivered on starch microparticles grafted with 
polydimethylsiloxane stimulated systemic and mucosal immune responses122. 
Similarly to studies done with chitosan, the route of administration of starch 
influences the immune response123. Among oral, subcutaneous, and intramuscular 
administrations, the subcutaneous induced stronger Th2 responses. However, when 





oral primary administration and a stronger Th1 response after oral booster doses. 
Although the adjuvant capabilities of starch were proved with success in mice 
studies, a human vaccine trial was not successful166.  
Alginate microparticles offer several advantages for vaccine applications, 
including good biocompatibility, ease of preparation, and antigen protection during 
fabrication and administration121, 167.  Alginate microparticles have been 
administered to several animal species ( i.e. mice, rabbits, cattle, and chicken)167. 
The enhancement of the immune response induced in the animals after oral 
administration with antigen-loaded alginate microparticles shows promise for the 
development of veterinary vaccines. Nevertheless, in vitro studies show that alginate 
is not the optimum chemistry to activate human-derived DCs, as it decreases the 
expression of co-stimulatory molecules and antigen presenting complexes when 
compared to non-treated cells168. Other in vitro studies that simulated gastric fluid 




Some novel polymer chemistries have been researched to overcome the 
limitations of available polymers as vaccine carriers.  The novel poly(ester-amide) 
(PEA) copolymers, composed of amino acid residues, diols, and dicarboxylic acids, 
have been shown to enhance cellular immunity124.  Polyamide gives PEA its superior 
mechanical and thermal properties, while the polyester portion is responsible for its 





period of time. It is biodegradable, however, in contrast to polyester and 
polyanhydrides, PEA degrades by enzymatic cleavage within the body135, 170.  Thus, 
shelf life and handling doesn’t affect its degradation rate and the polymer remains 
intact until is needed for therapy.  PEA has been conjugated with several 
therapeutics peptides, including human melanoma antigen-derived peptides 
(MART), a synthetic peptide based on the gp120 protein of HIV, and a MHCII 
restricted T-cell epitope from the influenza A virus hemagglutinin (HA) protein124.  In 
general, the studies evaluating PEA-peptide conjugates demonstrated that cellular 
immunity, encompassing both MHCI- and MHCII-restricted T-cell responses, was 
enhanced. 
More recently, in vivo studies in mice have shown that poly(ethylene glycol)-
stabilized poly(propylene sulfide) nanoparticles target the APCs directly in the lymph 
nodes137, 138. In these studies it was found that particles in the size range of 20 to 
45nm enter lymphatic vessels and subsequently target DCs in the lymph nodes. The 
cross-linked polymer system used here degrades into a water soluble polymer under 
oxidative conditions.  
 
2.6.4.3 Polymers in Plasmid DNA Vaccines 
Plasmid DNA vaccines represent a promising alternative against intracellular 
pathogens.  Even though plasmid DNA immunogens have elicited strong cell-
mediated responses in small laboratory animals, these have not had success in 
limited human clinical trials125.  Ideal adjuvants will improve the magnitude of 





facilitate the DNA plasmid uptake into cells.    Several polymer chemistries have 
been evaluated in conjunction with DNA vaccines and a thorough discussion of this 
topic is beyond the scope of this review. In short, microspheres of polylactic, 
polycarbonates, polystyrene, and poly-(ortho-esters) have been used in DNA 
vaccination and their administration resulted in enhanced immune responses when 






















2.7 Peptide Antigen-based Cancer Vaccines 
2.7.1 Introduction 
 Currently, there are three standard therapies for cancer treatment, including 
surgery, chemotherapy, and radiation. Immunotherapy is becoming a fourth 
promising therapy, with several successful clinical trials currently investigated171. 
Immunotherapy requires the development of complementary strategies that address 
all the variables involved in immune surveillance68. The immune system does not 
recognize cancer cells as foreign bodies to be eradicated, even though tumor cells 
display characteristic antigens on their surface. In other words the tumor cells are 
known to be antigenic but not immunogenic. A possible explanation is that patients 
with tumor progression have shown a remarkable secretion of immunosuppressive 
factors and downregulation of various components of the antigen presentation 
pathway68. The immune activation still exists but to a lower extent, where tumor 
progression rate is slower but not prevented. The goal of the vaccines is to trigger 
the immune system to attack these malignant cells by means of recognition of these 
surface antigens and efficiently present them to the cells that are responsible to 
minimize tumor progression. The focus of this work is on pancreatic cancer, as it is 
one of the most lethal forms in cancer related diseases. 
 
2.7.2 Antigens for Cancer Therapy 
 Immunotherapy is becoming the fourth alternative to cancer treatment, with a 
$6 billion market expected by 2010 171. These immunotherapy treatments pretend to 





display specific antigens on their surface. By proper recognition of these markers, an 
enhanced immune response could be achieved. Two of the pancreatic tumor cell 
markers that have been well characterized are the glycoproteins Mucin-1 and Mucin-
4, which are part of a major group of mucins. 
 Mucins are a family of large, heavily glycosylated proteins that are expressed 
by various epithelial tissue. The structural feature common to all mucins is the 
tandem repeat domain, which comprises identical or highly similar sequences that 
are rich in serine, threonine and proline residues. These tandem repeats can be 
differentially O-glycosylated, a characteristic that will determine their structure and 
function. It has been long suspected that alterations in mucin expression and 
inappropriate expression of aberrant forms of mucins contribute to the development 
of cancer by influencing growth, differentiation and immune surveillance172. This 
aberrant expression in cancer cells is a consequence of the degradation of core 















Among mucins, Mucin-1 is normally produced by epithelial tissue and 
expressed aberrantly in carcinomas of pancreas, lung, breast, and prostrate. The 
process that leads to over-expression of Mucin-1 in malignant cells is a result of the 
alterations in the glycosylation pattern with exposure of internal core peptides that 
are normally masked in normal tissues173. It is precisely this exposure that leads to 
possible targeting of these peptide epitopes in tumor cells. Fig. 2.6 shows a model of 
how Mucin-1 is presented on the surface of tumor cells for recognition by the 
immune system. 
 
Figure 2.6. Tumor antigen processing and presentation. Mucin-1 enters the cytoplasm where is degraded into 
small peptide fragments by the protesomes. These fragments are then transported into the endoplasmic 
reticulum (ER), where they bind to MHC I molecules and subsequently are presented on the surface for immune 
system’s recognition 
 
2.7.3.1 Ex vivo Characterization 
 Extensive research has investigated the characteristics of Mucin-1 in tumor 
cells. A study done in two pancreatic cell lines, Panc-1 and S2-013, revealed that 
more than 98% were positive for surface expression of an epitope-tagged form of 
Mucin-1 174. These results demonstrate for the first time that the heavily O-











block binding to adhesion molecules with some molecular specificity and further 
support the hypothesis that Mucin-1 plays a role in the metastatic spread of tumor 
cells175. 
 
2.7.3.2 In vivo Responses  
 The antigenicity of Mucin-1 has been widely investigated in animal models. 
Among all the studies, a remarkable research done in chimpanzees showed that the 
key to elicit potent immunity to tumor Mucin-1 may be in generating Mucin-1 specific 
T-helper cell responses and cytotoxic T cell responses by priming Mucin-1 specific 
CD4+ T cells and promote Th1 cytokine profile176. These results are in concordance 
with the hypothesis that a cancer vaccine should prime the activation of MHC II 
pathway as discussed in the previous section. 
 Studies in murine models have provided a better understanding of 
immunogenicity of Mucin-1. A transgenic mice model offers a useful tool to examine 
how human genetic diseases can be modeled by introducing the same mutation into 
a mouse or other animal. In 1998, a C57BL/6 mouse transgenic for human Mucin-1 
(Mucin-1.Tg) was developed to evaluate Mucin-1 specific tumor immunity. These 
Mucin-1.Tg mice recognized Mucin-1 as a self protein, and similar to cancer 
patients, specific responses to this protein should result in autoimmunity. This 
investigation compared immune responses induced in both, Mucin-1.Tg and wild 
type (wt) mice, after tumor challenge. Results revealed that wt mice developed 
protective tumor immunity mediated by Mucin-1 specific CD4+ T lymphocytes, while 





not be controlled177. This implies that by tuning the immune response to actively 
recognize Mucin-1 as a non-self protein on cancer cells will lead to tumor rejection.   
 
2.7.3.3 Influence of Injection Location  
 Tumor immunity specific for Mucin-1 was produced in wt mice (C57BL/6) by 
two different procedures: subcutaneous (sc) immunization with a low dose of the 
pancreatic cancer cell line Panc02-Mucin-1 and by adoptive transfer of spleen and 
lymph node cells harvested from wt mice previously immunized sc with Panc02-
Mucin-1. Positive results of the two procedures were obtained, which demonstrated 
that immune responses to Mucin-1 presented at the sc site can be detected and 
adoptively transferred178. Similarly, another study compared mice challenged with 
the same cancer cell line (Panc02-Mucin-1) by orthotopic injection into the pancreas 
and by sc injection179. The immune responses produced by sc injection resulted in 
rejection of tumors that were subsequently challenged at the pancreatic site. This 
paper disproved the hypothesis that the sc environment down regulates expression 
of Mucin-1 in these tumor cells. These studies evidenced that Mucin-1 can be 
successfully recognized when injected as a vaccine and induce the immune 
response when is properly presented.  
 
2.7.3.4 Clinical Studies  
 Several clinical studies have investigated the characteristics of Mucin-1 in 
pancreatic cancer patients. In one of the immunohistochemical studies, invasive 





many of the non-invasive tumors with favorable outcome showed a pattern of Mucin-
1 negative180. This confirms that Mucin-1 is a molecule typically expressed in 
malignant tumors, which is in concordance with previous findings on ex-vivo and in-
vivo studies discussed above. Other clinical studies on pancreatic cancer patients 
showed that tumor antigen specific T cell responses occur regularly during 
pancreatic cancer disease and lead to the enrichment of tumor cell-reactive memory 
T cells in the bone marrow181, clearly indicative of the immunogenicity of the 
disease. These memory T cells have a therapeutic potential as they display a 
predominant Th1 cytokine profile upon stimulation of DCs and are able to kill 
autologous tumor cells ex-vivo. Several questions to be answered regarding tumor 
immunity include does the immune system has all the tools to fight cancer, why it 
becomes tolerant and does not produce the necessary response against the 
disease. Previous research has reported a dominance of Th2 cytokines in the blood 
of 41 cancer patients181. The dominance of Th2 cytokines suggests systemic tumor-
induced immunosuppression, which potentially inhibit the induction of tumor-reactive 
T cells and tumor surpass immune surveillance. The ability of polyanhydride-based 
adjuvants to provide immunomodulatory capabilities makes them promising carriers 











 Other mucin that has been envisioned as a potential candidate for tumor 
vaccine antigen is Mucin-4, which is also a membrane associated mucin. It contains 
three epidermal growth factors domains that function in receptor-ligand interactions, 
two regions rich in potential N-glycosylation sites, one hydrophobic transmembrane 
region, and one short cytoplasmic tail172, 182. Similarly to Mucin-1, Mucin-4 
contributes to the regulation of differentiation, proliferation, and metastasis of tumor 
cells. It is aberrantly expressed in pre-malignant and malignant lesions of the 
pancreas but not expressed in normal pancreatic epithelial cells, a characteristic that 
makes this antigen very promising for cancer immunotherapy as healthy tissues will 
likely remain healthy183. Studies done in nude mice showed that after injecting 
pancreatic cell lines expressing human Mucin-4, high levels of Mucin-4 were 
detected in the tumor injected orthotopically but not in the tumor injected 
subcutaneously nor in the normal pancreas tissue182. 
 Mucin-4 has also been correlated with poor patient prognosis in other types of 
cancer such as lung adenocarcinomas184. In this recent work, it has been 
demonstrated that antibodies against Mucin-4 have been detected in patients with 
lung cancer, suggesting that this glycoprotein is immunogenic in cancer patients and 











 Polyanhydrides are promising as biomaterials since they possess a unique 
combination of properties that includes hydrolytically labile backbone, hydrophobic 
bulk, and chemistry that can be easily combined with other functional groups to 
design novel materials.  These materials are primarily surface-erodible and offer the 
potential to stabilize protein drugs and sustain release from days to months.  The 
microstructure characteristics of copolymer systems can be exploited to tailor drug 
release profiles.  The versatility of polyanhydride chemistry promises a new class of 
drug release systems for specific applications. The powerful combination of protein 
stabilization and immune deviation provided by amphiphilic polyanhydrides offers 
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3.1 Research Objectives 
 The overall goal of this research was to design novel biodegradable adjuvants 
that can be used a single dose vaccine with the dual functions of protein stabilization 
and enhanced immune response. In order to accomplish this goal, a fundamental 
characterization of the novel material system must be performed, as the chemistry 
and properties of the material affects drug stabilization and release. The importance 
of preserving conformational epitopes to elicit a protective immune response is 
essential for vaccine effectiveness. In vitro evaluation of this stability is essential to 
prove that a new formulation will not be deleterious for the therapeutic value of the 
protein drug. For this reason, an accurate assessment of the stability of the protein 
drug during conditions that mimic the in vivo release environment will be analyzed 
with several model proteins. Using the insights gained, the immunomodulatory 
capabilities of CPTEG:CPH microsphere formulations will be evaluated for testing 











3.2 Specific Goals 
The specific goals (SG) of this work are: 
SG1: Synthesis and characterization of the novel amphiphilic CPTEG:CPH system. 
SG2: Assessment of protein stabilization and sustained release from CPTEG:CPH 
system. 






































SYNTHESIS AND CHARACTERIZATION OF NOVEL POLYANHYDRIDES WITH 
TAILORED EROSION MECHANISMS 
 
Reprinted from a paper published in Journal of Biomedical Materials Research 
76A(1), 102-110, Copyright  2006, with permission from Wiley InterScience Inc. 
  




 We have designed a new synthesis route to create polyanhydrides based on 
monomers that contain hydrophilic entities within highly hydrophobic backbones. 
The method results in polyanhydrides that can be easily processed into drug-
containing tablets. The synthesis, characterization and erosion studies of 
polyanhydride copolymers based on 1,6-bis(p-carboxyphenoxy)hexane (CPH), 
which is highly hydrophobic, and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG), which has hydrophilic oligomeric ethylene glycol segments in the 
monomer unit, was performed using a combination of molecular spectroscopy, 
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thermal analysis, gravimetry, and scanning electron microscopy. The studies 
demonstrate that by increasing the CPH content in the CPTEG:CPH copolymers, the 
erosion of the system can be tailored from bulk-eroding to surface-eroding 
mechanism.  These systems have promise as protein carriers.   
 
4.2 Introduction 
 Polyanhydrides are a class of surface bioerodible polymers that have been 
extensively used as carriers for controlled drug delivery. The promising 
characteristics of this class of polymers has led to extensive research on the 
chemistry, microstructure, and biocompatibility in the last two decades1-12. The 
biocompatibility studies, both in vitro and in vivo, have shown that these biomaterials 
degrade into non-mutagenic and non-cytotoxic products13,14. The surface erosion 
mechanism exhibited by these polymers leads to a controlled release profile with a 
predictable hydrolytic degradation, which can range from days to months, depending 
on the polymer chemistry.  
 The overall goal of our research is to engineer biomaterials suitable for the 
stabilization and sustained release of proteins. Currently there are several hundred 
investigational new protein drugs that have not been approved by the United States 
Food and Drug Administration (FDA) due the lack of a suitable delivery device 15. 
Finding the appropriate carrier for proteins is a complex task that involves a 
fundamental understanding of the inactivation mechanisms of the protein, the 





 It has been suggested that the use of carriers containing both hydrophobic 
and hydrophilic entities may provide a gentler environment for proteins16,17. Previous 
research has demonstrated that polyanhydrides, which are highly hydrophobic, can 
prevent covalent aggregation by reducing the water penetration into the core18-20. 
However, strong hydrophobic interactions between the polymer and the protein may 
lead to non-covalent aggregation. Thus, our central focus involves the incorporation 
of hydrophilic entities, i.e. oligomeric ethylene glycol, into the backbone of an 
aromatic polyanhydride to create a potentially suitable protein carrier21. The choice 
of ethylene glycol is motivated by its advantageous properties, including the stealth 
effect provided to various active macromolecules, its biocompatibility, and its low 
toxicity22. Previous studies have demonstrated that poly(ethylene glycol) is a useful 
carrier for oligonucleotides and ribozymes when polymerized with an aliphatic 
polyamine23,24. When copolymerized with bulk eroding poly(lactide-co-glycolide) or 
poly(lactic acid), polyethylene glycol adds the hydrophilicity necessary for a faster 
degrading system for delivery of peptides and proteins16,17,25, with the added 
disadvantage of not preventing potentially deleterious water-protein interactions.  
 It is important to point out that aliphatic polyanhydrides have been 
copolymerized with segments of polyethylene glycol26 resulting in a fast degrading 
system that is not desirable for a long-term controlled release application. To 
overcome this disadvantage, we incorporated oligomeric ethylene glycols (i.e., 
triethylene and pentaethylene glycol) into the monomer of a hydrophobic 
anhydride21. These materials were synthesized by halogenation of oligomeric 





produce the monomer. The monomer was then polymerized with acetic anhydride 
and heated under vacuum. The yields of the resulting monomer were low, the 
procedure was complex, and the resulting polymer did not have desirable 
characteristics for device fabrication21.  
In this paper, we have developed a modified synthesis route, in which the 
halogenation of the ethylene glycol chain is not necessary. This method results in 
polymers that are easy to process into pharmaceutical formulations such as tablets 
and microspheres. This paper focuses on copolymers based on the anhydride 
monomers 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG), which contains oligomeric ethylene 
glycol moieties (the chemical structures are shown in Fig. 4.1). The synthesis, 






























Figure 4.1. Chemical structures of poly(CPH) (top) and poly(CPTEG) (bottom). The letters (a-i) represent the 







4.3.1 Materials  
 The chemicals 4-hydroxybenzoic acid, 1,6-dibromohexane and tri-ethylene 
glycol were purchased from Sigma Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile 
was purchased from Apollo Scientific (Cheshire, UK); acetic anhydride, methylene 
chloride, potassium carbonate, petroleum ether, toluene, dimethyl formamide (DMF), 
sulfuric acid, acetic acid, and acetonitrile were obtained from Fisher Scientific 
(Fairlawn, NJ). Deuterated chemicals for NMR analysis (chloroform and dimethyl 
sulfoxide (DMSO)) were purchased from Cambridge Isotope Laboratories (Andover, 
MA). 
 
4.3.2 Monomer Synthesis 
 The CPH monomer was synthesized from 4-hydroxybenzoic acid using a 
procedure that was first developed by Conix 27. To synthesize the CPTEG monomer, 
45 mL of tri-ethylene glycol, 100mL of toluene, 300 mL of dimethyl formamide and 
0.897 mol of potassium carbonate were mixed in a round bottom flask placed in an 
oil bath at 170 C. The addition of toluene allowed the azeotropic distillation of water 
from the reaction mixture prior to reaction. Next, 0.684 mol of 4-p-fluorobenzonitrile 
was added and allowed to react overnight at 150 C. After cooling, all the solvents 
were removed using a rotary evaporator. The resulting dinitrile solution was 
hydrolyzed with a mixture containing equal volumes (50 mL) of water, acetic and 
sulfuric acid. The reaction was carried out at 160 C under a nitrogen atmosphere. 





was obtained after successive washes with acetonitrile. A generalized procedure for 
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Scheme 4.1. Synthesis of CPTEG monomer. 
 
4.3.3 Polymer Synthesis 
 Due to problems with prepolymer isolation, a new procedure for making 
poly(CPTEG) and CPTEG:CPH copolymers, starting directly from the diacids, was 
developed. The synthesis of poly(CPTEG) is shown in Scheme 4.2. In a typical 
experiment, 2g of the monomer and 100mL of acetic anhydride were added to a 
round bottom flask and reacted for 30 minutes at 125 C. The acetic anhydride was 
removed in the rotary evaporator and the resulting viscous liquid was polymerized in 





isolated by precipitating from methylene chloride into petroleum ether in a 1:10 ratio. 
The copolymer compositions synthesized were 20:80, 50:50, and 80:20 
CPTEG:CPH. Additionally, homopolymers of CPH and CPTEG were synthesized. 
The CPTEG homopolymer was synthesized by polycondensation of the CPTEG 

























Scheme 4.2. Synthesis of poly(CPTEG). 
 
4.3.4 Characterization 
 The purity of the monomers and polymers was verified using 1H NMR spectra 
obtained from a Varian VXR-300 MHz NMR spectrometer and infrared spectra 
obtained from a Nicolet 6700 FT-IR spectrometer. Number average molecular 
weights were estimated by end group analysis from 1H NMR spectra. Perkin Elmer 
DSC 7 and DMA were used for the thermal characterization. The samples were 
heated in two cycles from -20 to 110 C at a rate of 5 C/min in the DSC. For the DMA 





three point bending test was performed at a frequency of 1 Hz, a dynamic force of 
90 mN and a static force of 100 mN. Scanning Electron Microscopy (SEM) (Hitachi 
S-2460 N) was used to study the surface and the cross section of the polymer 
tablets during erosion. The dried tablets were coated with gold prior to imaging. 
 
4.3.5 Erosion and Degradation Studies 
 Tablets of 100 mg of poly(CPTEG), poly(CPH) and 50:50 CPTEG:CPH 
copolymer were melt compressed for 2 min in a Carver Press (Wabash, IN) at a 
pressure of 600 psi and at a temperature just above the melting point of the polymer. 
Then the tablets were placed into 25 mL of phosphate buffer (0.1M, pH 7.4) in an 
incubator operating at 37 C and 100 rpm. The buffer was replaced daily. At different 
time intervals, duplicate samples of tablets were taken out of the buffer for further 
analysis. The water swelling and the mass loss of the tablets were determined by 
gravimetric analysis. The surface morphology of the tablets was monitored by SEM.  
 
4.3.6 CPTEG Monomer Solubility 
 To further characterize the erosion mechanism, the solubility of CPTEG 
monomer was determined by dissolving an excess of diacid in 15 mL of phosphate 
buffer at different pH values. The pH values were adjusted with 0.1 M NaOH or 0.1 
M HCl 19,28. The diacid concentration was calculated from UV absorbance 






4.4 Results and Discussion 
4.4.1 Structural Characterization  
  The 1H NMR spectrum of CPTEG monomer is shown in Fig. 4.2. The peak 
designation demonstrates the purity of the diacid produced with the new synthesis 
route, as no traces of solvents were present in the product. The 1H NMR spectra in 
Fig. 4.3 confirm the successful synthesis of poly(CPTEG), CPTEG:CPH copolymers, 
and poly(CPH). The peak designations with respect to deuterated chloroform 
( =7.26 ppm) was confirmed based on reported values21,29. The aromatic proton 
peaks of CPTEG and CPH monomers (a-d) have the characteristic chemical shifts in 
the =6.8-8.1 ppm range. The inner chain protons close to the electronegative 
oxygen atoms in both monomers (e-h) are represented in the expected range of 3.6-
4.4 ppm, and the protected protons in the inner chain of CPH (j,k) are represented at 
=1.7 and 1.5 ppm. Finally, the acetylated end groups (i) have a chemical shift at 
=2.1 ppm. The actual composition of the polymers after polymerization was 
calculated from an end group analysis of the spectra and the results are shown in 
Table 4.1. There is excellent agreement between the molar feed ratio and the actual 
compositions of the polymers. This behavior has also been observed for 
polyanhydrides based on sebacic anhydride (SA), 1,3-bis(p-
carboxyphenoxy)propane (CPP), and CPH29,30. 
 Table 4.1. Composition of CPTEG:CPH copolymers calculated from NMR after polymerization. 
















Figure 4.2. 1H NMR spectrum of CPTEG Diacid. 
 
Fourier Transform-Infrared (FT-IR) spectroscopy was also used to 
characterize polyanhydride composition. The IR spectra (not shown) of CPTEG:CPH 
copolymers had a doublet at 1720 and 1780 cm-1 indicating the presence of a 
carboxylic anhydride of an aromatic polymer3. The presence of a peak at ~2900 cm-1 
represented the O-H bond of the carboxylic acid1 in the IR spectrum of the 
monomers (not shown). 
  The number average molecular weight of the polymers was estimated by 
calculating the degree of polymerization (DP) using the peak area normalized with 
the protons represented (as shown in Eq. 1). In Eq. 1, the parentheses indicate peak 


















represents hydrolyzed chains and Ac represents acetylated chains. The molecular 
weights of the polymers synthesized ranged from 4,000-14,000 g/mol, which is in the 
sensitivity range of 1H NMR31. We note that the sensitivity is high because of the 





























4.4.2 Thermal Characterization 
 A summary of the thermal properties is shown in Table 4.2. The glass 
transition temperatures were determined from the DMA studies. The CPTEG 
homopolymer and all the CPTEG:CPH copolymers have Tgs below 20 C and hence 
are rubbery at room temperature.  The rubbery state of these polymers at room 
temperature is desirable for processing into tablets. The DSC studies for the CPTEG 
homopolymer and the CPTEG:CPH copolymers did not exhibit any melting peaks, 
indicating that these polymers are amorphous. In contrast, poly(CPH) melts at 143 C 
and has a Tg of 47 C 12, indicating that when copolymerized with CPTEG, the crystal 
formation is disrupted. This is important since polymer crystallinity affects the 
erosion mechanism of the polymer, since crystalline regions erode more slowly than 
the amorphous ones28. Thus, it is expected that copolymers rich in CPTEG and the 
poly(CPTEG) homopolymer would have faster erosion rates and erosion 
mechanisms that deviate from pure surface erosion. 
 
Table 4.2. Thermal characterization (* Data from Ref. 12).  
Polymer Tg ( C) Tm ( C) 
poly(CPTEG) 9 --- 
80:20 CPTEG:CPH 7 --- 
50:50 CPTEG:CPH 8 --- 
20:80 CPTEG:CPH 18 --- 









4.4.3 Erosion and Degradation 
  Polymer erosion is a complex process that is determined by numerous factors 
that include the molecular weight loss (degradation), the swelling, the dissolution 
and diffusion of oligomers and monomers, and morphological changes32,33. The 
erosion of poly(CPTEG), poly(CPH), and the 50:50 CPTEG:CPH copolymer was 
monitored by following mass loss, polymer swelling, molecular weight changes, 
monomer dissolution, and surface morphology.   
 The mass loss from the polyanhydride tablets was determined by gravimetry 
(Fig 4.4). In a period of 28 days, the poly(CPTEG) homopolymer lost ~80% of its 
total mass, which is attributed to the increased hydrophilicity due the oligomeric 
ethylene glycol in the aromatic polyanhydride. In the same period, less than 5% 
mass was lost in the same period from the highly hydrophobic poly(CPH) 
homopolymer. The 50:50 CPTEG:CPH copolymer eroded at a rate in between that 
of the two homopolymers. From these results it can be seen that the polymers 
exhibit distinct erosion profiles that can be controlled by tailoring copolymer 
composition. These results are also consistent with the DSC studies, which showed 
that both poly(CPTEG) and the 50:50 CPTEG:CPH copolymers are amorphous, 
































Figure. 4.4. Fractional mass loss from tablets of poly(CPTEG), 50:50 CPTEG:CPH copolymer and poly(CPH). 
Error bars indicate standard deviation. 
 
  
The swelling induced in the polymers due to water uptake may affect the rate 
of drug release. In surface erodible materials, the drug release is mainly controlled 
by erosion kinetics28, since no water can penetrate into the system. On the other 
hand, bulk erodible polymers release drugs as a result of various processes 
occurring in unison, including erosion kinetics, swelling, and diffusion16,25. The water 
content present in each sample is shown in Fig 4.5. Even though the mass loss of 
poly(CPTEG) and 50:50 CPTEG:CPH copolymer was remarkably different (Fig. 4.4), 
the water content of both polymers followed the same trend. A significant amount of 
water entered into these tablets, suggesting a transition to a bulk erodible system as 





poly(CPTEG) exceeded 50%, while in poly(CPH), the water content did not exceed 
5%, demonstrating the well known surface erosion mechanism of these hydrophobic 
polyanhydrides. The water content in the 50:50 CPTEG:CPH copolymer was in an 
intermediate range between the two homopolymers for the duration of the erosion 
studies. These data suggest that the erosion of this family of polyanhydrides (i.e., 
CPTEG-based) can be tuned from “bulk” to “surface” by copolymerizing with 
hydrophobic CPH. 
 The degradation of the polymers was studied using 1H NMR spectra of 
eroded tablets in deuterated DMSO ( ~2.5 ppm). Fig. 4.6 shows the degradation 
progress of 50:50 CPTEG:CPH copolymer from day 0 to day 28. As degradation 
proceeds, the end group (i) shifted from =2.1 ppm to =3.3 ppm. It is instructive to 
note the significant decrease of the peak area of the protons corresponding to the 
polymer backbone (e-k) and the increase in the end group acid peak (i, ~3.3 ppm) 
after 28 days of degradation. On day 28, the decreased peaks that still prevail in the 
spectra correspond to the CPH monomer, clearly indicating that CPH is the last 
monomer to be released. The molecular weight loss from each polymer composition 
studied is shown in Fig. 4.7. It is observed that poly(CPTEG) and the 50:50 
CPTEG:CPH copolymer display similar rates of molecular weight loss, i.e., 93% for 
poly(CPTEG) and 85% for the 50:50 CPTEG:CPH copolymer. As expected, the 
hydrophobic poly(CPH) loses only 8% of its initial molecular weight after 28 days. 
These studies demonstrate that the added hydrophilicity enhances the degradation 
rate of the polyanhydride and this is supported by the water penetration data into 
































Figure 4.5. Fractional water content in tablets of poly(CPTEG), 50:50 CPTEG:CPH copolymer and poly(CPH). 















































Figure 4.7. Percent molecular weight loss from eroding tablets of poly(CPTEG), 50:50 CPTEG:CPH copolymer, 
and poly(CPH).  
 
The studies indicate that poly(CPTEG) and the 50:50 CPTEG:CPH copolymer 
have different erosion rates, but similar water swelling and polymer degradation 
rates. Since erosion is a combination of polymer degradation, water swelling, 
monomer dissolution, and diffusion28,34, we investigated the solubility of both 
monomers (Fig. 4.8). The data indicate that the saturation concentration for CPTEG 
is at least an order of magnitude greater than that of CPH. This difference in 
monomer solubility may govern the erosion mechanism of the polymer that can be 
varied from bulk to surface erosion by increasing the CPH content.  The solubility 
data was also used to estimate the logarithmic scales of acidity constants for each 
diacid, i.e. pKa. These values were estimated by the inflection points of the fitted 





CPTEG has pKa’s at 5.8 and 8.4, indicating that CPH is a stronger acid. This data is 
important since the dissolution of the monomers decreases the pH of the 
microenvironment of an eroding polymer, which in turn limits the monomer solubility, 



























Figure 4.8. Saturation concentration data of CPTEG and CPH monomers in aqueous buffer (CPH solubility data 
from Ref. 31). 
 
 Finally, we studied the surface morphology of the tablets during erosion using 
SEM. The surface morphology of the polymers after 7 and 28 days of exposure to 
buffer are shown in Fig. 4.9. The poly(CPTEG) images show the homogeneous 
porosity characteristic of bulk eroding polymers where water entered easily into the 
tablet35. In contrast, the 50:50 CPTEG:CPH copolymer exhibited a smooth surface 
with small erosion fronts throughout the tablet. This behavior is typical of systems 




poly(CPH) exhibited a smooth surface throughout the 28 day study, consistent with 
the water penetration studies discussed previously (Fig. 4.5). These results indicate 
that by varying the CPTEG content in copolymer systems, the erosion mechanism 
can be tailored from bulk to surface erosion. 
 
 
Figure 4.9. SEM micrographs depicting surface morphology of poly(CPTEG), 50:50 CPTEG:CPH copolymer, and 
poly(CPH) tablets after 7 days (top) and 28 days (bottom) of erosion. 
poly(CPTEG) 











 We have synthesized a new class of “bulk eroding” polyanhydrides with 
tailored amphiphilicity with potential for controlled drug and protein delivery. An 
improved procedure was developed to synthesize these polymers, which resulted in 
low-Tg materials that can be easily processed. When copolymerized with 
hydrophobic aromatic polyanhydrides, these systems can be tailored from “bulk-
eroding” to “surface-eroding”.  Such a combined erosion mechanism may prevent 
protein denaturation by avoiding both hydrophobic non-covalent interactions and 
covalent aggregation of proteins. We are currently evaluating the potential of these 
novel biomaterials as protein carriers. 
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CHAPTER 5 
AMPHIPHILIC POLYANHYDRIDES FOR PROTEIN STABILIZATION AND 
RELEASE  
 
Reprinted from a paper published in Biomaterials 28, 108-116, Copyright  2007, with 
permission from Elsevier. 
 
Maria P. Torres1,2, Amy S. Determan1,3, Gretchen L. Anderson1,4, Balaji 
Narasimhan1,5, and Surya K. Mallapragada1,5 
 
5.1 Abstract 
The overall goal of this research is to design novel amphiphilic biodegradable 
systems based on polyanhydrides for the stabilization and sustained release of 
peptides and proteins. Accordingly, copolymers of the anhydrides, 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG), which is a monomer containing oligomeric ethylene glycol moieties, have 
been synthesized. Microspheres of different CPTEG:CPH compositions have been 
fabricated by two non-aqueous methods: solid/oil/oil double emulsion  and cryogenic 
atomization. The ability of this amphiphilic polymeric system to stabilize model 
proteins (i.e., lysozyme and ovalbumin) was investigated. The structure of both the 
encapsulated as well as the released protein was monitored using gel 





the CPTEG:CPH system preserves the structural hierarchy of the encapsulated 
proteins. Activity studies of the released protein indicate the CPTEG:CPH system 
retains the biological activity of the released protein. These results are promising for 
future in vivo studies, which involve the design of novel biodegradable polyanhydride 





 A recent study revealed that over a quarter of all new drugs approved are 
biopharmaceuticals with an annual global market surpassing $30 billion1. This group 
includes peptides and proteins intended for therapeutic treatment of a wide range of 
diseases, including reproductive disorders, blood related diseases, hepatitis B and 
C, and cancer 2. Nevertheless, the efficient delivery of these fragile molecules, which 
exhibit both physical and chemical instability leading to short in vivo half lives, 
remains a challenge.  
 The ideal protein carrier must protect the protein from the physiological 
environment and provide sustained release kinetics ranging from days to months 
depending on the application. Biodegradable polymeric microspheres have been 
used successfully in protein delivery3. Some of the characteristics of biodegradable 
carriers that can be manipulated to maintain protein stability include: water swelling, 
hydrophobicity, and chemical nature of degradation products4.  
 Proteins must be stabilized during device preparation, storage, and 





lead to protein inactivation. During device fabrication, the common methods 
employed for encapsulation expose the protein drug to aqueous/organic interfaces, 
which are known to be problematic for protein stability5, 6. Protein migrates towards 
the aqueous dispersing phase and as much as 40% of protein loaded has been 
shown to be lost during fabrication3, 7. New attempts to improve protein stability and 
maximize loading during microsphere fabrication circumvent this problem by using 
non-aqueous methods, such as solid/oil/oil (S/O/O) double emulsion and cryogenic 
atomization (CA)8-11. Besides promoting protein stability, these techniques increased 
the encapsulation efficiency, with efficiencies as high as 85% in S/O/O and ~100% in 
CA, as we reported recently10.  
 During protein administration, the chemistry of the polymeric carrier must be 
carefully chosen so as to provide a gentle environment that will maintain the activity 
of the protein drug. Among biodegradable polymers, bulk-erodible polyesters (e.g., 
poly(lactic-co-glycolic acid) or PLGA) have been extensively investigated12-18. 
Deleterious processes occurring during protein release from these polymers have 
been reported including an acidic microenvironment and strong hydrophobic 
interactions4, 19, 20. As PLGA degrades, the water content increases, characteristic of 
bulk erodible systems, and the local acidic environment produced by accumulation 
of degradation products are significant sources for irreversible physical and chemical 
inactivation of polypeptides and proteins. 
 Another class of biodegradable polymers investigated for protein delivery is 
polyanhydrides, which differ from polyesters in their erosion mechanism. 





reducing water penetration into the device21-24. However, these materials are 
hydrophobic and strong hydrophobic interactions between the polymer and the 
protein may lead to non-covalent aggregation.  
 A promising alternative for the polymers discussed above is the use of 
amphiphilic carriers for protein stabilization25-28. Correspondingly, we have designed 
a novel amphiphilic polyanhydride system based on copolymers of the anhydride 
monomers, 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) (Fig. 5.1), which contains oligomeric 
ethylene glycol29, 30. The incorporation of oligomeric ethylene glycol into the 
backbone of an aromatic polyanhydride creates the necessary hydrophilicity to 
create the amphiphilic environment needed for protein stabilization. Moreover, it is 
due to this amphiphilicity that the erosion mechanism of the CPTEG:CPH system 




















Figure 5.1.  Chemical structures of poly(CPH) (top) and poly(CPTEG) (bottom). 
  
 This paper focuses on protein stabilization and sustained release from 
microspheres based on the CPTEG:CPH system. The proteins chosen for this study 
are hen egg white lysozyme (Lys) and ovalbumin (Ova). Lys is an acid stabilized 





using it as a model protein for release relies on its similar size to therapeutic 
cytokines such as interferons and interleukins17. On the other hand, Ova has been 
well studied as a model antigen and is composed of 385 residues (48 kDa). It has a 
molten globular or intermediate unstable state in acidic surroundings, which is 
deleterious for its activity31.  Two non-aqueous methods, S/O/O and CA, were used 
to fabricate the microspheres. 
 
5.3 Materials and Methods 
5.3.1 Materials 
 The chemicals needed for monomer synthesis 4-p-hydroxybenzoic acid, 1,6-
dibromohexane, 1-methyl-2-pyrrolidinone, and tri-ethylene glycol were purchased 
from Sigma Aldrich (St Louis, MO); 4-p-fluorobenzonitrile was obtained from Apollo 
Scientific (Chesire, UK); potassium carbonate, dimethyl formamide, toluene, sulfuric 
acid, acetic acid, and acetonitrile were purchased from Fisher Scientific (Fairlawn, 
NJ). The chemicals needed for the polymerization, acetic anhydride, methylene 
chloride, and petroleum ether, were purchased from Fisher Scientific (Fairlawn, NJ). 
Chicken egg white Ova, hen egg white Lys, monoclonal anti-chicken egg albumin 
(clone Ova-14), rabbit anti-chicken egg albumin, alkaline phosphatase conjugated 
goat anti-rabbit IgG, fetal calf serum (FCS), Coommasie R-250, Sigma 104 
phosphatase substrate, p-nitrophenyl phosphatase (pNPP) liquid substrate system, 
and XTT in-vitro toxicology assay kit were purchased from Sigma Aldrich (St Louis, 
MO). Ready precast gels (15% acrylamide) and protein molecular weight standards 





Lys was determined with the EnzCheck® Lysozyme assay kit from Invitrogen 
(Carlsbad, CA). Bicinchoninic acid (BCA) protein assay kit and Slide-A-Lyzer dialysis 
cassettes (10,000 MW cut off membrane) were obtained from Pierce (Rockford, IL).     
 
5.3.2 Polymer Synthesis and Characterization 
 As we reported recently, CPTEG:CPH copolymers were synthesized by melt 
polycondensation of CPH and CPTEG diacids29. The purity and degree of 
polymerization of the polymers was analyzed using 1H NMR spectra obtained from a 
Varian VXR-300 MHz NMR spectrometer.  
 
5.3.3.Protein Incubation in Monomer Solutions 
 Saturated solutions of CPTEG and CPH diacids in deionized water and 
phosphate buffer (0.1 M, pH 7.4) were placed in the incubator for two days (37 ºC, 
100 rpm) and, subsequently, were filtered (0.22 μm). Lyophilized protein (final 
concentration 250 μg/mL) was added to the respective solutions (CPTEG, 50/50 
CPTEG/CPH, CPH, phosphate buffer) and incubated for 1 week (37ºC, 100 rpm) 
prior to structural analysis of the protein. These studies were performed in triplicate 










5.3.3.1 Primary Structure 
 The amino acid sequence of each protein before and after incubation was 
studied with sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing conditions. After centrifuging samples (10,000 rpm, 4 ºC, 10 
min), 10 μL of each sample was mixed with 10 μL of the reducing buffer (SDS (1% 
w/v), Tris-HCl (pH 6.8, 0.06 mM), glycerol (3 mM), bromophenol blue (0.01% w/v), 
and β-mercaptoethanol (0.05% v/v)). The 20 μL solution was heated for 10 minutes 
at 96 ºC, cooled to room temperature, and loaded into 15% acrylamide pre-cast gel 
and run for 60 minutes at 130 V. 5 μL of pre-stained low range protein standards 
were used for reference. After running the gels, these were stained with Coommasie 
Blue for 30 min and destained overnight.    
 
5.3.3.2 Secondary Structure 
 Far UV Circular Dichroism (CD) (190-250 nm) was used to monitor the 
protein secondary structure as recently described32. 
 
5.3.3.3 Tertiary Structure 
 Fluorescence spectra characteristic of protein residues were used to monitor 
changes in tertiary structure after incubation in monomer solutions. The emission 








5.3.3.4 Ovalbumin Antigenicity 
 An enzyme-linked immunosorbent assay (ELISA) was used to study the 
antigenicity of Ova prior to and after incubation with monomer solution and the 
protocol followed is described elsewhere32. The epitope availability of incubated 
samples was obtained by normalizing with protein solutions prior to incubation with 
the CPTEG:CPH monomers and the antigenicity was reported as relative epitope 
availability. The assay was also performed for protein released from microspheres 
(see below). 
 
5.3.3.5 Lysozyme Enzymatic Activity 
 The enzymatic activity of Lys after incubation with degradation products was 
evaluated with the EnzChek® Lysozyme Assay Kit. Lys hydrolyzes linkages of 
various cell walls of microorganisms. This assay measures the activity in 
Micrococcus lysodeikticus cell walls, which are previously labeled with fluorescein. 
The experimental protocol was followed as described by the manufacturer. 
Triplicates of each sample were averaged. Assays were also performed on samples 
after release from CPTEG:CPH microspheres (see below). The results were 
normalized by the activity measured initially (i.e., prior to incubation and release) and 









5.3.4 Microsphere Fabrication 
5.3.4.1 Solid/oil/oil (S/O/O) 
 Prior to protein encapsulation, the protein was lyophilized as described 
before10. The S/O/O method was modified from previous reports8-10. Briefly, 
lyophilized protein (2-3mg) was suspended in a solution of 100 mg of 20:80 
CPTEG:CPH copolymer dissolved in 2 mL of methylene chloride to produce the first 
emulsion. The suspension was obtained by homogenizing the solution at 20,000 rpm 
for 3 minutes using a Tissue-TearorTM. The second emulsion was produced after 
adding a solution of Dow Corning oil 550 (3mL) saturated with methylene chloride 
(4mL). The mixture was then poured into 200 mL of heptane on ice bath and stirred 
for 2 h at 300 rpm. Microspheres were collected by filtration and dried under vacuum 
overnight. 
 
5.3.4.2 Cryogenic Atomization (CA) 
 As we obtained higher encapsulation efficiencies with CA in previous 
experiments with unmodified polyanhydrides10, we fabricated microspheres of both 
20:80 and 10:90 CPTEG:CPH with this method. The procedure was modified from 
previously reported studies10, 11. Lyophilized protein (2-3 mg) was suspended in a 
polymer solution of methylene chloride (7mL for 20:80 CPTEG:CPH and 4mL for 
10:90 CPTEG:CPH) at 10,000 rpm for 1 min using a Tissue-TearorTM. The solution 
was then pumped with a syringe pump through an 8700-1200 MS ultrasonic 
atomizing nozzle (Sono Tek Corporation, Milton, NY) into 200 mL of frozen ethanol 





were: 3 mL/min and 1.5 W for 20:80 CPTEG:CPH and 1.5 mL/min and 2.5 W for 
10:90 CPTEG:CPH. This procedure was performed at 4ºC in order to maintain the 
temperature below the glass transition temperature of the polymer during pumping. 
After atomization, the resulting polymer/protein solution was stored at -80°C for three 
days to allow the methylene chloride to be extracted. The microspheres were then 
collected by filtration and dried under vacuum overnight.  
 The microsphere morphology was characterized by SEM. The particle size 
distribution was obtained from SEM images (250-500x) using a soft imaging system 
software (analySIS®, Soft Imaging System Corp, Lakewood, CO). An average of 
250 particles per image was analyzed. 
 
5.3.5 Protein Release 
 Microspheres (15 mg) were placed in 1 mL of phosphate buffer (0.1 M, pH 
7.4) and incubated at 37°C and 100 rpm. Sodium azide (0.01% w/w) was added to 
the buffer to prevent microbial contamination33. At different time intervals, aliquots of 
750 μL of supernatant were collected and replaced with fresh buffer. The aliquots 
were stored at 4°C and were centrifuged (10,000 rpm for 10 min) prior to BCA 
analysis. Protein concentration was measured using the BCA analysis from the 
absorbance at 570nm. At least two replicates of samples in each experiment were 
evaluated. The experiment was repeated twice, the values were averaged, and the 







5.3.5.1 Total Protein Encapsulated 
 After one month of release, the remaining microspheres were analyzed for 
residual protein content. Using a recently reported procedure10, the microspheres 
were suspended in 1 mL of 17 mM of sodium hydroxide and sonicated (Sonics & 
Materials Inc., Newton, CT). The sample was withdrawn with a syringe, and the vials 
were washed twice with 1 mL of the same solvent to ensure no residual protein was 
lost. The 3 mL solution was transferred to a dialysis cassette (Slide-A-Lyzer® 10,000 
MWCO, Pierce Biotechnology Inc., Rockford, IL) using the same syringe. The 
cassettes were placed in 600 mL of 17 mM sodium hydroxide and incubated at 100 
rpm and 40°C for 1 week in order to accelerate the degradation of the polymer. This 
temperature was chosen as it is below the denaturation temperature of lysozyme 
(81ºC) and ovalbumin (71ºC)34. After the incubation period, the protein was 
quantified by BCA analysis. The total protein encapsulated in the microspheres was 
determined by adding the protein released and the amount remaining in the 
microspheres. The cumulative release was normalized by this total amount and 













5.4.1 Protein Stability in the Presence of Degradation Products  
5.4.1.1 Primary Structure 
 The primary structure of Ova and Lys was analyzed with SDS-PAGE (Fig. 
5.2). Samples prior to and after incubation were loaded into the gels and were 
compared to molecular weight standards. Non-lyophilized protein was also loaded to 
ensure that lyophilization process did not alter the primary structure of native protein. 
From Fig. 5.2 it can be seen that no structural change occurred in the proteins 
during lyophilization or incubation as no aggregation or hydrolysis was perceived in 
the gels. Saturated concentrations of both CPTEG and CPH diacids were not 
detrimental to the model proteins used in this study, and characteristic bands of Ova 
at 48 KDa and Lys at 14 kDa were unchanged after 1 week of incubation.  
 
5.4.1.2 Secondary Structure 
 Circular dichroism (CD) was used to monitor the secondary structure of Lys 
and Ova during the incubation studies to estimate the type of secondary structure (α-
helix vs. β sheet vs. coil) present in the proteins35. The CD spectra of Ova (Fig. 5.3) 
incubated in CPTEG and CPH diacid saturated solutions were identical at 0 and 7 
days, showing two minima (208 and 222 nm) that are signatures of α-helices and α-
helices + β-sheets. The secondary structure of Lys was also preserved and the 





                                                         
 
Figure 5.2. SDS-PAGE of Ova (a) and Lys (b). Lane 1: MW standard ladder; lane 2: Non-lyophilized protein; 
lanes 3, 4 protein in CPTEG solution (day 0, 7); lanes 5,6: protein in 50/50 CPTEG/CPH solution (day 0, 7); 
lanes 7,8: protein in CPH solution (day 0, 7); lanes 9,10 in gel (a) Ova in phosphate buffer (day 0, 7). 
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5.4.1.3 Tertiary Structure  
 Proteins are usually biologically active only when folded in their native 
conformations, so understanding their 3-D structures is key to understanding how 
they function36. The  most common exception to two state folding transitions is the 
occurrence of a stable, partially folded state, known as the molten globule36. The 
formation of a molten globule state may retain the secondary structure, as it is 
almost as compact as the fully folded protein, but the tertiary structure is 
disrupted/unfolded37. It has been reported that this molten globular state can be 
produced in Ova as a result of harsh environments38. On the other hand, Lys does 
not have a molten globule structure and unfolds globally by guanidine hydrochloride 
in the two state type36, 39, 40. With this in mind, the fluorescence spectra were 
analyzed. Fig. 5.4 shows that in the fluorescence spectra of Ova incubated in 
CPTEG and CPH saturated solution, the maximum wavelength at days 0 and 7 was 
in the 336-340 nm range, and suggested that a molten globule state was not formed 
during the incubation period. Similarly, fluorescence spectra of Lys contained 
maximum wavelengths in the 343-345 nm range (data not shown). The emission 
spectrum at the wavelength range of 330-345 nm is characteristic of the tryptophan 
residues41. No loss of tertiary structure was detected, and it can be concluded that 
conformational stability of the two model proteins (Ova and Lys) was preserved in 












5.4.1.4 Protein Activity 
 The activity after incubation of the model proteins with CPTEG:CPH 
degradation products was assessed by measuring the antigenicity of Ova and the 
enzymatic activity of Lys. The results of the ELISA performed in the Ova samples 
(Fig. 5.5a) demonstrate that neither CPTEG nor CPH diacid solutions caused a 
statistically significant change in the antigenicity of Ova after 7 days of incubation. 
More perturbations were caused when the protein was incubated in phosphate 
buffer alone, where an increase of ~50% after incubation suggests that protein 
exposed more epitopes to be recognized and quantified by the assay. The 
enzymatic activity of lysozyme was also measured (Fig. 5.5b), and as expected, it 
was maintained during the incubation period, with less than 10% loss in all the 
solutions analyzed. All these results support our hypothesis that the novel 
























































                
Figure 5.5. Protein activity after incubation with CPTEG:CPH degradation products. (a) antigenicity of Ova and 
(b) enzymatic activity of Lys. Error bars indicate standard deviation of triplicate samples.  
 
 
5.4.2 Microsphere Fabrication 
 It is desirable to minimize drug particle size during encapsulation in order to 
minimize the burst effect42. As the size of the protein particles and stability of the 
dispersion are directly relevant for microsphere performance, the proteins (Ova, Lys) 
were lyophilized prior to their encapsulation into CPTEG:CPH microspheres. 
 Microspheres fabricated by S/O/O had a relatively smooth surface of the 
microspheres prior to and following protein encapsulation (images not shown). The 
typical size distribution of these microspheres was in the range of 4-60 μm, with the 



























































 The second method studied was CA, which besides avoiding the deleterious 
effect of the water/organic interface, maximizes protein encapsulation10. 
Microspheres of 10:90 and 20:80 CPTEG:CPH were successfully fabricated and 
images of 10:90 CPTEG:CPH microspheres and particle size distribution are shown 
in Fig. 5.6. Similar microsphere surface structure was obtained for the 20:80 
CPTEG:CPH copolymers, indicating that the slight change in hydrophobicity did not 
have any effect on the microsphere formation (images not shown). The difference in 
surface roughness when compared to S/O/O microspheres is due to the difference 
in solvent extraction rates during the fabrication process. The particle size from 
cryogenic microspheres resulted in unimodal distributions with diameters in the 
range of 2-16 μm. 
 
Figure 5.6. SEM image and particle size distribution of Ova loaded 10:90 CPTEG:CPH microspheres fabricated 
by cryogenic atomization. Scale bar represents 20 μm. 
 
 
5.4.3 Protein Release 
 The release of Ova and Lys from CPTEG:CPH microspheres is shown in Fig. 
5.7. The cumulative protein release was normalized with respect to the total protein 
























encapsulation efficiencies were observed for both proteins and fabrication methods 
studied, which is in agreement with previous work10. A sustained protein release and 
relatively low initial burst were achieved with all the CPTEG:CPH formulations, which 
is characteristic of amphiphilic systems where protein is more uniformly distributed. 
In addition, the initial burst of both CA and S/O/O microspheres were comparable to 
recently published studies with polyanhydride microspheres composed of 20% CPH 
10.  
                          
Figure 5.7. Protein released from CPTEG:CPH microspheres. (a) Ova released from 20:80 and 10:90 CA 
microspheres, (b) Lys released from 20:80 CA and S/O/O microspheres. Error bars represent standard deviation 
of triplicate samples. 
 
 Ova was released from both 20:80 and 10:90 CPTEG:CPH microspheres 
fabricated by CA to study the effect of copolymer composition on protein release 





















































as protein released faster from 20:80 CPTEG:CPH (67% ) than from 10:90 
CPTEG:CPH microspheres (54%) in one month.  
 The effect of microsphere fabrication method on protein release was analyzed 
from Lys release from 20:80 CPTEG:CPH microspheres fabricated by CA and 
S/O/O (Fig. 5.7b). As can be seen, there is excellent agreement between the two 
fabrication methods. During one month of release, 49% and 51% of the total Lys 
encapsulated were released from CA and S/O/O microspheres, respectively. It is 
important to note that bursts of less than 10% were observed in these microspheres, 
suggesting that Lys was homogenously distributed. These results, when compared 
to the Ova studies described above, demonstrate that protein characteristics 
influence their distribution and hence the subsequent release. Ova encapsulated in 
the same polymer formulation (i.e., 20:80 CPTEG:CPH CA microspheres) produced 
an initial burst of 35%, compared to the 10% obtained with Lys.  
 
5.4.3.1 Protein Activity after Release 
 The activity of Ova and Lys was analyzed after release from the CPTEG:CPH 
microspheres similar to the methods used to analyze the proteins incubated in the 
presence of the degradation products. The antigenicity of Ova released from the CA 
microsphere formulations (i.e., 20:80 and 10:90 CPTEG:CPH) shown in Fig. 5.8a 
indicates that the released Ova did not lose significant antigenicity after being 
released from the two copolymer compositions. Similarly, the activity of Lys was 
essentially maintained in both 20:80 CPTEG:CPH CA and S/O/O microspheres 





activity of the protein when released from the CA microspheres. On the contrary, Lys 
activity released from the S/O/O formulation was statistically different (p < 0.05). 
Possible causes for this difference among the microspheres are the processes 
involved during fabrication, where different solvents (i.e., methylene chloride, ethanol 
in CA; methylene chloride, silicon oil, heptane in S/O/O) were involved. The 
methylene chloride extraction rate in each method was different. In S/O/O, the 
protein-loaded microsphere formulations were subjected to more stress and organic 
phases than in CA. These studies suggest that minimizing protein instability during 
processing and maximizing protein encapsulation are desirable characteristics of the 
CA method, which make it suitable for protein delivery applications.        





Figure 5.8. Protein activity after release from CPTEG:CPH microspheres. (a) antigenicity of Ova after release 
from 20:80 and 10:90 CA microspheres, (b) enzymatic activity of Lys after release from 20:80 S/O/O and CA 
microspheres. Error bars indicate standard deviation of triplicate samples. * represents p-value < 0.05 as 































































 Loss of the folded structure of proteins can be readily followed by observing 
changes in absorption spectra, CD, fluorescence spectra or in the dimensions of the 
protein, which generally increase upon denaturation. The interactions are so 
dependent upon each other that disruption of a very limited number of interactions 
tends to disrupt all of them36. Any structure present in unfolded proteins is local, 
however, and the global co-operative interactions characteristic of the native state 
are absent. Thus, it is important to verify that the native structure of the protein is 
preserved at all structural levels (i.e., primary, secondary, and tertiary structures). 
The stability of proteins in the presence of degradation products provides invaluable 
information by mimicking the microenvironment inside the polymeric device during 
release. After ensuring that no perturbations take place at the structural level, it is 
equally important to check if the protein maintained its activity.  The results obtained 
in these studies indicate that the two model proteins studied maintained both their 
structure and activity in the presence of the CPTEG:CPH monomers. 
 When designing delivery systems for protein drugs, all the processes 
involved, from fabrication to delivery, which can alter the stability and hinder the 
therapeutic drug efficacy, must be considered. This paper demonstrates that during 
the three stages of device fabrication using amphiphilic polyanhydrides, the model 
proteins Ova and Lys were efficiently stabilized. The stability of the proteins in 
saturated concentrations of degradation products of CPTEG:CPH was unaltered at 
all the structural sublevels. In Table 5.1, the pH of the CPTEG and CPH diacid 





polyesters. It is interesting to note that an acidic microenvironment is produced by 
the ester monomers even below their saturation concentration. On the other hand, 
saturated solutions of CPTEG and CPH diacids have pH of 6.5 and 5.5 respectively. 
Thus, even at saturated monomer concentrations, the microenvironments of the 
CPTEG:CPH eroding device show little decrease in pH. Not surprisingly, the protein 
released from CPTEG:CPH microspheres was stable and the activity was essentially 
unaltered. 
 






Type of monomer pH 
CPTEG 9(saturated) Anhydride 6.5 
CPH* 1 (saturated) Anhydride 5.5 
LA* 5 Ester 3.5 
GA* 5 Ester 3.6 
 
 
 The model proteins (Ova and Lys) differed in their chemical structure and 
function, and therefore their mechanisms of instability were dissimilar. The less 
acidic microenvironments (i.e., CPTEH:CPH) improved Ova stability than at acidic 
pH, where stronger complexation can result in protein aggregation31, 43. On the other 
hand, precipitation of albumin is expected when the pH of the aqueous environment 
approaches the isoelectric point (~4.8). Under these conditions most proteins 
expose hydrophobic domains which are inherently attractive, a process that will 
likely occur in degrading environment of polyesters, but not in the CPTEG:CPH 
system43. In contrast, Lys is a monomeric globular protein that is acid stabilized44, 





and severe methods such as disulfide scrambling are needed for its partial 
denaturation39. It is not surprising that the acidic environment of the polyester 
degradation products provide a stable environment for this protein32.  
 
5.6 Conclusions 
 This study demonstrates that the amphiphilic CPTEG:CPH system is a 
promising protein carrier. Our studies showed that the amphiphilic environment does 
not alter protein structure and provides a sustained release profile from 
microspheres. These results are promising for future in vivo studies, which involve 
the design of novel biodegradable polyanhydride carriers suitable for the stabilization 
and sustained release of different therapeutic peptides and proteins.  
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CHAPTER 6 
EFFECT OF POLYMER CHEMISTRY AND FABRICATION METHOD ON 
PROTEIN RELEASE AND STABILITY FROM POLYANHYDRIDE 
MICROSPHERES 
Reprinted from a paper submitted to Journal of Biomedical Materials Research B: 
Applied Biomaterials, 2008. 
Senja K. Lopac1,2, Maria P. Torres1,3, Jennifer H. Wilson-Welder3,4, Michael J. 
Wannemuehler4,5, and Balaji Narasimhan1,6 
  6.1 Abstract 
The release kinetics and protein stability of ovalbumin-loaded polyanhydrides 
microspheres with varying chemistries were studied.  Polymers based on the 
anhydride monomers sebacic acid (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH), 
and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were chosen.  
Microspheres were fabricated using two non-aqueous methods: a solid/oil/oil 
emulsion technique and cryogenic atomization.  Studies found no significant 
difference in release kinetics of ovalbumin.  Ovalbumin released from microspheres 
prepared by cryogenic atomization was studied for preservation of primary structure 
by SDS-PAGE and availability of immunogenic epitopes by western blot.  The more 
hydrophilic polyanhydrides containing CPTEG showed favorable protein stability, 






 Biodegradable polymers have been used as carriers for the controlled 
delivery of drugs and proteins for over two decades. These carriers have the 
advantages of providing sustained release over long periods of time, well-controlled 
release profiles, and biocompatibility. The most common biodegradable polymers 
used in drug delivery applications are polyesters such as poly(D,L-lactide-co-
glycolide) (PLGA), polyanhydrides, and poly(orthoesters). A potential draw-back in 
using the bulk-erodible PLGA for protein delivery is that the water penetration into 
the bulk is fast and that the degradation products are fairly acidic; for example, a pH 
of less than 3 for degradation products1 and a pH of 2 inside a PLGA drug delivery 
device2 have been reported. Studies have shown that at these pH values, some 
proteins can undergo denaturation by unfolding, and in some cases, irreversible 
aggregation3. This is problematic for most proteins because a loss in structure is 
detrimental to function. In comparison, the pH values produced by polyanhydride 
degradation products are much higher, notably 4.2 for sebacic acid (SA) and 5.5 for 
1,6-bis(p-carboxyphenoxy)hexane (CPH)4. The hydrophobic polyanhydrides help 
prevent water-induced covalent aggregation of proteins since water penetration into 
the bulk is negligible; however, non-covalent aggregation due to hydrophobic 
interactions may result5, 6. This has motivated research to make these materials less 
hydrophobic7, 8. This was achieved by incorporating oligomeric ethylene glycol units 
into the backbone of hydrophobic aromatic polyanhydrides, such as poly(CPH), 
leading to amphiphilic polymers with mixed erosion mechanisms, which result in the 





 Polyanhydrides have been studied for drug delivery applications since 1983, 
when Langer and co-workers reported their potential for controlled drug delivery 
based on their biodegradable properties, and non-toxic and non-mutagenic nature9. 
Due to their ability to erode at the surface, polyanhydrides result in drug release 
profiles that exhibit a predictable zero-order release rate, making them attractive 
candidates for drug delivery applications10. Degradation of polyanhydrides occurs by 
base-catalyzed hydrolysis of their anhydride linkages, in the presence of water, to 
form dicarboxylic acids; their rate of degradation depends upon on the monomer 
used11-13. SA and CPH tablets, for example, degrade in 54 days and 1 year, 
respectively14. In contrast, 80% of the ethylene glycol containing polyanhydride, 
poly(1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane) (poly(CPTEG)), degrades  in 28 
days7. Thus, by combining different anhydride monomers in various ratios, 
copolymer degradation rates can be tailored for specific applications15. 
 Biodegradable polymers are also preferred for parenteral drug delivery 
systems as there is no need to remove them following implantation. A size of less 
than 125 μm is normally preferred for such applications; this size allows for delivery 
into the tissue by the use of a syringe and needle16. Typical methods for 
microsphere fabrication include hot melt microencapsulation17, double emulsion10, 18-
22, spray drying23, 24, and cryogenic atomization20, 25-28. In particular, previous 
research has shown that double emulsion methods in which water/organic interfaces 
are present are potentially detrimental for protein stabilization21, 29-32. Thus, several 
groups have focused on developing non-aqueous methods for preparing protein-





microspheres include solid-oil-oil (S/O/O) double emulsion and cryogenic 
atomization (CA); besides avoiding the water/organic interface, these techniques 
prevent hydrolysis of the polymer by eliminating water from the process33. 
The objective of this work is to systematically study the effects of polymer 
chemistry and fabrication method on the release kinetics of proteins from 
polyanhydride microspheres and on the stability of the released protein. Polymer 
chemistries based on the anhydride monomers SA, CPH, and CPTEG were chosen 
(Fig. 6.1). Ovalbumin (ova) from chicken egg white was selected as the model 






















Figure 6.1. Chemical structures of polymers used, from top, left to right: poly(sebacic acid) (SA), poly(1,6-bis(p-
carboxyphenoxy)hexane) (CPH), and poly(1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane) (CPTEG). Here n 












6.3 Materials and Methods 
6.3.1 Materials 
Albumin from chicken egg white (ovalbumin/Ova), 1,6-dibromohexane, 4-
hydroxybenzoic acid, 1-methyl-2-pyrrolidinone, sebacic acid (99%), monoclonal anti-
chicken egg albumin (clone Ova-14), rabbit anti-chicken egg albumin, alkaline 
phosphatase conjugated goat anti-rabbit IgG, and tri-ethylene glycol were purchased 
from Sigma-Aldrich (St. Louis, MO). 4-p-fluorobenzonitrile was purchased from 
Apollo Scientific (Cheshire, UK). Acetic acid, acetic anhydride, acetone, acetonitrile, 
dimethyl formamide, ethyl ether, heptane, hexane, methylene chloride, petroleum 
ether, potassium carbonate, sodium hydroxide, sulfuric acid, and toluene were 
purchased from Fisher Scientific (Fairlaw, NJ). Dialysis cassettes, bicinchoninic acid 
(BCA) assay reagents, and GelCode blue were purchased from Pierce (Rockford, 
IL). Low protein molecular weight standards were purchased from BioRad (Hercules, 
CA). 12% tris-glycine PAGE Duramide Precast Gels were purchased from Lonza 
Bioscience (Basel, Switzerland). Dow Corning oil, ethanol, and liquid nitrogen were 
obtained from in-house bulk chemical supplies. 
 
6.3.2 Monomer/polymer Synthesis 
To produce the CPH monomer, the method described by Conix34 for 
synthesizing 1,3-bis(p-carboxyphenoxy)propane was altered, using 1,6-
dibromohexane instead of 1,3-dibromopropane. Prepolymers for both CPH and SA 
were synthesized using a method outlined by Shen et al.35; CPH:SA copolymers of 





using a procedure outlined by Kipper and coworkers36. The CPTEG monomer and 
CPTEG:CPH copolymers were produced using a technique described by Torres et 
al7. The polymers, pre-polymers, and diacids were characterized by 1H NMR, using a 
Varian VXR-300 NMR (Palo Alto, CA), to ensure purity; a Waters GPC (Milford, MA) 
was used to measure the polymer molecular weight. 
 
6.3.3 Protein Preparation 
Ova obtained from chicken egg white was lyophilized prior to use. 
Lyophilization occurred by pumping ova (50 mg) in 50 mM ammonium bicarbonate 
solution (10 mL) over 400 mL of liquid nitrogen. The liquid nitrogen was allowed to 
boil off, and the remaining protein was placed in a dryer oven overnight; 
denaturation of freeze-thawed ova at neutral pH has been shown to be highly 
unlikely37. 
 
6.3.4 Contact Angle Measurements 
To characterize the relative hydrophobicity of the polymers, contact angle 
measurements were carried out. Polymers were dissolved in a 2.5 w/v% solution of 
tetrahydrofuran (for poly(CPTEG) and CPTEG-containing copolymers), or methylene 
chloride (for poly(CPH), poly(SA), and their copolymers). After filtering solutions with 
0.2 μm filters, the solutions were pipetted onto separate round glass cover slides. 
After the solvent dried, more solution was added until a suitable polymer thickness 
was obtained. To measure the contact angle, a water droplet was carefully placed 





Image J software (NIH, Bethesda, MD) was used to measure the contact angle. The 
experiment was performed in triplicate. A student-t test (α=0.05) was performed with 
the statistical analysis software JMP® 6 (Cary, NC).  
 
6.3.5 Microsphere Fabrication Methods 
Two non-aqueous methods were used to fabricate polyanhydride 
microspheres: S/O/O double emulsion and CA. As discussed before, previous 
research has demonstrated that these methods are effective at encapsulating and 
stabilizing proteins4, 20. 
 
6.3.5.1 Solid-oil-oil (S/O/O) Double Emulsion 
This method was modified from a previously published procedure21. Briefly, 
100 mg of polymer and 6 mg of ova were dissolved in methylene chloride. A Tissue-
TearorTM homogenizer (Biospec Products Inc., Bartlesville, OK) was used to agitate 
the solution for one minute. For the second emulsion, Dow Corning oil and 
methylene chloride were added while the homogenizer was turned down to 10,000 
rpm and used for one minute, to allow for thorough mixing during addition. The 
parameters used for each emulsion step for the different polymer chemistries are 
shown in Table 6.1. The solution was added drop-wise to a beaker of 200 mL of 
heptane immersed in an ice bath and stirred at 300 rpm for two hours using a 
Caframo overhead stirrer (Wiarton, Ontario, Canada). Finally, the microspheres 






Table 6.1. Parameters for S/O/O double emulsion  
 Methylene 
chloride for inner 
emulsion 
Rate for inner 
emulsion 
homogenization 
Rate for outer emulsion 
homogenization 
20:80 CPTEG:CPH 2 mL 20,000 rpm 3 min 
3mL oil/4 mL MeCl2 
20,000 rpm, 3 min 
Poly(CPTEG) and 
50:50 CPTEG:CPH 2 mL 
20,000 rpm 
3 min 
4mL oil/6 mL MeCl2 
20,000 rpm, 3 min 
Poly(SA) 3 mL 30,000 rpm 1 min 
3mL oil/4 mL MeCl2 
20000 rpm, 1 min 
20:80 CPH:SA 2 mL 30000 rpm 1 min 
3mL oil/4 mL MeCl2 
30000 rpm, 1 min 
50:50 CPH:SA 2 mL 20000 rpm 1 min 
3mL oil/4 mL MeCl2 
30000 rpm, 1 min 
 
6.3.5.2 Cryogenic Atomization (CA) 
CA, which employs an ultrasonic generator to produce a fine mist, was also 
modified from previously published work21. Briefly, 100 mg of each polymer was 
dissolved in methylene chloride with 6 mg of ova. Using a glass syringe, 20 gauge 
capillary tube, and programmable syringe pump (KD Scientific, Holliston, MA), the 
polymer solution was pumped over 200 mL of 200 proof ethanol (frozen by liquid 
nitrogen), leaving a small layer of liquid nitrogen overlaying the ethanol. The 
atomizing mist was provided by an ultrasonic atomizing nozzle (SonoTek 
Corporation, Milton, NY). The beakers were placed in a -80 °C freezer for three days 
to allow the liquid nitrogen to boil off, the ethanol to thaw, and the methylene chloride 
to slowly be extracted. Afterwards, the microspheres were filtered and placed in a 
vacuum oven to dry overnight. Table 6.2 summarizes the operating parameters for 







Table 6.2. Parameters for CA 
 Methylene chloride Flow rate Wattage 
20:80 CPTEG:CPH, 
50:50 CPTEG:CPH, and 
Poly(CPTEG) 
7 mL 3 mL/min 1.5 W 
50:50 CPH:SA 3 mL 1.5 mL/min 2.5 W 
Poly(SA) and 
20:80 CPH:SA 3 mL 3 mL/min 1.5 W 
 
6.3.6 Microsphere Characterization 
A JEOL 840A scanning electron microscope (SEM) was used to determine 
relative size and shape of microspheres. Microspheres were smeared onto carbon 
stubs, coated with 200 Å of gold, and imaged. Size distribution analysis was 
performed using Image J software (NIH, Bethesda, MD). 
 
6.3.7  Ova Release 
Polyanhydride microspheres (10 mg) fabricated by S/O/O or CA were 
suspended in 1mL of phosphate buffer solution (pH 7.4) with 0.01% sodium azide 
and placed in an incubator at 37 °C and 100 rpm. The release samples were 
collected two hours after the initial time point, daily for one week and every other day 
for 30 days. An aliquot of 750 μL was sampled each time and subsequently replaced 
with 750 μL of fresh phosphate buffer solution to ensure perfect sink conditions; the 
samples were also centrifuged before sampling to ensure that no microspheres were 
removed from the system. In order to quantify the amount of protein released, a 
bicinchoninic acid (BCA) assay was run on each sample, in duplicate, as described 






After one month of release, the samples were added to 10 kDa molecular 
weight cut-off dialysis cassettes to determine the amount of protein remaining inside 
the microspheres. The remaining microspheres were suspended in 3 mL of 17 mM 
NaOH and sonicated to break up any aggregates. The exposure to a high pH allows 
for fast degradation of the polymer, since anhydride degradation is base-catalyzed23. 
Each release sample was added to dialysis cassettes and incubated for one week at 
40 °C and 100 rpm. A BCA assay was run on each sample in triplicate. The total 
protein loaded into the microspheres was calculated by adding the protein that was 
released in one month to the protein extracted from the remaining microspheres. 
The release data is presented as cumulative fraction of protein released, which is 
normalized by the total protein loaded into the microspheres. 
 
6.3.8 Sodium Dodecyl Sulfat Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Ova-loaded microspheres (5% w/w) were fabricated using CA. 15 mg of these 
microspheres were added to 1 mL of .phosphate buffer solution (pH 7.4), with 0.01% 
sodium azide, and placed in an incubator at 37 C and stirred at 100 rpm for 2 hours; 
750 μL of solution was removed and replaced with 2.75 mL of 0.01 mM NaOH 
solution. This was performed to ensure that all analysis was performed on released 
protein and not on protein adsorbed to the surface of the microsphere. The 
microspheres were added to 10k molecular weight cut-off dialysis cassettes, placed 
in 1 L of 0.01 mM NaOH solution, and incubated for 2 weeks at 40 °C and 100 rpm. 
After two weeks, the solution was removed from the dialysis cassette and 





solution. A BCA assay, performed in triplicate, was used to determine the 
concentration of ova released from the microspheres. 
Using the concentration from the BCA assay, 2 μg of protein from each sample 
was placed on a rotovap until completely dry. Samples were prepared under 
reducing conditions by adding 20 μL of 2-mercaptoethanol sample buffer to each 
sample and placing samples on a heating block at 90 °C for 10 minutes to break up 
the disulfide linkages. The gels were made in triplicate, to allow for two to be used 
for western blot analysis (described below). Gels were run at a constant voltage of 
120 V until the dye front reached the bottom. The gel set aside for SDS page 
analysis was rinsed with DI water and placed in gel fixative (50% methanol, 36% DI 
water, 14% acetic acid) overnight. The next day, the gel was stained with Gelcode 
blue for a few hours and destained with water overnight; the staining process was 
repeated to obtain a darker stained gel. The gel was placed between cellophane 
sheets and dried in a jet drier for 2 hours. This procedure was repeated for pure ova 
to ensure that the protein structure was preserved under the conditions of the 
experiment. Therefore, the SDS-PAGE results obtained after release from the 
microspheres could be related to the stability of the protein released from the 










6.3.9 Western Blot 
For western blot analysis, the gels were immediately removed after gel 
electrophoresis, placed between filter paper and a PVDF membrane, and placed 
back in the electrophoresis chamber for 3 hours at a constant current of 70mA. The 
membranes were blocked with a casein solution of TBST (tris buffer solution with 
0.05% Tween, pH 7.6) and milk powder overnight. The following day, the 
membranes were rinsed in DI water, placed in a 50 mL centrifuge tube, and 12 μL of 
primary antibody (anti-ova developed in rabbit) in TBST (1:1000) was added. The 
membranes were spun for four hours, washed thrice with TBST to remove any 
unbound antibody, and placed back on the spinner with 12 μL of secondary antibody 
(anti-rabbit IgG alkaline phosphate developed in goat) in TBST (1:1000). After two 
hours, the membranes were removed and rinsed thrice with TBST. A colorimetric 
detection method with napthol phosphate and fast red solution was used to reveal 















6.4.1 Contact Angle 
In order to assess the hydrophobicities of the various polymers, the contact 
angles of each of the polymers were measured, as shown in Figure 6.2. As 
expected, poly(CPTEG), the most hydrophilic and bulk-erodible polymer with a fast 
degradation profile (within weeks7), has the lowest contact angle (29°) of all the 
polymer chemistries. As demonstrated by the statistical analysis, poly(CPTEG) was 
significantly more hydrophilic than all the other polyanhydride chemistries analyzed. 
In contrast, poly(CPH), which is the most hydrophobic and surface-erodible polymer, 
and takes years to degrade38 has the highest contact angle (60°). As Figure 6.2 
demonstrates, an increase in CPH content within the CPTEG:CPH copolymers 
results in an increase in contact angle, which is consistent with an increase in 
hydrophobicity. In the surface erodible CPH:SA system, since both CPH and SA are 
hydrophobic, their copolymers have relatively similar hydrophobicities, as evidenced 


































































Fig. 6.2. Contact angle of polyanhydride films. Error bars represent standard deviations from three experiments. 
A student-t test was performed at P-value<0.05  ( = statistically different from CPH and SA homopolymers , 




6.4.2 Release of Ova from Polyanhydride Microspheres 
SEM images of 50:50 CPH:SA and 20:80 CPTEG:CPH fabricated by S/O/O 
and CA methods are shown in Figures 6.3 and 6.4. Size distributions of the CPTEG 
particles ranged from 4 to 60 μm for S/O/O, with the majority being between 10 and 
15 μm in diameter, and 2 to 16 μm in diameter for CA microspheres20. For the 
CPH:SA system, the majority of the microspheres fell in the 6 to 10 μm diameter 






Figure 6.3. 50:50 CPH:SA microspheres fabricated by S/O/O (left) and CA (right) methods. Scale bars represent 
50 μm.  
 
               
Figure 6.4. 20:80 CPTEG:CPH microspheres fabricated by S/O/O (left) and CA (right) methods. Scale bars 
represent 20 μm.  
 
In Figure 6.5 the release profiles of ova from Poly(SA), 20:80 CPH:SA and 
50:50 CPH:SA copolymer microspheres fabricated by S/O/O and CA fabrication 
methods are shown. As can be seen, all these chemistries exhibit near zero-order 
release kinetics after the initial burst of protein, which is consistent with previous 
work21. Each polyanhydride chemistry exhibited a different release rate consistent 
with the hydrophobicity of the polymer, but upon comparing the two fabrication 
methods, this was found to be unrelated to the fabrication method; for example, 
poly(SA) microspheres fabricated by both S/O/O and CA released 90% of the 





polymer hydrophobicity increased, the release rate of the protein decreased. The 
fabrication method influences the size of the burst. Microspheres produced by the 
S/O/O technique experienced a smaller initial burst of protein. This is attributed to 
the interplay between two phenomena: the rate at which the polymer precipitates 
during microsphere formation, and the rate at which the methylene chloride is 
extracted into the non-solvent to form the microspheres. In addition, polymer 
hydrophobicity appears to have an influence on the burst effect, as a greater 































































Figure 6.5. Fraction of ova released from poly(SA) and CPH:SA copolymer microspheres using S/O/O (left) and 
CA (right) fabrication techniques. Error bars indicate standard deviation. 
 
The ova release profiles from poly(CPTEG), 20:80 CPTEG:CPH and 50:50 
CPTEG:CPH copolymer microspheres fabricated by S/O/O and CA methods were 
also analyzed (Fig. 6.6). Since poly(CPTEG) is bulk-eroding, the protein release 
kinetics is not directly proportional to the degradation kinetics, but rather depend 





expect the protein released from poly(CPTEG) microspheres to have the fastest 
release profile, the 50:50 CPTEG:CPH copolymer actually releases protein at the 
same rate (~90% for CA) or slightly faster (90% vs. 80% for S/O/O) than 
poly(CPTEG). Previous work has shown that even though the mass loss (i.e., 
erosion) was consistent with the hydrophobicities of poly(CPTEG) and 50:50 
CPTEG:CPH copolymer, the water swelling and polymer degradation rates of both 
chemistries were very similar7. Our protein release data is consistent with these 
observations. On the other hand, the 20:80 CPTEG:CPH microspheres released ova 
at a slower rate, and both fabrication methods are consistent in their sustained 
release profiles by releasing ~50% of protein in one month. Once again, the only 
variation of release kinetics as a result of the fabrication methods is in the initial 
burst; poly(CPTEG) microspheres demonstrated the largest difference in burst (8% 
































































Figure 6.6. Fraction of ova released from poly(CPTEG) and CPTEG:CPH copolymer microspheres using S/O/O 






6.4.3 SDS-PAGE  
Since the release kinetics studies did not show significant differences 
between the S/O/O and CA microspheres, cryogenic atomized microspheres were 
used for the protein stability studies due to the ease of scale-up and the simplicity of 
fabrication. Additionally, in vaccine delivery applications, it is advantageous to have 
a high initial burst, which results in the induction of a primary immune response. 
Ova has a tendency to form moisture-induced covalent aggregates39, which is 
shown by the presence of characteristic bands between 54 and 97 kDa (lane 2), in 
addition to the normal ova band at 48kDa (Figure 6.7). The ova released from the 
poly(SA), 20:80 CPH:SA, and 50:50 CPH:SA microspheres (lanes 3, 4, and 5, 
respectively) show the higher molecular weight band as the non-encapsulated ova 
(lane 2), but failed to display the bands at 45 kDa. This indicates that the CPH:SA 
system fails to prevent non-covalent aggregation of the protein, presumably due to 
hydrophobic interactions; however, considering that no low molecular weight bands 
are displayed, it can be implied these hydrophobic chemistries did not promote 
hydrolysis or degradation of the protein. This is consistent with the surface erodible 
nature of these polymers. However, results obtained with SDS-PAGE will be 






Figure 6.7. SDS-PAGE of ova released from microspheres over two weeks. Lane 1 – protein ladder; lane 2 – ova 
at pH 10; lane 3 – poly(SA); lane 4 – 20:80 CPH:SA; lane 5 – 50:50 CPH:SA; lane 6 – poly(CPTEG); lane 7 –
20:80 CPTEG:CPH; and lane 8 – 50:50 CPTEG:CPH. 
 
The amphiphilic polymers (poly(CPTEG), 20:80 CPTEG:CPH, and 50:50 
CPTEG:CPH) all showed normal ova bands at 45 kDa as well as the aggregated 
state, which are both observed in the non-encapsulated ova. The bands for the 
unaggregated ova became darker with an increase in CPTEG content. Once again, 
no low molecular weight bands were present, suggesting these polyanhydride 
chemistries did not degrade or cause hydrolysis of the protein.  
 
6.4.4 Western Blot 
Figure 6.8 shows the western blot analysis conducted on the released protein 
from each of the fabricated polyanhydride preparations.  Again, ova shows strong 
bands at both an aggregated (54 to 97 kDa) and unaggregated (45 kDa) states. 





the protein released from each of the CPTEG-containing polymers (lanes 6-8), 
indicating that the protein epitopes are readily conserved, and that the protein 
structure is not perturbed.  50:50 CPH:SA preserved the epitopes at the 
unaggregated ova state, but  produced only faint bands for the aggregated protein.  
Poly(SA), due to the acidic nature of its degradation product, sebacic acid, degrades 
the protein below detection of the polyclonal western blot; 20:80 CPH:SA also 
showed a similar effect.  After analyzing these results, it can be implied that the 
absence of bands in the SDS-PAGE of the ova released from these polymers was 
caused by the severe hydrolysis of the protein into small fragments.  
 
Figure 6.8. Polyclonal western blot of ova released from microspheres over two weeks. Lane 1 – protein ladder; 
lane 2 – ova at pH 10; lane 3 – poly(SA); lane 4 – 20:80 CPH:SA; lane 5 –  50:50 CPH:SA; lane 6 – 












As expected, the higher the hydrophobicity of the polymer, the slower the 
degradation rate, as the rate at which water penetrates into the bulk slows in 
correlation40.  In regards to the release kinetics of ova, both fabrication methods 
were consistent.  CA is a preferential method of preparing microspheres, due to its 
ease of scale up and increased encapsulation efficiencies21.  Burst profiles are 
correlated with the polymer hydrophobicity, as the most hydrophobic CPH:SA 
microspheres  display the largest bursts regardless of the fabrication method used.  
This may be attributable to the thermodynamic incompatibility of the protein with 
hydrophobic copolymers. Therefore, though the actual amount of protein released at 
the start of the degradation/erosion cycle may vary, the trend of hydrophobicity 
correlates with the observed burst effect.    
When a drug or a protein is incorporated into a microsphere, the drug/protein 
molecules may be non-uniformly distributed due to thermodynamic incompatibility 
with the polymer carrier.  Therefore, when drug-loaded microspheres are immersed 
into a solution, the drug that is closer to the surface immediately escapes into the 
bulk solution, resulting in a large, instantaneous release of the drug. Microspheres 
fabricated with S/O/O method exhibited different burst characteristics than CA, with 
higher initial bursts resulting from the cryogenic atomized microspheres. This could 
be attributed to the differences in polymer precipitation and solvent extraction rate 
kinetics for each method.  For CA, for example, the polymer solution is sprayed into 
frozen ethanol with an overlaying layer of liquid nitrogen, which hardens the polymer 





the polymer solutions it will lead to higher bursts. In addition, the beaker is placed in 
a -80 C freezer for three days, over which the methylene chloride is slowly 
extracted into the ethanol.  Due to the slow rate kinetics of the solvent extraction, the 
protein is also extracted to the surface instead of being evenly dispersed, resulting in 
a greater burst effect.  Microspheres made by the S/O/O method may have more 
uniformly distributed protein, as the process is conducted in an ice bath, the 
extraction occurs over 2h, and the solution is poured into the non-solvent rather than 
controlling the flow rate.  Polymer chemistry affected both of these rate kinetics; the 
more hydrophobic the polyanhydride, the less likely these kinetics had an effect on 
the initial burst. 
As previous studies have shown, hydrophobic polymers affect the stability of 
the protein10, and the data reported here is consistent with the literature.  Overall, 
these studies indicate that polymer chemistry affects protein stability.  The acidity of 
the SA and 20:80 CPH:SA degradation products affected both the primary structure 
and recognization of epitopes; only 50:50 CPH:SA fared better at epitope 
conservation at the unaggregated ova state.  This is consistent with previous 
research which has demonstrated that acidic environments are detrimental to 
proteins and that lower pH’s produced inside eroding microspheres as a 
consequence of its degradation products magnify the unfavorable effect41-43. Among 
the degradation products involved here, SA is the more acidic and, therefore, high 
SA-containing polymers are expected to be less gentle to proteins.  Nevertheless, it 
is important to mention that the acidity of the degradation product of SA is not as 





structure and epitope availability of ova was better maintained in microspheres 
fabricated using CPTEG regardless of composition or method.  This is likely due to 
the amphiphilic nature of the polymer and less acidic degradation products, which 
has been shown to be conducive to protein stability20, 44.   
These studies are of particular importance when designing protein delivery 
carriers.  As discussed earlier, the polymer chemistry plays an important role that 
can be beneficial or detrimental for proteins.  A balance between hydrophobic and 
hydrophilic environment (i.e. amphiphilic) is necessary to ensure protein stability, as 
discussed elsewhere44.  Drugs such as insulin have important stability implications; it 
has been proven to undergo structural changes upon release from encapsulated 
PLGA microspheres, due to the acidic nature of the polymer as discussed above45.  
Insulin can also undergo both covalent and noncovalent aggregation when 
introduced to moisture-rich environments46. Uterocalin, an acute phase protein being 
investigated for therapeutic use in wound healing applications, has also been 
theorized to become biologically inactivated upon structural modification47, 48.  Since 
proteins are well structured and ordered, their integrity must not be upset in order for 
it to function as intended; thus, it is imperative that the delivery device must not 
cause any disruptions to the structure.  This is especially crucial in the areas of 
vaccination, where multi-epitope vaccines have been proven more effective than 
their single-epitope counterparts for diseases such as cancer49 and AIDS50. By 
constructing a multi-epitope antigen, antibodies learn to recognize all epitopes, thus 
becoming more effective.  In addition, mutation or evasion of cells is decreased 





structure to avoid such problems51.  However, if the polymer delivery vehicle is not 
capable of preserving the availability of epitopes, the multi-epitope antigen is not 
able to deliver at its full capacity. 
 
6.6 Conclusion 
These studies established the effects of polyanhydride chemistry and 
microsphere fabrication methods on release kinetics and protein stability.  
Cryogenically atomized polyanhydride microspheres containing CPTEG 
demonstrated the best preservation of epitopes and primary structure, thus 
confirming previous work done on amphiphilic environments being the best suited for 
ensuring protein stability44.  
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7.1   Introduction 
According to the World Health Organization (WHO) 2002 global report, 26% of 
the total deaths worldwide were due to infectious or parasitic diseases, nearly 14.8 
million deaths, compared to 3.4 million due to cancers (malignancies) and 5.2 million 
to injury (including war violence))1. In an effort to minimize these casualties, the 
WHO and the United Nations Children’s Fund (UNICEF) together with other partners 
developed a Global Immunization Vision and Strategy (GIVS) two years ago. One of 
the main strategic areas of GIVS is the introduction of new vaccines and 





with the fact that the rapid development of biopharmaceuticals suggests that many 
future vaccines will involve the delivery of peptide or protein subunits that lack a 
suitable carrier, there is an urgent need to search for viable solutions to design 
efficacious vaccines and  improve public health2.  
When designing novel vaccine strategies, it is essential to have a detailed 
understanding of the complex interplay between immune cells of the innate and 
adaptive immune systems. As the first line of defense, cells of the innate immune 
system are involved in the recognition of foreign invaders by means of pathogen-
associated-molecular patterns (PAMPs)3. Not surprisingly, the most crucial step to 
activate the immune system involves the activation of antigen presenting cells 
(APCs). Antigen presenting cells phagocytose pathogens and damaged cells and 
present antigens derived from these sources to helper T cells. Dendritic cells (DCs) 
are the only type of APC present in significant numbers in the T cell areas of lymph 
nodes4. Other experimental evidence shows that DCs are the essential APC for 
naïve T cell initiation and may also be involved in directly presenting MHC class II 
antigen to B cells and natural killer cells4. 
Immature DCs are found under the skin and mucous membranes where they 
sample surroundings for possible pathogens through PAMPs, including toll-like 
receptors (TLRs) and C-type lectins5, 6. After detecting a pathogen, these cells engulf 
it through phagocytosis and pinocytosis and migrate to lymph nodes (LN) where they 
become mature. Once mature, the surface expression of co-stimulatory molecules 
(i.e., CD80, CD86, CD40) and antigen presenting complexes, such as Major 





on the surface of DCs7. Once inside the DC, pathogens are degraded into small 
fragments that are further expressed at the surface in the context of MHC molecules, 
where they can be presented to T cells and B cells3, 8. Exogenous pathogens are 
presented to CD4+ T cells by means of MHC II molecules. Subsets of CD4+ T cells 
include the T helper 1 (Th1) and Th2 cells, which are involved in the cell-mediated 
and humoral immune pathways, respectively. On the other hand, endogenous 
pathogens are presented to CD8+ T cells by means of MHC I complexes on the DC, 
which in turn activate cytotoxic T lymphocytes (CTLs). Consecutively, after the 
specific T cell and B cell become activated, these cells generate a cascade of events 
that lead to attack of the disease. 
In addition of presenting antigens to cells of the adaptive immune system, 
activated DCs are involved in the polarization of the immune response. Besides the 
upregulation of co-stimulatory molecules and antigen presenting complexes, 
activated DCs produce cytokines that communicate with the adaptive immune 
system. Activated DCs may produce the cytokine tumor necrosis factor alpha 
(TNFα), which mediates acute inflammation, and a variety of interleukins, such as IL-
1 , IL-6, IL-10, and IL-12. IL-1 induces secretion of IL-2 from T cells, which 
enhances proliferation of the precursors for antigen specific CTLs, natural killer (NK) 
cells, and helper T cells. Th1 (or cell-mediated) responses are associated with the 
release of interferon gamma (IFNγ), which is an immunoregulatory protein, and 
tumor necrosis factor beta (TNFβ)9. A Th2 (or humoral) response is associated with 





Adjuvants are added to vaccine to enhance the immune response to the antigen 
of interest. An adjuvants can be catagoized by one of three main functions 1) acting 
as a depot for the antigen, slowing antigen clearning from the body as does 
aluminum-based or mineral oil emulsions, 2) directing the antigen to an APC as is 
seen with particulate vaccines like liposomes, and 3) activating the APC directly 
causing a “danger signal” which can be triggered with many bacterial components 
(i.e. LPS, CpG motifs, lipotecholic acid). Currently, the common adjuvants employed 
in human vaccines are aluminum-based, which cause some adverse reactions, need 
multiple doses (i.e., booster shots) to achieve protective immunity, and induce a 
humoral response with little to no demonstrable T cell response11. Biodegradable 
polymers have shown promise in vaccine design as the controlled release provided 
by the degrading polymer can modulate the immune response against a particular 
disease, patient compliance is vastly improved with fewer doses, and both humoral 
and cellular immune responses have been observed12, 13. The controlled release of 
antigens by parenteral administration of biodegradable polymeric microspheres has 
been extensively studied2, 14-17. Microspheres greater than 10 μm can act as depots 
at the site of injection, while smaller microspheres can be efficiently taken up 
(phagocytosed) by APCs2. After the APCs take up the microspheres, they can 
present the antigen to immune cells responsible for eliciting an immune response.  
 Polyanhydrides are a class of biodegradable polymers that have shown 
promise as carriers for controlled drug delivery and have been approved by the FDA 
for use in humans18-30. Biocompatibility studies have shown the safety of these 





Another advantage of these polymers is their degradation by a surface erosion 
mechanism, which leads to a controlled release profile with predictable degradation 
profiles that can vary from days to months depending on the polymer chemistry. The 
polyanhydride chemistries used in the present study are based on the aliphatic 
sebacic acid (SA), the aromatic 1,6-bis(p-carboxyphenoxy)hexane (CPH), and the 




















The biocompatibility of CPH:SA and CPTEG:CPH copolymer libraries has 
been recently studied using  high throughput cell-based screening methods33. 
CPH:SA and CPTEG:CPH copolymer libraries were incubated with standard 
myeloma, epithelial, and macrophage cell lines and were found to have no 
pronounced cytotoxic effect for any polymer composition at concentrations of 2.8 
























  Previous work by Kipper et al. has shown that polyanhydrides based on 
CPH:SA chemistries are suitable vaccine carriers with enhanced adjuvanticity and 
possess immunomodulatory (i.e., Th1 vs. Th2) capabilities depending on polymer 
chemistry13. These studies showed that a single dose of CPH:SA microspheres was 
able to enhance and modulate the induced immune response, depending on the 
composition of the polymer. While TT loaded 20:80 CPH:SA microspheres indicated 
a Th2 dominant response in C3H/HeOuJ mice, the 50:50 CPH:SA formulation 
produced a balanced Th1/Th2 response. Strong Th2 responses have been 
implicated in development of allergies and hypersensitivity reactions34. The 
preferential reduction of the Th2 immune response is a unique and valuable 
characteristic of this delivery vehicle that makes it a promising candidate for 
vaccines. Although no in vivo experiments have been published with the 
CPTEG:CPH system, this system has shown excellent characteristics for protein 
stabilization and release35, 36. Preliminary in vivo studies in our laboratories have 
shown polymer-chemistry mediated immunomodulation in this system. 
The purpose of the current study is to obtain a mechanistic understanding of the 
adjuvanticity and immunomodulatory capabilities of CPH:SA and CPTEG:CPH 
microspheres and to determine if the polymers act as adjuvants. Since the most 
potent APCs involved in the immune response are DCs, the in vitro evaluation of 
murine bone marrow derived DC (BMDC) activation after incubation with 
polyanhydride microspheres was assessed. The surface expression of the antigen 
presenting complexes MHC I and MHCII, the co-stimulatory molecules CD86 and 





CD209, which is related to DC migration and the initial DC-T cell binding, was 
evaluated37. Cytokine secretion from these activated DC was evaluated as a 
measure of Th1 or Th2 polarization of an immune response. Two different 
polyanhydride polymer chemistries (CPH:SA and CPTEG:CPH) both with different 
copolymer compositions were analyzed giving rise to the central hypothesis that 
surface chemistry plays a major role for DC activation.  
 
7.2 Materials and Methods 
7.2.1 Materials 
The chemicals needed for the synthesis of CPH and CPTEG monomers include: 
4-p-hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, and tri-
ethylene glycol that were purchased from Sigma Aldrich (St Louis, MO); 4-p-
fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); potassium 
carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, and acetonitrile 
were purchased from Fisher Scientific (Fairlawn, NJ). Acetic anhydride, methylene 
chloride, and petroleum ether, were purchased from Fisher Scientific (Fairlawn, NJ). 
Sebacic acid (99%), β-mercaptoethanol, E. coli lipopolysaccharide (LPS) and rat 
immunoglobulin (IgG) were purchased from Sigma Aldrich (St. Louis, MO). The 
materials needed for the DC cell culture media include: RPMI 1640, 7.5% sodium 
bicarbonate, Penicillin-Streptomycin Solution (10,000 UI Penicillin and 10,000 ug/ml 
Streptomycin), and L-glutamine 200mM Solution, purchased from Mediatech 
(Herndon, VA); granulocyte macrophage colony stimulating factor (GM-CSF), 





purchased from Valley Biomedical (Winchester, VA). For flow cytometry 
experiments, the materials needed were: unlabeled mouse IgG, purchased from 
Pharmingen, Becton Dickinson (Franklin Lakes, NJ); unlabeled CD36/16 FcγR, 
purchased from Southern Biotech (Birmingham, AL); Purified Hamster IgG Isotype 
Control clone eBio299Arm, Alexa Fluor® 700 anti-mouse CD11c (clone N418), FITC 
conjugated anti mouse/rat MHC Class II (I-E ) (clone 14-4-4S), FITC conjugated 
anti mouse MHC class II (I-A/I-E) (clone M5/114.15.2), PE conjugated anti-mouse 
MHC Class I (H-2Kd/H-2Dd)(clone 34-1-2S), PE/Cy7 anti-mouse CD86 (clone GL-1), 
allophycocyanin (APC) anti-mouse CD40 (clone 1C10), PE conjugated anti-mouse 
CIRE (DC-SIGN CD209) (clone 5H10); and corresponding isotypes: Alexa Fluor® 
700 conjugated armenian hamster IgG (clone eBio299Arm), FITC  conjugated 
mouse IgG2a  (clone eBM2a), PE/Cy7 conjugated rat IgG2b (clone KLH/G2b-1-2),  
APC rat IgG2a  (clone eBR2a), and PE-conjugated rat IgG2a (clone eBR2a) were 
all purchased from e-Bioscience (San Diego, CA). 
 
7.2.2 Polymer Synthesis and Characterization 
CPH:SA and CPTEG:CPH copolymers were synthesized by melt 
polycondensation as described previously38. The purity and degree of polymerization 
of the polymers was analyzed using 1H NMR spectra obtained from a Varian VXR-








7.2.3 Microsphere Fabrication 
Prior to fabricating microspheres, all the glassware and equipment was washed 
with 70% ethanol to prevent microbial contamination. The procedure used to 
fabricate microspheres was modified from previously reported studies39, 40. Briefly, 
polymer dissolved in methylene chloride was pumped with a syringe pump through 
an 8700-1200 MS ultrasonic atomizing nozzle (Sono Tek Corporation, Milton, NY) 
into 200 mL of frozen ethanol overlaid with approximately 100 mL of liquid nitrogen. 
This procedure was performed at 4ºC for 50:50 CPH:SA and CPTEG:CPH 
microspheres in order to maintain the temperature below the glass transition 
temperature of the polymers during microsphere preparation. After atomization, the 
hardened microspheres were stored at -80°C for three days to allow the methylene 
chloride to be extracted into the ethanol. The microspheres were then collected by 
filtration and dried under vacuum overnight. 
 The microsphere morphology was characterized by scanning electron 
microscopy (SEM) after being covered with gold. The particle size distribution was 
obtained from SEM images (150-250x) using a soft imaging system software 
(analySIS®, Soft Imaging System Corp, Lakewood, CO). An average of 800 particles 
per image was analyzed. The parameters used during fabrication process are shown 









Table 7.1: Parameters used for microsphere fabrication (Lopac et. al)  





7 mL 3 mL/min 1.5 W 
10:90 CPTEG:CPH 4 mL 1.5 mL/min 2.5 W 
50:50 CPH:SA 3 mL 1.5 mL/min 2.5 W 
SA 
20:80 CPH:SA 




7.2.4 Endotoxin Assay 
To ensure that the endotoxin levels of polyanhydride microspheres were under 
the limit of contamination, a Limulus Amebocyte Lysate (LAL) QCL-1000 (Cambrex, 
Walkersville, MD) test was used to quantify the bacterial endotoxin levels after 
microsphere fabrication. Solutions of CPTEG:CPH and CPH:SA microspheres (5 
mg/mL) were prepared in endotoxin-free sterile water and placed overnight in a 
rotator incubated at 37ºC. After centrifuging microspheres solution, the LAL test was 
performed according to manufacturer procedure. 
 
7.2.5 Culture and Stimulation of DCs 
Bone marrow derived dendritic cells (BMDCs) were isolated from the femurs and 
tibia of C3H/HeOuJ mice (ISU Laboratory Animal Resource Facility, Ames, IA) or 
C56BL/6 (purchased from Harlan Sprague Dawley, Inc, Indianapolis, IN) with a 
previously developed method41. Briefly, after euthanizing mice, the tibia and femur 
were removed, muscle and other tissue removed, and bone cavities were washed 
three times with 1mL of culture media. After centrifuging at 200 x g for 10 minutes, 





with GM-CSF (10 ng/mL), 1% L-glutamine, 1% penicillin-streptomycin solution, 1% 
HEPES, 10% heat inactivated fetal bovine serum (FBS). Then cells were placed in 
20 x 100 mm Petri dishes (4 x 105 cells/mL) and incubated at 37 ºC under 5% CO2 
atmosphere. On day 3 and 6, 10ml of additional culture media was added. On day 7, 
DCs were removed from plates and, after suspending in fresh media, these were 
transferred to 24-well plates (2.5 x 106 cells/well). On day 9, DCs were incubated 
with the different stimulation treatments. Non-stimulated (NS) DCs and LPS (200 
ng/ml) treated DCs were used as negative and positive controls, respectively. After 
suspending polyanhydride microspheres, these were incubated at concentrations of 
0.06, 0.125, or 0.25 mg/mL. These concentrations correlate to approximate 
microsphere: DC ratios of 1:12, 1:6, and 1:3, respectively. The DC were incubated in 
the presence of microspheres or stimulants for 48h (37°C, 5% CO2). Cell viability 
and morphology was monitored visually with an inverted microscope.  
 
7.2.6 DC Activation 
7.2.6.1 Cell Surface Markers 
The surface expression of DC markers, co-stimulatory molecules, and antigen 
presenting complexes was analyzed with flow cytometry. After 48h of incubation with 
stimulation treatments, DCs were harvested and placed on polystyrene tubes (BD 
FALCONTM, Franklin Lakes, NJ). After centrifuging (1,500 x g, 7min), DCs were 
resuspended in FACS Buffer (phosphate buffered saline pH 7.2 with 1% FCS and 
0.5% Sodium Azide) based Fc blocking solution, containing 0.5 ug/ml purified anti-





(generated in-house). After blocking DCs for 1h on ice, cells were stained for flow 
cytometry with CD11c, MHC I, MHCII, CD86, CD40, and DC-SIGN CD209 
antibodies. Respective isotype, single color, and unstained controls were included. 
Propidium iodide (PI) was used for live/death cell gating. The samples were run on a 
Becton-Dickinson FACSCanto flow cytometer (San Jose, CA) and analyzed with 
FlowJo (TreeStar Inc, Ashland, OR).  
 
7.2.6.2 Cytokine Release 
After incubating the DCs with the respective stimulation treatments for 48 h, 
200 μL of cell-free supernatants were collected and stored at -20°C until ready for 
analysis. Cytokines such as TNF-α, which mediate acute inflammation, and 
interleukins such as IL-4, IL-6, IL-10, and IL-12(p40) concentration was assayed 
using Luminex® Multiplex assay (The FlowMetric System, Luminex, Austin, TX) and 
MasterPlex QT Quantification Software v2.0 (MiraiBio, Alameda CA) . Cell-free 
supernatants were harvested after 72 h of culture and then analyzed for the 
concentration of TNFa, interferon c (IFNc), IL6, IL4, IL10 and IL12 using a 
multiplexed flow cytometric assay (The FlowMetric System,Luminex, Austin, Texas, 
USA). Samples were analyzed in duplicate for three separate experiments. 
 
7.2.7 Statistical Analysis 
A student-t test (α=0.05) was performed with the statistical analysis software 
JMP® 6 (Cary, NC). Flow cytometry data of the BMDCs incubated with the different 





7.2.8 Principal Component Analysis (PCA) 
PCA is a dimension reduction technique, whose goal in this study is to uncover 
latent features of the data that explain the relationships between polymer chemistry 
and cell marker expression. By reducing N original variables to a small number (K) 
of the principal components, PCA accomplishes data reduction and facilitates 
interpretation. The K principal components are a linear combination of the original N 
variables, and make up new axes that represent the directions with maximum 
variability. An analysis of principal components often reveals relationships that were 
not previously suspected and thereby allows interpretations that would not ordinarily 



















7.3.1 Microsphere Fabrication 
After microsphere fabrication by cryogenic atomization, the surface morphology 
was analyzed with SEM (Fig. 7.2). The images show that poly(CPTEG) and poly(SA) 
microspheres had a smoother surface than the other compositions which is 
attributed to processing conditions and differences in polymer properties (e.g., Tg). 
However, when the size distribution was analyzed from SEM images, the majority of 
the particles of all the polyanhydride chemistries used in this study were under 10μm 
(Fig 7.3). Thus, most of the microspheres were in a size range that is readily 





















Fig. 7.2. SEM Images of blank microspheres: (a) CPTEG, (b) 50:50 CPTEG:CPH, (c) 20:80 CPTEG:CPH, (d) 
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Fig 7.3. Size Distribution of polyanhydride microspheres. Error bars represent standard deviation of two 




7.3.2 Endotoxin Assay 
To ensure that the subsequent results of DC stimulation with CPTEG:CPH and 
CPH:SA microspheres are due to the polymers themselves and not a result of their 
microbial contamination all microsphere formulations were analyzed for endotoxin 
content using a limulus amebocyte lysate assay. All the polyanhydride microspheres 
exhibited an endotoxin content of less than 0.1 EU/mL, which is five times lower than 
the maximum level permitted by the Food and Drug Administration (FDA) for new 
drugs tested by the LAL test44.  
 
7.3.3 Culture and Stimulation of DCs 
During the cell culture of BMDCs, cell viability and morphology was visually 





most of the non-adherent cells, characteristic dendrites of DCs. On day 11, after the 
48h stimulation treatments, polyanhydride microspheres appeared to be readily 
phagocytosed by the DCs (Fig.7.4). Further assessment is needed to show that 
polyanhydride microspheres are in fact contained in intracellular compartments 
(manuscript in preparation). 
 
 
Fig.7.4. Inverted microscope images of NS BMDCs (left) and BMDCs incubated with 20:80 CPTEG:CPH 
microspheres (right). White arrows indicate microspheres that appear to be phagocytosed by the BMDCs. 
 
 
7.3.4 DC Activation 
7.3.4.1 Cell Surface Markers 
The surface expression of co-stimulatory molecules was analyzed after gating 
live (PI negative) cell subpopulations that were CD11c+. The CD11c+ BMDCs in the 
different experiments represented more than 80% of live cells (Fig.7.5). The flow 
cytometry histograms of BMDCs expressing MHCII show that all the polyanhydride 
chemistries enhanced the expression of MHCII in comparison with the untreated 
group (Fig. 7.6). More than 70% of the BMDCs incubated with the different 





ratio) expressed MHCII in contrast to the NS cells, where only 57% were MHCII+. A 
notable observation from these histograms is that LPS, and most polyanhydrides 
chemistries, especially the more hydrophobic ones, had two characteristics 
subpopulations: a broader and taller peak at a dimmer fluorescence and a smaller 
peak at brighter intensities. This indicates that the cell population was not completely 
homogenous and there were different levels of maturation. The surface expression 
of MHCII was also enhanced in the BMDCs incubated with the other concentrations 
(0.06 and 0.25 mg/mL) in a dose-dependent manner (data not shown). 
 
Fig. 7.5. Representative flow cytometry histogram of BMDCs stained with anti-CD11c. Positive population was 
gated with respect isotype control.  
 
Although antigen presentation by MHCI usually involves endogenous 
pathogens derived within the cell, processing of exogenous antigens, especially the 
particulate ones, for MHCI can occur by MHCI cross-presentation45, 46.    The 
expression of MHCI on DCs was also analyzed after being stimulated with 
polyanhydride microspheres and the microspheres of the more amphiphilic polymers 
(i.e. high CPTEG content), enhanced more significantly the expression of MHCI (Fig. 
7.7). It can be seen from the histograms shown that 50:50 CPTEG:CPH 
microspheres enhanced more markedly the expression of MHCI when compared 





the more hydrophobic CPH, it suggests that the increased stimulation of 50:50 
CPTEG:CPH was a consequence of the more amphiphilic CPTEG. Nevertheless, no 
matter the polyanhydride composition, all microspheres enhanced MHCI expression 
at different stimulation levels, suggesting that there is a role of chemistry for DC 
activation (data not shown). All the BMDCs incubated with CPTEG:CPH 
microspheres enhanced the surface expression of MHCI and the stimulation level 
was directly proportional to the CPTEG content. The CPH:SA microspheres did 
enhance MHCI expression as well. The general trend for MHCI surface expression 
on BMDCs after being incubated with polyanhydride microspheres is shown in 
Figure 7.8.  
                                
Fig. 7.6. MHCII Histograms of BMDCs incubated with different stimulation treatments: (a) NS, (b) LPS, (c) 
CPTEG, (d) 50:50 CPTEG:CPH, (e) 20:80 CPTEG:CPH, (f) 10:90 CPTEG:CPH, (g) SA, (h) 20:80 CPH:SA, and 
(i) 50:50 CPH:SA.  DCs expressing MHCII (open histograms), were gated with respect to the background 
staining with isotype controls (solid black histograms). Concentration of polyanhydride microspheres was 0.125 
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Fig. 7.7 MHCI histograms of NS BMDCs (solid black), 50:50 CPH:SA-treated BMDCs (tinted gray), and 50:50 
CPTEG:CPH-treated BMDCs (dashed line). Concentration of polyanhydride microspheres was 0.125 mg/mL 







Fig. 7.8. Stimulation trend of polyanhydride microspheres for MHCI surface expression 
 
 The surface expression of the co-stimulatory molecule CD86 was also 
evaluated and clear trends with respect to polymer chemistry were observed again 
(Fig 7.9). For the CPTEG:CPH system, stimulation was enhanced in the cells 
incubated with high CPTEG-containing copolymer microspheres, indicative that the 
amphiphilic environment was more favorable for the activation of BMDCs. Poly 
CPTEG, 50:50 and 20:80 CPTEG:CPH compositions enhanced the CD86 
expression at a level similar to that of LPS-treated cells as indicated by the statistical 
analysis. The CPH:SA system enhanced the expression of CD86 at a significantly 
CPTEG > 50:50 CPTEG:CPH > 20:80 CPTEG:CPH > 10:90 CPTEG:CPH > 
 





lower level than the CPTEG:CPH system. However, the trend with the CPH:SA 
system indicated that an increase in hydrophobicity (i.e. CPH content) was more 
favorable, and poly(SA) microspheres down regulated the CD86 expression. A 
possible explanation for the poly(SA) results may be that the degradation of the high 
SA content polymers produce acidic environments47 that could be detrimental to the 
surrounding cells during the 48 h incubation period.  
The magnitude of the fold increase in the surface expression of CD40 of 
stimulated BMDCs was much higher than that with the other surface molecules 
analyzed (Fig. 7.10). The LPS-treated BMDCs enhanced the expression of CD40 
~20 fold compared to the expression of the NS group. The stimulation trends in both 
CPTEG:CPH and CPH:SA systems indicated that a decrease in hydrophobicity 
increases the expression of this co-stimulatory molecule. The chemistries that 








Fig. 7.9. CD86 surface expression of BMDCs after stimulation with CPTEG:CPH microspheres (0.25 mg/mL, 
microsphere:DC 1:3). The data is presented as fold increase over NS BMDCs. Error bars represent standard 
error from 3-4 separate experiments.  A student-t test was used for statistical analysis (P-value<0.05). (* = 
statistically different from NS; +=statistically different from LPS)    
 
 
Fig. 7.10. CD40 surface expression of BMDCs after stimulation with CPTEG:CPH microspheres (0.25 mg/mL, 
microsphere:DC 1:3). The data is presented as fold increase over NS BMDCs. Error bars represent standard 
error from 3-4 separate experiments.  A student-t test was used for statistical analysis (P-value<0.05). (* = 






The expression of DC-SIGN CD209 was also enhanced with all the 
polyanhydride chemistries tested (Fig. 7.11). As shown with the other markers 
studied, the amphiphilic chemistries poly(CPTEG) and 50:50 CPTEG:CPH 
enhanced the expression more significantly and, in the particular case of DC-SIGN, 
it was significantly increased when compared to both NS and LPS-treated cells. As 
has been shown in the past, LPS did not up regulate the expression of DC-SIGN37, 
48. In the case of the CPH:SA system, the expression of this surface molecule was 
significantly enhanced in the 20:80 CPH:SA-treated BMDCs. The surface expression 
of DC-SIGN is of particular importance, as even though it has been demonstrated 
that viral pathogens target DC-SIGN for transmission, non-viral pathogens modulate 
DC maturation through DC-SIGN5, 49.  
 
Fig. 7.11. DC-SIGN CD209 surface expression of BMDCs after stimulation with CPTEG:CPH microspheres (0.25 
mg/mL, microsphere:DC 1:3). The data is presented as fold increase over NS BMDCs. Error bars represent 
standard error from 3-4 separate experiments.  A student-t test was used for statistical analysis (P-value<0.05). 






The surface expression of CD86, CD40 and DC-SIGN CD209 were also 
enhanced in the BMDCs incubated with the other concentrations of polyanhydride 
microspheres (0.06 and 0.125 mg/mL) in a dose-dependent manner (data not 
shown). 
7.3.4.2 Cytokine Release 
It is well known that activated DCs secrete cytokines that act as messengers to 
the adaptive immune cells. The measurement of the cytokines secreted by 
stimulated BMDCs support the flow cytometry findings that polyanhydride 
microspheres are able to activate BMDCs efficiently (Fig 7.12). The specific cytokine 
profile will determine what immune response is elicited and if the polymer by itself 
acts as a potential adjuvant to enhance this response. The cytokines that were 
secreted by the cells incubated with the microspheres were TNFα, IL-6, and IL-12. 
The cytokines IL-10 and IL-4 were also measured but their levels were below 
detection with all the polyanhydride chemistries. The secretion of IL-12 and the 
absence of IL-4 in the cell cultures suggest that polyanhydride chemistries induce a 






































































In this study, cell marker expressions of CD40, DC-SIGN CD209, and CD86 
are studied when the BMDCs are incubated with different polymer chemistries. PCA 
is applied on standardized data and the original data is projected on to a “biplot” 
(Fig. 7.13). A biplot is a graphical representation of information of both principal 
components and variables. The first principal component (PC1) explains 62.16% of 
data variance, and the second principal component (PC2) explains 33.51% of data 
variance. PC1 and PC2 together account for 95.67% of the data variance, which 
means PC1 and PC2 could replace the original three variables (CD86, CD40 and 
CD209) with little loss of information.  
We observed that both the CPH:SA and the CPTEG:CPH systems activate 
DCs. However, the two polymer systems are different from each other in terms of 
the magnitude of the effect on DC activation. From Fig. 7.13 we can see data points 
representing cell marker expression when the cells are incubated with polymer (blue 
and yellow circles) locate clearly differently from the NS data points (red circles). The 
analysis indicates that as more SA or CPTEG is added to the copolymer, the data 
move further away from NS, which means more DCs are activated by reducing the 
hydrophobicity of the polymer (i.e., polymers with higher composition of SA or 
CPTEG). Additionally, the analysis indicates that the addition of CPTEG has a 
stronger influence on DC activation than the addition of SA. DCs treated with the 
CPTEG:CPH system (yellow points) locate further away from NS than DCs treated 
with CPH:SA system (blue points). The arrows in Fig.7.13 indicate the direction of 





away from NS, which means DCs are more activated. The data suggests that 
50:50CPTEG:CPH appears to more strongly influence the cell marker expression 
than poly(CPTEG). This suggests that there may be an optimal amphiphilic 
chemistry that may maximize DC activation. 
 
 
Fig.7.13. The biplot of PCA on adjuvant cell marker expression data.  Each point corresponds to the projection of 
an experiment data point on PC1 and PC2. Data of SA system are colored blue, and CPTEG system yellow. 
Circles are used to show the distribution of data under the same treatment. For convenience, only the 
compositions of SA and CPTEG are used as circle labels. PC1 and PC2 together explain 95.67% data variance. 
Increasing amount of SA or CPTEG to CPH increases dissimilarity from untreated cell. CPTEG system has a 















7.4 Discussion  
There is an immediate need for novel adjuvants to improve vaccine efficacy 
and at the same time to redirect the immune response against a particular disease. 
As has been explained before, the design for new adjuvants involves an in-depth 
understanding of the complex function of the communication between the innate and 
adaptive immune systems. These studies demonstrated that polyanhydride 
microspheres are promising candidates as vaccine adjuvants. One important 
attribute of these biodegradable polymers is that even small amounts of 
microspheres were capable of enhancing the maturation of murine BMDCs at 
significant levels. The ratios of polyanhydride microspheres to DCs used in these 
studies were significantly lower compared to previous studies with polyester 
microspheres50-52. In these studies50, the polyester microspheres were used at ratios 
that were more than 50 times the ratio used with polyanhydrides in the current study, 
and in other studies, immune stimulators were added52. In spite of these differences, 
the extent of DC stimulation by the polyanhydride microspheres is superior and they 
also promote the expression of DC-SIGN CD 209, which suggests that 
polyanhydride microspheres also promote DC maturation and migration to the LN. 
The low dosage of the polyanhydride microspheres is a very important characteristic 
to take into consideration when designing vaccines, as more potent immune 
responses with minimum amount of adjuvant carriers are desirable. 
Overall, the results indicate that an increase in polymer hydrophilicity 
enhanced the surface expression of MHCII and MHC I complexes and the co-





chemistry plays a major role in the activation of DCs. It is very interesting to note that 
all the surface molecules were enhanced at different levels, which indicates that 
different polyanhydride chemistries might activate DCs by different pathways. 
Moreover, it has been recently published that polyanhydride chemistry also affects 
protein release and stability36. In these studies, the amphiphilic, high CPTEG-
containing microspheres enhanced protein stability, which is in accordance with the 
fact that carriers containing both hydrophobic and hydrophilic entities may provide a 
gentler environment for proteins53, 54. Taking together with the results of activation of 
the BMDCs, high CPTEG-containing polyanhydrides are very promising candidates 
for the delivery of vaccines. However, both the CPTEG:CPH and CPH:SA 
chemistries significantly improved the activation of BMDCs (with low doses and 
especially in comparison with polyesters) and since it is known that a small number 
of DCs are sufficient to induce strong immune responses48, all the polyanhydride 
chemistries studied  here are potential adjuvants. This activation caused by these 
biodegradable polymers is in accordance with the “danger signal” model described 
by Matzinger55. In this model a hydrophobic molecule that is exposed to innate cells 
is recognized as a “danger signal” and the cells become activated. Since all the 
polyanhydrides included in these studies are relatively hydrophobic, especially when 
compared to sugars and lipids, it is more likely that DCs are activated due the 
hydrophobicity of the polymers and the extent of activation is then further influenced 
by the individual chemistries. We suggest that an optimal vaccine formulation might 
consist of a cocktail of microspheres of different compositions, with different release 





time enhances the activation and maturation of BMDCs and induces a preferential 
Th1 immune response. 
 
Implications for Vaccine Design 
As the mere activation of BMDCs is not an absolute indicator of an effective 
immune response, the further evaluation of the activation of effector cells is required. 
In this regard, a model describing the signals required for DCs to activate T cells has 
been proposed and based on this model, it appears that BMDC activation by 
polyanhydride microspheres encompasses the major signals for T cell activation 
(Fig. 7.14)48, 56. The first signal starts when a DC recognizes a pathogen through 
PAMP receptors such as toll like receptors (TLR) and C-type lectins. Subsequently, 
these pathogens are degraded within different intracellular compartments after being 
phagocytosed and different pathways lead to DC activation. This signal mainly 
involves the antigen-specific stimulation provided by MHC-antigen complexes on the 
DC surface, which are expressed at higher levels after its maturation. Even though 
this signal is essential for a specific immune response, it will not induce a strong T 
cell activation after migrating to the LN without the help of the second signal that 
involves other accessory molecules expressed by the DCs. The emergence of the 
B7 co-stimulatory molecules, such as CD86, in DCs after maturation is crucial to 
activate the clonal expansion of naïve T cells, thus directing the magnitude of the 
resulting immune response. It has been also proposed that the C-type lectin DC-
SIGN has an adhesion role that is essential for the initial DC-T cell interaction in the 





maintenance and polarization of the T helper cells that will lead to the selection of 
the most appropriate effector mechanism. Of particular importance is the expression 
of the co-stimulatory molecule CD40, as it induces the maintenance of high levels of 
MHC class II antigens and up regulates the expression of B7 molecules after its 
binding to the CD40 ligand on T cells. The antigen presenting capacity is enhanced, 
the response of the T cells is sustained, and the DC survival is prolonged. In 
addition, the DCs are capable of inducing the polarization of the immune response 
towards Th1 (cell-mediated) versus Th2 (humoral) pathways as indicated by the 
cytokine profiles of the activated DCs.  
In summary, the polyanhydride microspheres used in this study show that 
these biodegradable polymers have promising characteristics for the development of 
vaccine adjuvants. The three major functions of an adjuvant, which are covered by 
these polymers, include: (1) providing a “depot” or reservoir for the antigen for a slow 
release; (2) enhancing antigen phagocytosis by APCs; and (3) modulating and 
enhancing the immune response against the particular antigen alone. All three 
characteristics are exhibited by polyanhydride microspheres with the added 
advantage of enhancing protein/antigen stability. Further studies in our laboratories 
involve the evaluation of antigen presentation by DCs that have been stimulated with 










Fig. 7.14 Immune activation of DCs. Signal 1: Pathogens can interact with different PAMPs present in the 
DCs. Pathogens that interact with TLRs are processed by intracellular signaling that lead to DC maturation and 
induction of inflammatory cytokines. Other receptors, such as C-type lectins recognize specific carbohydrate 
structures on the pathogens that are subsequently internalized and degraded in the lysosomes to enhance 
antigen processing and presentation. After DC becomes mature, it migrates to the lymph nodes where the DC-
SIGN expression optimizes the initial T cell binding.  Signal 2: The antigen presentation by MHC-peptide 
complexes and the expression of the co-stimulatory molecules (CD86, CD40) seals the immunologic synapse 
needed for T cell activation. Signal 3: The sustained interactions of DC with T cells enhance the antigen 
presenting capacity of DCs by maintenance of MHC complexes and upregulation of co-stimulatory molecules. 













Despite the advantages of enhancing and modulating immunogenicity using 
polymeric microspheres as vaccine carriers, no vaccines based on polymeric 
carriers have been approved for human use to date. The challenge of overcoming 
antigen instability, antigen immunogenicity, and the ability to activate APCs, limits 
the range of materials that can be used for this purpose. The ability of polyanhydride 
microspheres to activate murine BMDCs in conjunction with their biocompatibility 
and gentle environment demonstrates that these are promising candidates for the 
development of vaccines. In addition, the studies described here clearly point out the 
role of polymer chemistry in APC activation in vitro and lay the foundation for further 
studies to probe the molecular and cellular mechanisms responsible for this effect. 
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EVALUATION OF NON-SPECIFIC IMMUNITY OF POLYANHYDRIDE 





 According to the National Cancer Institute, pancreatic cancer is among the 
top five leading causes of cancer-related deaths in the United States. Essentially all 
human pancreatic adenocarcinomas are resistant to conventional therapy protocols. 
Thus, there is an urgent need to search for effective treatments for this lethal 
disease1, and the promise of cancer vaccines is leading to the use of 
immunotherapy as a viable alternative2. As discussed in Chapter 2, extensive 
research on tumor markers have led to the discovery of the glycoproteins, Mucin-1 
and Mucin-4, as potential pancreatic cancer targets for immunotherapy3-13. Humoral 
and cellular immune responses to Mucin-1 and Mucin-4 have been observed in 
cancer patients with poor prognosis5, 14. Although there is an aberrant expression of 
these surface molecules on pancreatic tumors, these are not strongly immunogenic. 
Thus, an important goal is to design a novel vaccine delivery system that will lead to 
strong anti-tumor responses against these malignant cells. The potential vaccine will 
be comprised of two essential components that will function in conjunction: the 
antigen that is over expressed in the tumor (i.e., Mucin-1 or Mucin-4) and the 
adjuvant in charge of protecting, stabilizing and delivering this antigen efficiently and 





In order to understand the potential anti-tumor effects that an adjuvant may 
have, the evaluation of the immunity of the adjuvant by itself needs to be well 
understood. This chapter evaluates non-specific anti-tumor immunity conferred by 
the novel biodegradable amphiphilic system based on the anhydride monomers 1,6-
bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG). As the results of the previous chapters have shown, 
microspheres that were fabricated from CPTEG-containing polymers showed 
excellent characteristics for the design of vaccine adjuvants. The ability of 
CPTEG:CPH microspheres to stabilize and deliver functional proteins in a controlled 
and sustained  manner has been demonstrated in Chapters 5 and 6. Furthermore, 
we have shown that CPTEG:CPH microspheres enhance the expression of antigen 
presenting complexes and T cell co-stimulatory molecules on dendritic cells (DCs), 
indicating that this novel polyanhydride system has the capability of enhancing the 
maturation and activation of DCs, which is the crucial step for immune activation 
(Chapter 7). Although the importance of effective DC activation is highlighted by 
studies that show few DCs infiltrating tumors and this likely accounts for some of the 
ability of tumors to escape immune surveillance15, the activation of antitumor effector 
cells needs to be assessed. As explained in Chapter 2, DCs presenting tumor 
antigens are capable of activating tumor specific CD8+ T cells, which in turn kill 
tumor cells directly by activating cytotoxic T lymphocytes (CTLs). The ability of 
CPTEG:CPH blank microspheres to non-specifically enhance antitumor effector cells 





an experimental approach towards the design of the pancreatic cancer vaccine is 
described.  
 
8.2 Experimental Methods 
8.2.1 Fabrication of CPTEG:CPH Microspheres 
As explained in Chapter 4, CPTEG:CPH copolymers were synthesized at 
various monomers ratios by melt polycondensation16. Endotoxin-free microspheres 
were fabricated by the non-aqueous method of cryogenic atomization and 
characterized with scanning electron microscopy (SEM) as previously described 
(Chapter 7)17. 
 
8.2.2 In Vitro Activation of Effector Cells: CTL Assay 
Human peripheral blood mononuclear cells (PBMCs) that express human 
leukocyte antigen genes of MHCI (i.e., HLA-A2) were isolated by a Ficoll-Hypaque 
method. Stimulator (γ-irradiated lymphocytes) and responder lymphocytes were 
incubated in 1:2 ratio with CPTEG:CPH microspheres (0.25 mg/mL). Lymphocytes 
were fed with media supplemented with rh-IL2 every 3 days. Cells-free supernatants 
were sampled every 3 days and stored at -80°C for further cytokine analysis. After 
two weeks, 2 x 105 lymphocytes (Effector, E) were incubated for 4 h with 104 Panc-1 
(Target, Tr) on triplicate wells (96-well V-bottom wells) and the cytotoxicity of T cell 
lymphocytes (CTL) was evaluated with the non-radioactive cytotoxicity assay 





lactate dehydrogenase (LDH) that is released upon cell lysis. Based on the 
manufacturer’s protocol, the % cytotoxicity was calculated as: 
100-  %
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8.2.3 In Vivo Activation of Effector Cells 
The non-specific activation of CD8 T cells was evaluated after injecting 20:80 
and 50:50 CPTEG:CPH blank microspheres (0.5 mg) into female C57BL/6 mice 
(N=5) by subcutaneous route. The control group was injected with phosphate 
buffered saline (PBS). After two weeks, the spleen (SP), the auxiliary, brachial and 
inguinal lymph nodes (LNs) were removed from each animal after being euthanized 
with carbon dioxide. LN (lymphocytes) and SP (spleenocytes) single cell 
suspensions for each animal were prepared with a hand held tissue grinder. After 
removing remaining tissue and cellular debris with a cell strainer and washing by 
centrifuging, the cells were counted with a hemocytometer. Trypan blue was added 
to count viable cells. For the SP suspensions, the red blood cells were lysed prior to 
counting. Cells were kept on ice until ready for use in the 51Cr release and flow 
cytometry assays described below. 
 
8.2.3.1 51Cr Release Assay 
A 51Cr release assay was performed with the murine pancreatic cancer cell 
line Panc02 as the target cells (Tr) and LN and SP suspensions of each individual 
animal as the effector (E) cells. Briefly, the Tr cells were labeled with Na251CrO4 (300 





media and counted. The assay was then performed in 96-well V-bottom plates. The 
E:Tr ratio used were 50:1, 25:1, and 12.5:1 on triplicate wells. The number of Tr cells 
was maintained constant in each well (2 x 103 cells/well). Triplicate wells for 
maximum (detergent solution: 1%NP40/%10 acetic acid) and spontaneous (medium 
only) Tr release were included. After incubating the plate for 5 h (37°C, 5%CO2), 100 
μL of the supernatants were collected and the radioactivity was measured with a 
1480 Wallac® Wizard Gamma Counter (Perkin-Elmer Life and Analytical Sciences, 
Wellesley, MA). The % cytotoxicity was then calculated as: 
 
100 %
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8.2.3.2 Flow Cytometry 
For the flow cytometric analysis, 0.5 x 106 cells of the LN and SP suspensions 
were placed on polystyrene round bottom tubes (BD Falcon , Franklin Lakes, NJ). 
The protocol of immunofluorescent staining of cell suspensions of mouse lymphoid 
tissue from eBioscience (San Diego, CA) was followed with some modifications. All 
the staining antibodies were also obtained from e-Bioscience and recommended 
concentrations were used. After centrifuging the already counted LN and SP cells, 
these were suspended in 100 μL of blocking buffer (0.5 μg of anti-CD16/CD32 in 
FACS buffer) and incubated at 4°C for 30 min. The primary antibodies, fluorescein 
isothiocyanate (FITC) anti-mouse CD8a (Ly-2), Phycoerythrin (PE) anti-





suspended at the respective concentrations and 50 μL of the staining solution was 
added to each tube and incubated for 30 min at 4°C protected from light. Control 
tubes included single color, isotype controls, and unstained cells. After the staining 
incubation period, the cells were washed three times (FACS buffer, 1% fetal bovine 
serum (FBS)) and fixed in 2% parafomaldehyde solution until the next day. Samples 
were run on a Becton Dickinson FACSAria (Franklin Lakes, NJ) cytometer. Data 
analysis was performed after gating viable cells that expressed CD8. The CD62L vs. 
CD44 dot plots were used to analyze the CD8 cells that were naïve, in transition 
from naïve to effector, and effector. A student-t test (α=0.05) was performed with the 
statistical analysis software JMP® 6 (Cary, NC). 
 
8.2.4 In Vivo Evaluation Non-Specific Tumor Immunity 
On day 0, pancreatic tumor cells (Panc02) (7.5 x 105 cells) were injected in 
combination with blank CPTEG:CPH microspheres (0.3 mg) by subcutaneous 
injection into female C57BL/6 MUC-4 knockout mice (N=5). After three weeks of 
immunizations mice were sacrificed and tumors were measured and embedded in 











8.3 Results and Discussion 
8.3.1 CTL Assay 
A CTL assay was performed on PBMCs incubated with blank CPTEG:CPH 
microspheres in order to evaluate if the adjuvant stimulates the proliferation of CD8+ 
effector cells. It was found that the PBMCs stimulated with polyanhydride 
microspheres induced the lysis of ~70% of the human pancreatic cancer cells Panc-
1 (Fig 8.1). On the other hand, the unstimulated cells induced less than 15% 
cytotoxicity. It is known that Panc-1 expresses antigen by means of the major 
histocompatibility complex class I (MHCI) and tumor cell lysis is caused by CTLs, 
which is MHCI-restricted18. It is important to note that the CPTEG:CPH copolymers 
do not induce cell death at the concentration used in this experiment (0.25 mg/mL) 
as previous experiments have shown that these polymers are not cytotoxic at 
concentrations that were over one fold higher19. Thus, the lysis was not caused by 
the direct contact of the cells with the polymer, instead it was caused by effector 
cells that were present in the culture. A possible explanation to the increased non-
specific proliferation of CTLs of the PMBCs incubated with the polyanhydride 
microspheres is that monocytes of the PBMCs might have differentiated into DCs 
that eventually matured with the increased expression of MHCI and T cell co-
stimulatory molecules, a process that is enhanced with CPTEG-containing 
microspheres17. Additionally, even if rh-IL2 was added to the cell culture to induce T 
cell growth and differentiation, this cytokine can be produced by activated T cells as 
well20. Thus, if the polyanhydride microspheres induced DC differentiation and 





production of rh-IL2 will further increase their proliferation. Unfortunately, the 
cytokine results were not available. Although the results obtained were non-antigen 
specific, it has been demonstrated that lymphocytes can become activated non-
specifically21 and that compounds that induce DC maturation, such as LPS, can 
induce differentiation of monocytes into DCs22. These are preliminary studies that 







Figure 8.1. SEM image of blank 20:80 CPTEG:CPH microspheres and CTL assay results of PBMCs incubated 





















8.3.2 In Vivo Activation of Effector Cells 
 As in vitro studies may not be truly reflective of in vivo responses, the non 
specific activation of anti tumor effector cells by CPTEG:CPH microspheres was 
evaluated on animal models.  
 
8.3.2.1 51Cr Release Assay 
 In an analogous assay of the in vitro CTL assay, the non-specific CTL 
activation was evaluated after injecting blank CPTEG:CPH microspheres into 
C57BL/6 mice. The microspheres were injected subcutaneously and after two 
weeks, the spleenocytes and lymphocytes were evaluated for CTL activity against 
the murine pancreatic cancer cell line Panc02. Although a different assay was used, 
both the 51Cr and LDH release methods have shown to be sensitive for cytotoxicity 
quantitation. As opposed to the preliminary results shown in the previous section, 
the CPTEG:CPH microspheres induced less than 3% cytotoxicity against cancer 
cells obtained from LNs (Fig 8.2) and spleen suspensions (data not shown). These 
are not unexpected, since the microspheres have the ability to activate DCs at the 
injection site, but when these mature and migrate to the LNs, in the absence of a 
specific antigen expression, the naïve cells would not become activated into effector 


























Figure 8.2. Cytotoxicity of lymphocytes from mice injected with blank CPTEG:CPH microspheres measured by 
51Cr release assay. 
 
 
8.3.2.2 Flow Cytometry 
The phenotype of the lymphocytes and spleenocytes of the mice injected with 
PBS and blank CPTEG:CPH microspheres was analyzed with flow cytometry. The 
surface molecules analyzed were CD44, CD62L and CD8a. As explained earlier, the 
cells in charge of anti-tumor immune responses are the CTLs, which are activated 
by CD8+ T cells. To analyze the flow cytometric data of the cells isolated from the 
secondary lymphoid organs, the viable cells of each individual mouse were gated for 
the surface expression of CD8 (Table 8.1). As noted, there were no significant 
differences within spleenocytes and lymphocytes across the different formulation 
groups. It is important to note that percentage of CD8 cells was doubled in the 
lymphocytes when compared to the spleenocytes, as further analysis is based on 
these populations. Representative histograms of lymphocytes expressing CD8a are 






Table 8.1 Percent of lymphocytes and spleenocytes expressing the surface marker CD8. (N=5 mice)  
Formulation % Viable lymphocytes 
expressing CD8 
% Viable spleenocytes 
expressing CD8 
PBS 21  9 11  1 
20:80 CPTEG:CPH 24  5 12  2 
50:50 CPTEG:CPH 26  1 13  5 
 
 
Figure 8.3. Flow cytometry histograms of LN cells expressing CD8a from mouse injected with 20:80 (left) and 
50:50 CPTEG:CPH microspheres (right). Cells were gated with respect to the corresponding isotype. 
 
In order to evaluate the phenotype of the CD8a cell populations, dot plots of 
CD62L vs. CD44 of gated CD8a cells from each individual animal were analyzed 
(Fig. 8.4). It is known that the cell adhesion molecule CD62L is expressed on naïve 
CD8 T cells  and the molecule CD44 is expressed on effector CD8 T cells20. 
Accordingly, the lymphocytes and spleenocytes were classified as naïve CD8 cells 
(CD62Lhi, CD44lo), cells that were in transition from naïve to effector (CD62Lhi, 






Figure 8.4. Analysis of CD8 lymphocytes population. CD62L vs. CD44 representative dot plots of lymphocytes of 
mice injected with: (a) PBS, (b) 20:80 CPTEG:CPH, and (c) 50:50 CPTEG:CPH microspheres. 
  
 
As shown in Figure 8.5, the majority of the lymphocytes CD8 populations 
were in the transition from naïve CD8 to effector CD8 T cells. The lymphocytes 
isolated from the groups that were injected with CPTEG:CPH microspheres showed 
this transition more significantly than in the group injected with PBS, indicating the 
potential of polyanhydride microspheres to induce activation of naïve CD8 T cells. 
The percentage of CD8 lymphocytes that were effector CD8 T cells were lower than 
naïve CD8 T cells and the differences between the formulation groups were not 
significant. 
 The phenotype of the spleenocytes expressing CD8 is shown in Figure 8.6. 
Whereas it appears that the number of effector CD8 T cells that were induced in the 
SP was quadrupled from the ones induced in the LN, the results are not as drastic. 
Taking into account that the overall CD8 cell population in the SP was near half of 
the overall population when compared to the lymphocytes, the effector CD8 T cells 
induced in the SP was doubled instead of quadrupled. Nevertheless, the percentage 
of cells that were classified in transition from naïve to effector CD8 T cells in the LN 





was much higher than in the SP. As a clarifying point, the statistical analysis done in 
all the groups showed no significant differences, and hence no effect can be 




















Figure 8.5. Flow cytometric results of lymphocytes expressing CD8. Error bars represent standard deviations. 





























8.3.3 In Vivo Evaluation Non-Specific Tumor Immunity 
 
The tumor mass of the mice that received blank CPTEG:CPH microspheres 
in conjunction with Panc02 cells  was weighed (Fig 8.7). Even when the number of 
tumor cells injected was the same in every animal, the chemistry influenced the 
tumor growth. The tumor grew more noticeably in the mice injected with 50:50 
CPTEG:CPH microspheres than in the ones injected with 20:80 CPTEG:CPH 
microspheres. These results are surprising as instead of suppressing the 
proliferation of malignant cells, the CPTEG content stimulated tumor growth. A 
logical explanation is that, as has been shown before, the high CPTEG-containing 
copolymers enhanced the activation of DCs and in consequence the production of 
proinflammatory cytokines such as IL-6 and TNFα was increased17. Additionally, 
although the vaccine formulations were composed of cancer cells that have the 
antigenic expression of malignant cells, live cells have still the capability of 
proliferating. The secretion of proinflammatory cytokines, such as IL-6, has been 
linked with the development of cancer by the activation of the nuclear factor-kappa B 
(NF- B) and thus promoting proliferation of tumor cells instead of apoptosis23. We 
hypothesize that after the subcutaneous injection of the microspheres and Panc02 
cells, the DCs that were resident in the injection site became activated and 
consequently released the proinflammatory cytokines that prevented the apoptosis 
of the rapid growing cancerous cells. The immunohistochemical analysis of the 



































These results support our previous findings that the CPTEG:CPH system 
represents a promise alternative for the delivery of vaccines. Although these are 
preliminary results, these demonstrate that CPTEG:CPH microspheres enhance the 
key factors of the innate immune response, indicating adjuvant characteristics for the 
development of cancer vaccines. Further studies needs to be performed and these 
will involve the encapsulation of tumor associated antigens (i.e. Mucin-1 and Mucin-
4) into CPTEG:CPH microspheres. The experimental approach combines the 
development of novel biodegradable CPTEG:CPH microspheres with studies that 
elucidate the induction of appropriate cell-mediated immunity (i.e., antigen-specific T 
cell responses). The proposed rational experimental design for the development of 







8.5 Experimental Design of CPTEG:CPH Cancer Vaccines 
8.5.1 Antitumor Immune Response of CPTEG:CPH Microspheres 
 The ability of CPTEG:CPH microspheres to induce an antitumor immune 
response will be evaluated with microspheres encapsulating whole cell tumor lysates 
(mixture of tumor antigens). After 2-3 weeks of inducing Panc02 tumors in C57BL/6 
mice, the mice will be immunized with tumor antigens-loaded CPTEG:CPH 
microspheres of various compositions. Injection groups (N=5) will include PBS 
(negative control), tumor lysate only (positive control), blank CPTEG:CPH 
microspheres only, tumor lysate-loaded CPTEG:CPH microspheres, and tumor 
lysate-loaded microspheres plus soluble tumor lysate. After monitoring the tumor 
size until it becomes unbearable by positive control animals, the mice will be 
sacrificed. LN and SP suspensions of individual animals will be stimulated in vitro 
with tumor lysate and the production of CTLs against Panc02 malignant cells will be 
assessed by 51Cr release. The phenotype of fresh LN and SP suspensions will be 
analyzed with flow cytometry to elucidate the activation of natural killer (NK) cells, 
CTL, and CD4+ effector cells. The immune cells infiltrating the tumors will be 
investigated by immunohistochemical staining of tumor sections.    
 
8.5.2 Design of Mucin-1 and Mucin-4 Cancer Vaccine 
 As cancer cells are composed of many antigens that might be expressed in 
other tissues, the main goal when designing a cancer vaccine is to modulate the 
response specifically against the malignant cells and not to healthy tissues. As has 





Mucin-1 and Mucin-4 in pancreatic cancer provides evidence that anti-tumor immune 
response is feasible. Experiments are described based on Mucin-1. However, similar 
experiments with Mucin-4 will be performed.  
 
8.5.2.1 Antigen Presentation by DCs 
 Blank CPTEG:CPH microspheres enhance the maturation of DCs, the key 
step in an immune response. In addition to the efficient activation of the DCs, these 
must be able to present the antigen, in this case Mucin-1 or Mucin-4, in the context 
of MHC I and/or MHC II in order to effectively initiate a specific immune response. 
Antigen presentation will be evaluated by assessing the ability of primed T cells to 
secrete cytokines and to proliferate following incubation in the presence of DCs 
previously incubated with Mucin-1 loaded microspheres. Culture supernatants will be 
assayed for the presence of cytokines (IL-2, IL-4, IL-10, and IFNγ) using a 
fluorescent bead assay.  
 
8.5.2.2 In Vivo Studies  
 A major challenge in cancer immunotherapy is the development of vaccine 
formulations that can elicit a cell-mediated immune response in the face of 
immunological tolerance to the tumor antigen. The success of a cancer vaccine is 
dictated by the magnitude of the immune response induced, type of immunity 
generated, and how long this will persist after administration. The studies described 
above will help determine which CPTEG:CPH composition(s) possess the 





CPTEG:CPH compositions that enhanced activation of DCs will be evaluated on 
animal models to identify formulations that facilitate the induction of anti-tumor 
immunity.  
 
8.5.2.3 Vaccine Regimen 
 Injection formulations will include blank microspheres, Mucin-1 loaded 
microspheres, Mucin-1 alone, and a mixture of free and antigen-loaded 
microspheres. Groups of 5 mice will be used for each formulation. C57BL/6 wild type 
(wt) mice will be immunized subcutaneously (sc) at the base of the tail with 0.5 mg of 
the corresponding formulation, based on previous work29. The serum will be 
analyzed prior to and after immunization twice a week for two months. Controls of 
the experiment will be mice injected with blank microspheres, PBS, and Mucin-1 
peptide alone. 
 
8.5.2.4 Antibody Production 
 The induction of Th1 and Th2 responses will be determined by isotype 
distribution in the serum using an anti-Mucin-1 antibody. The antibody production will 
be measured by ELISA, and the production of the immunoglobulin IgG3 will be an 
indication of Th1, while immunoglobulin IgG1 will be an indicator of a Th2 immune 
response. Because Mucin-1 peptides are known to be highly immunogenic in wt 
mice, high titer antibody responses are expected if Mucin-1 is efficiently presented 






8.5.2.5 Cell Proliferation and Cytokine Analysis 
  After two months of the vaccine injection, mice will be euthanized and 
cytokine production will be tested in cells derived from their lymph nodes (LN). The 
supernatant fluid will be analyzed for the presence of cytokines (e.g., IFNγ, IL-2, IL-
10, and IL-4) using a fluorescent bead assay. 
 
8.5.2.6 Vaccine Evaluation in Transgenic Model  
 The studies in this section (8.5.2) evaluate the ability of CPTEG:CPH 
microspheres to induce an immune response to Mucin-1.  The vaccine formulations 
with the best outcomes based on the experiments proposed in this section and the 
previous evaluation of antitumor responses (8.5.1) will be tested in transgenic mice 
and the cellular mechanisms of immune response and therapeutic value will be 
investigated. The real success of the vaccine formulation must be evaluated in the 
responses generated in a Mucin-1 transgenic animal model, which express Mucin-1 
as a self antigen, in the same way as in most cancer patients developing 
autoimmunity. Recently, human Mucin-1 transgenic (Tg) mice have become 
available, which enables the testing of immunotherapeutic strategies within the 










8.6 Overall Conclusions 
 The results and experiments outlined in this chapter provide a rational 
approach for the design of a cancer vaccine based on novel amphiphilic 
polyanhydrides. It is expected that the encapsulation into and sustained release of 
stable Mucin-1 and Mucin-4 from CPTEG:CPH microspheres will provide superior 
adjuvanticity against pancreatic cancer and will provide insights for a broad 
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CONCLUSIONS AND FUTURE WORK 
9.1 Conclusions 
 Cancer vaccines are still in the investigational phase and none have been 
licensed by the FDA for human use. The powerful combination of protein 
stabilization and immune deviation provided by the amphiphilic CPTEG:CPH 
polyanhydride system make it a promising prospect for development of cancer 
vaccines. The synthesis and characterization of the properties of these biomaterials, 
which can be tailored to obtain desirable controlled release and amphiphilic 
behavior, have been addressed in this thesis (Chapter 4) to accomplish the first 
logical step in the design of a novel delivery device. Subsequently, as most vaccines 
involve the delivery of peptides or protein subunits, protein stabilization in the 
CPTEG:CPH environment was analyzed in Chapters 5 and 6. It was demonstrated 
that CPTEG:CPH system does provide a gentle environment for proteins and a 
sustained release from copolymer microspheres is attained. In order to evaluate the 
adjuvant characteristics of CPTEG:CPH system, the activation of immune cells 
incubated with CPTEG:CPH microspheres and the implications for vaccine design 
were addressed in Chapter 7. The promising adjuvant capabilities of CPTEG-content 
microspheres were evidenced by an enhanced maturation of the most potent 
antigen presenting cells of the immune system. Altogether, the studies presented in 
these four chapters provide an excellent foundation for testing the viability of this 
system as an effective adjuvant for the development of cancer vaccines. Finally, the 





and a rational approach for the design of a single dose cancer vaccine is discussed 
in Chapter 8. Although the main focus of this thesis is to design novel adjuvants that 
can be used in a cancer vaccine, the potential of the amphiphilic CPTEG:CPH 
























9.2 Future Work 
The promising characteristics of the novel amphiphilic polyanhydride system 
based on the anhydride monomers CPH and CPTEG have led to its use in a broad 
range of biomedical applications. The main advantages of these polymers are that 
by increasing the CPTEG content in the copolymer, it is ensured that: (1) proteins 
are stabilized while being released in a controlled and predictable manner and (2) 
the immune cells of the innate immune system are activated, thus inducing a strong 
immune response. This system has tremendous potential in vaccine design as well 
as in other therapeutic applications. The adjuvant capabilities of CPTEG:CPH are 
supported by experiments performed with a model antigen and the activation of 
other antigen presenting cells besides dendritic cells (DCs). The surface modification 
of CPTEG:CPH microspheres, the evaluation of the CPTEG:CPH biocompatibility by 
high throughput experiments, and the potential functions for wound healing 














9.2.1 Adjuvant Capabilities with Model Antigen 
In order to determine the capability of CPTEG:CPH microspheres to enhance 
an antigen-specific immune response, BALB/c mice were injected with CD4+ T cells 
from ovalbumin (Ova) transgenic mice (DO11.10 T cells) 24 h before immunization. 
The immunization groups injected subcutaneously included: saline, 
lipopolysaccharide (LPS), Ova alone, 20:80 CPTEG:CPH blank microspheres (MS), 
LPS + Ova, and MS + Ova. After two weeks, the animals were euthanized by CO2 
asphyxiation. The serum was analyzed for Ova-specific antibodies with an enzyme-
linked immunosorbent assay (ELISA) and the mice immunized with MS enhanced 






























Figure 9.1. Total Ova-specific serum antibodies of immunized mice. Error bars represent standard deviation in a 
group (N=5). (    = statistically different from each other, P-value<0.05). 
 
 
An in vitro antigen-specific proliferation assay was performed after harvesting 
the inguinal, auxiliary, and brachial lymph nodes from each immunized mouse. After 
72 h of in vitro re-stimulation, the proliferation of T cells specific to Ova were 





amphiphilic CPTEG:CPH system enhanced T cell proliferation compared to Ova 
alone and at similar level to the LPS group, which is toxic for human applications. 
These studies demonstrate the ability of polyanhydrides to enhance the activation of 
CD4+ T cells which can be attributed to its promising adjuvant characteristics. The 
ability of CPTEG:CPH microspheres to enhance antigen presentation to CD4+ T 
cells provides evidence that T helper (Th) cells are activated. Further experiments 
are needed to determine if the polyanhydride microspheres induce Th1 (cell 
mediated) vs. Th2 (humoral) pathways. From the in vitro activation of DCs1, we 
hypothesize that CPTEG:CPH system has the ability to modulate the immune 
response towards Th1, which is needed to destroy intracellular pathogens. As 
mentioned earlier, current adjuvants approved for human use induce humoral 
immune responses against extracellular pathogens2. Therefore, the need for new 
adjuvants to elicit immune responses against intracellular pathogens such as 
viruses, certain bacteria and cancer, positions the CPTEG:CPH system as a viable 
alternative for treatments of these diseases.  
 The activation of CD4+ T cells also has implications for the design of cancer 
vaccines as it has been demonstrated that both CD4+ and CD8+ T cells are crucial 
for anti-tumor immunity3. In order to have a thorough understanding of anti-tumor 
immunity of a cancer vaccine, the experiments outlined on Chapter 8 must include 


























Figure 9.2. Antigen-specific proliferation of lymphocytes isolated from immunized mice. Error bars represent 




















9.2.2 Activation of other Immune Cells 
The professional antigen presenting cells (APCs) internalize antigen, and 
after intracellular degradation present antigen fragments to be recognizable to T 
cells by means of the context of Major Histocompatibility class I (MHCI) and class II 
(MHCII). There are three main types of professional APCs and these are B cells, 
macrophages, and the most potent APCs, the dendritic cells (DCs). It has been 
shown that CPTEG:CPH microspheres enhance the activation of DCs1. To study the 
ability of CPTEG:CPH microspheres to activate other professional APCs, the 
activation of B cells was assessed. Pre-B cells (7OZ/3) were incubated with 
CPTEG:CPH microspheres and their activation was measured by flow cytometry 
(Fig. 9.3). It is known that pre-B cells develop into immature B lymphocytes that 
express IgM at the surface after being mature4. As can be seen from the Figure 9.3, 
the polyanhydride microspheres enhanced the surface expression of IgM in the 
7OZ/3 to a similar extent as the positive control cells, which were incubated with 
LPS. When LPS and blank CPTEG:CPH microspheres were incubated together, 
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Figure 9.3. Activation of Pre-B cell line 7OZ/3. Flow cytometry histogram of cells incubated with 20:80 
CPTEG:CPH microspheres (top). Open histograms represent isotype control. The activation results obtained 
from flow cytometry were analyzed with respect to the % of positive cells expressing IgM and the corresponding 
mean fluorescence intensity (MFI) (bottom).  
 
 
An interesting finding about the activation of 7OZ/3 in the past concluded that 
the hydrophilic head group of the LPS was critical for their activation5. We 
hypothesize that CPTEG content in the copolymer was the main inducer for the pre-
B cell activation in the studies that are presented here, and this is in agreement with 
the activation of DCs by CPTEG:CPH microspheres as well. Therefore, the 








9.2.3 Carbohydrate Attachment  
 As has been discussed in previous chapters, the most important APCs are 
the highly specialized DCs, which expresses a repertoire of pattern recognition 
receptors, including toll-like receptors (TLRs) and C-type lectins that can recognize 
pathogens and modulate the immune response against them. In particular, C-type 
lectins recognize specific carbohydrate structures that are present on the cell-wall of 
pathogens or in self glycoproteins6. These receptors mediate key processes in an 
immune response such as cellular signaling, cell adhesion, and migration. We 
propose that the attachment of carbohydrates, such as lactose and di-mannose, to 
the surface of CPTEG:CPH microspheres will enhance their uptake by DCs. 
Currently both sugars have been incorporated into the microspheres by a coupling 
reaction (Fig. 9.4). The percentage of carboxylic acid groups that were present in the 
surface of the microspheres was estimated from an end group analysis from proton 
nuclear magnetic resonance (1H NMR) spectra of the polymers and the surface area 
of the microspheres. Then the conditions for the coupling reaction were determined 










Figure 9.4. Coupling reaction for attachment of Lactose and Di-mannose into CPTEG:CPH microspheres. The 
carboxyl activating agents 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (NHC) were used for coupling the sugars. 
 
A scanning electron microscopy (SEM) image of 20:80 CPTEG:CPH 
microspheres after lactose coupling is shown in Fig. 9.5. To ensure that majority of 
microspheres were under 10 μm for efficient phagocytosis by DCs, the size 
distribution was determined and it was found that 86% of the microspheres were 
below this size. Future experiments could involve the evaluation of DC activation of 
carbohydrate-modified CPTEG:CPH microspheres. 
 
 
Figure 9.5. SEM image of 20:80 CPTEG:CPH microspheres after coupling Lactose to the surface. Scale bar 






9.2.4 High Throughput Analysis 
The biocompatibility of CPTEG:CPH copolymer libraries has been recently 
studied using high throughput cell-based screening methods8. A rapid prototyping 
technique was used to synthesize a multi-well substrate for high throughput 
synthesis of polymer libraries. The CPTEG:CPH copolymer libraries were incubated 
with standard myeloma, epithelial, and macrophage cell lines and were found to 
have no pronounced cytotoxic effect for any polymer composition at concentrations 
of 2.8 mg/mL and below, which is much higher than that expected in in vivo 
applications (Fig 9.6). Future analysis can evaluate immune activation by cytokine 
secretion of DCs incubated with CPTEG:CPH libraries to discover optimum 
chemistries with desirable adjuvant capabilities. 






























9.2.5 Wound Healing Applications 
 The amphiphilic CPTEG:CPH system provides a gentle environment for 
protein delivery and stabilization9, 10. The model proteins incubated with degradation 
products and after being released from microspheres maintain their structural and 
biological integrity. Uterocalin is a protein that is hypothesized to expedite wound 
healing and it is known that this protein loses its biological activity if the structure is 
altered11, 12. The biological activity of uterocalin after release from CPTEG:CPH 
microspheres is currently being investigated with an in vitro cell migration assay. A 
wound line was induced on human colorectal carcinoma cells (HCT116) and after 24 
h of incubating with uterocalin-loaded 50:50 CPTEG:CPH microspheres, the cells 
that migrated were counted (Fig. 9.7). As can be seen from the images, the protein 
released from polyanhydride microspheres increased the rate of migration, indicating 
its functional activity. This preliminary study supports the hypothesis that 
CPTEG:CPH system provides a conducive environment for proteins and this is the 
first time it has been demonstrated with a protein with therapeutic value. Future 
studies can focus on in vivo experiments that investigate the wound healing 
properties of uterocalin-loaded CPTEG:CPH microspheres by studying the infiltration 
of inflammatory cells into an induced open wound and tissue regeneration after 







Figure 9.7. Optical photomicrographs of in vitro wound healing assay. HCT116 cells immediately after creating 
wound (left) and after being incubated for 24 h with uterocalin-loaded 50:50 CPTEG:CPH microspheres (right).  
 
  
Altogether, the preliminary results shown here clearly support our previous 
findings of the CPTEG:CPH system, substantiating our hypothesis of the potential of 
these novel polyanhydrides for biomedical applications. The combination of 
biocompatibility, the ability to stabilize proteins, the enhanced activation of immune 
cells and the enhanced immune response confers a wide range of applications with 
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